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Hepatocellular carcinoma (HCC) is the 5th most commonly-occurring cancer worldwide and the 
2nd highest cause for cancer-related deaths globally. The current treatment strategy is the direct 
injection of a chemotherapeutic agent (e.g. doxorubicin; DOX) into the hepatic artery, through a 
process called hepatic arterial infusion (HAI). Unfortunately, HAI is severely hindered by limited 
therapeutic efficacy against the tumor and high systemic toxicity to surrounding organs (e.g. 
cardiotoxicity). This thesis focuses on the development of a targeted, nanoparticle-based drug 
delivery system aimed to improve the clinical treatment of HCC. In particular, we employ 
generation 5 (G5) poly(amido amine) (PAMAM) dendrimers targeted to hepatic cancer cells via 
N-acetylgalactosamine (NAcGal) ligands attached to the surface through a poly(ethylene glycol) 
(PEG) brush. DOX is attached to the G5 surface through two different enzyme-sensitive linkages, 
L3 or L4, to achieve controllable release of the drug inside hepatic cancer cells. The combination 
of NAcGal-PEG targeting branches with either L3- or L4-DOX linkages led to the development 
of P1 and P2 particles, respectively.  
 
In Part 1, we discuss the development of these particles and measure their ability to target and kill 
hepatic cancer cells in vitro. In Part 2, we investigate the antitumor activity of P1 and P2 particles 
in tumor-bearing mice in comparison to the free drug, and we measure the cardiac function of mice 
undergoing treatment to assess differences in DOX-induced cardiotoxicity. Finally, in Part 3, we 




hepatic cancer cells. Ultimately, this thesis provides insight into the utility of nanoparticle-based 



















1.1 Incidence and Epidemiology 
Hepatocellular carcinoma (HCC), the most common form of primary liver cancer,1 is the 5th most 
commonly-occurring cancer worldwide and the 2nd highest cause for cancer-related deaths 
globally.2,3 The poor prognosis and treatment of HCC is highlighted by the 782,000 new cases that 
 
Figure 1: Global incidence of hepatocellular carcinoma (HCC) in 2012. Incidence of HCC varies based on 




developed in 2012 and the 746,000 deaths that resulted from it in the same year,3 leading to a 
global mortality-to-incidence ratio of 0.95.2–4 In the US, the incidence rate of HCC has more than 
doubled in the last three decades and is anticipated to reach peak incidence rates before 2030.5,6 In 
fact, primary liver cancer mortality rates have increased faster than mortality rates for any other 
leading cause of cancer.1  
 
The incidence rate of primary liver cancer differs greatly based on geographic region (Figure 1), 
with 4.1 in every 100,000 men being diagnosed in North America while in Middle Africa and 
Eastern Asia, this number is estimated to be as high as 24-35.7 The primary cause of liver cancer 
in developing nations is hepatitis B (HBV) and C (HCV) viral infections, with 80% of the cases 
resulting from these viral infections. 81% of the global cases of HCC originate in the developing 
world, indicating the severity of the disease in areas with poor detection and prognosis, on top of 
the lack of proper treatment witnessed globally. In the U.S. and Europe, alcohol and HBV are the 
primary causes for HCC, with alcohol-induced cirrhosis accounting for 45% of the cases.7  
 
Worldwide rates of liver cancer diagnosis are on average 2-4 times more likely in men than in 
women, with incidence in men increasing sharply after 50 years of age.1,7 Ethnically, incidence of 
HCC in the U.S. is the highest for Asian-Pacific islanders, followed by Hispanics, blacks, Native 
Americans, and whites.1 Over the past 2-3 decades, with the improvement of detection modalities, 
HCC can be detected earlier leading to a better overall survival rate for diagnosed patients.1 Despite 
increasing survival rates, however, HCC still causes 1- and 3-year survival rates of approximately 




HCC cases are not detected until their most advanced stages, contributing to the second worst 5-
year survival rate of 8.9%,8 trailing only behind pancreatic cancer.  
 
1.2 Etiology  
The major risk factors for HCC are cirrhosis, HBV, HCV, and alcohol-related liver disease (Figure 
2).1,2,9 Other less significant, yet prominent, risk 
factors are aflatoxins, type II diabetes, and 
obesity. While hepatocarcinogenesis begins 
differently depending on the etiology, the 
general process involves acute damage to 
hepatocytes that induces recurring cycles of 
necrosis-inflammation-regeneration, oxidative 
stress, fibrosis, and cirrhosis (Figure 3).10 The 
progression of hepatocyte damage generates 
various types of genomic instability, such as an inactivation of tumor suppressor p53, mutations 
in -catenin, telomere erosion, or defects in DNA-damage-response pathways.10 
 
Figure 2: Risk factors for HCC. There are multiple 





1.3 Detection and Staging  
The clinical symptoms of HCC typically do not develop during the early stages of disease,9 leading 
to the poor survival rates mentioned earlier. Instead, symptoms develop typically at the end-stage 
of disease, particularly for patients either at-risk or already presenting cirrhosis. Hepatic ultrasound 
imaging and serum α-protein (AFP) levels are used as the primary mechanisms of diagnosis.2,9 
Additionally, other serum markers like des-γ carboxyprothrombin and α-L-fucosidase have been 
shown to be elevated in patients with HCC, and many other biomarkers2,9,11 are under investigation 
for their association with HCC staging. Other imaging modalities such as computed tomography 
(CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) have all 
 
Figure 3: Pathway of hepatocarcinogenesis. Carcinogenesis results from a combination of hepatic injury 
from multiple risk factors that leads to recurring cycles of necrosis-inflammation-regeneration, cirrhosis, or 
fibrosis. These cycles of damage induce genetic instability that progresses into a loss of p53-mediated tumor 




shown some moderate efficacy in detecting HCC, but ultrasound (either B-mode or contrast-
enhanced) remains as the most effective imaging modality to date.9,10,12–14  
 
Proper staging of HCC is crucial not only for prognosis but also to direct treatment strategies. 
While there is no universal staging system in place, the Barcelona Clinic Liver Cancer (BCLC) 
Staging System is the most validated system and uses tumor burden, hepatic function (determined 
by the Child-Pugh score15), and performance status in an evidence-based algorithm to determine 
its scoring (Table 1).2,16  
 
Table 1: Staging of HCC according to the Barcelona Clinic Liver Cancer Staging System 






Very early (0) Single lesion <2cm A 0  
Early (A) Single lesion <5cm or three lesions 
<3cm each 
A-B 0-2 53 months 
Intermediate 
(B) 
Single lesion >5cm or multiple lesions, 
with largest >3cm 
A-B 0-2 16 months 
Advanced (C) Any tumor burden A-B 1-2 7 months 
Terminal (D) Any tumor burden C >2 3 months 
aChild-Pugh score is based on five parameters of normal liver function: bilirubin, serum albumin, prothrombin time, 
ascites, and hepatic encephalopathy.15  
bPerformance status 0: fully active and able to carry on with all predisease performance without restriction. 
Performance status 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light 
sedentary nature. Performance status 2: ambulatory and capable of self-care but unable to carry out any work 
activities; up and about 50% of waking hours. Performance status >2: capable of only limited self-care or completely 
disabled. 
  
1.4 Current Treatment Options  
The treatment options for HCC depend highly on the stage of diagnosis, with survival rates and 




effective forms of treatment currently are surgical resection or orthotopic liver transplantation 
(OLT), however more than 80% of patients are ineligible for these procedures due to advanced 
tumor stage and poor underlying liver function as a result of cirrhosis.2,17 Additionally, tumor 
recurrence rates are high (60%).18 For intermediate stage HCC patients, the more likely therapeutic 
options are either percutaneous ethanol injection (PEI) or radiofrequency ablation (RA).9,19,20 PEI 
is an inexpensive, ultrasound-guided injection of ethanol, but also has low rates of efficacy the 
further advanced the HCC burden is. RA is a comparable strategy where heat energy is applied to 
the tumor via electrodes, and is considered more efficacious than PEI for the same tumor burden. 
RA, however, is plagued with significant complications like peritoneal bleeding and pleural 
effusions.9  
 
The majority of advanced, unresectable HCC patients rely on loco-regional chemotherapy 
delivered via hepatic arterial infusion (HAI) or trans-arterial chemoembolization (TACE).2,11,17,21 
HAI involves the direct injection of a chemotherapeutic drug (e.g. doxorubicin; DOX) into the 
hepatic artery, given that the hepatic artery is the primary tumor-feeding vessel in clinical HCC. 
TACE is a modification of HAI in which DOX is delivered as a suspension in an embolizing agent 
(e.g. lipiodol) to simultaneously induce ischemia in the tumor. Unfortunately, however, HAI 
procedures have experienced limited antitumor activity in several clinical trials delivering DOX 
by itself or as part of a cocktail (e.g. drug-eluting microbeads).22,23 In fact, HAI response rates do 
not exceed 15% for the most advanced HCC stages (Child-Pugh score B/C),24,25 and the survival 
advantage over supportive care alone has been small (3.1 to 4.8 weeks).22,26 Further, there are 
several procedural complications that occur with HAI and TACE,27 such as hemorrhage, hepatic 




circulation leads to non-specific distribution and toxicity to hepatic,23,28 cardiac,26,29,30 and bone 
marrow tissue.23,31,20 
 
Sorafenib, an oral tyrosine kinase inhibitor, is a recently studied form of treatment for advanced 
HCC that inhibits several tumor cell pathways that lead to decreased angiogenesis and tumor cell-
signaling.2,11,21 However, the use of this drug has only been shown to extend patient survival by 
2.8 months,2 and the high cost of the drug leads to a low efficacy to cost ratio.32 Most importantly, 
clinical trials showing significant therapeutic advantage in the sorafenib group compared to 
placebo has been limited to early-stage HCC patients (Child-Pugh A).2 There still remains a need 
for a reliable therapy that can be effective for advanced stage HCC patients.  
 
 




1.5 Nano-Therapeutics for HCC Therapy 
1.5.1 General Nanoparticle Strategies  
It is evident that there is an urgent clinical need for novel molecular therapies that are able to 
deliver a high dose of chemotherapeutic agents to the cytoplasm of hepatic cancer cells while 
minimizing their non-specific distribution and toxicity to healthy tissues. The use of nanoparticles 
(NPs) to develop targeted HCC therapies have shown significant potential in being able to home 
selectively to tumor tissue and deliver their loaded therapeutic cargo, circumventing the issues 
brought about by macromolecular therapies currently. A range of nanoparticle carrier formulations 
have been investigated – such as liposomes,33 micelles,34 hydrogels,35 metallic nanoparticles,36 and 
polymers37 – all of which have been employed to deliver chemotherapeutic agents,34,35 gene 
agents,33,37 and therapeutic proteins36 to liver cancer cells in vitro and in vivo. Despite the ability 
for several of these NP formulations to load, stabilize, and deliver anticancer agents to tumor tissue, 
they have failed to be translated to the clinic due to several limitations, such as low water solubility, 
low stability in vivo, and by exhibiting a lack of selective drug release into tumor tissue, which 
leads to non-specific toxicity.  
 
1.5.2 Polymer-based Therapies 
Polymeric nanocarriers, however, are better able to deliver anticancer agents to liver cancer tissue 
due to their high water solubility, biocompatibility, biodegradability, stability, and ease of 
formulation.38,39 Accordingly, there have been several polymeric NP formulations able to achieve 
selective delivery of anticancer agents to the cytoplasm of hepatic cancer cells.40–44 For example, 




receptor monoclonal antibody (PLA-PLL-EGFRmAb).45 While they achieved tumor localization 
in a xenograft HCC tumor model, the widespread expression of EGFRmAb in epithelial, 
mesenchymal, and neuronal cells prevents the specific localization of the NP to HCC tissue.46 This 
lack of targeting moieties leads to non-specific distribution and drug release to healthy organs after 
intravenous (I.V.) administration, resulting in dose-limiting toxicities for several polymeric NP 
formulations.47 To address this issue, the attachment of sugar molecules to the polymeric carrier 
has been used to target NPs to the liver-specific asialoglycoprotein receptor (ASGPR)48 highly 
expressed on the surface of hepatic cancer cells,49,50 which can bind and internalize galactose, 
galactosamine, and N-acetylgalactosamine (NAcGal) sugar residues through receptor-mediated 
endocytosis.48 In particular, HepG2 human hepatic cancer cells express as many as 150,000 surface 
binding sites/cell,49 and in clinically obtained liver tumor biopsies, 80% of well-differentiated 
HCC tumors are positive for ASGPR, as determined by immunostaining techniques.51 Xue et al. 
prepared galactose-targeted iron oxide nanoparticles carrying a tumor suppressor gene and showed 
anticancer activity in hepatic cancer cells as well as orthotopically-transplanted HCC-bearing 
mice.44 Duncan et al. showed a 20-fold increase of internalization into HepG2 when they 
synthesized Gal-targeted N-(2-hydroxypropyl) methacrylamide (HPMA)-DOX conjugates, 
compared to non-targeted controls.52 Despite these conjugates reaching phase I/II clinical trials, 
they only exhibited 3.3% DOX release in tumor tissue, while 16.9% of the DOX dose was 
delivered to normal liver tissue.53 This is likely due to the lack of stealth properties incorporated 
into the particles, leading to protein adsorption while in systemic circulation and consequently 
clearance by macrophages in the liver and other organs (e.g. lungs, spleen, kidneys)  in the 





1.5.3 Limitations of Current Nano-Therapeutic Strategies  
It is evident that targeted polymer-drug conjugates have high potential to deliver high doses of 
chemotherapeutic agents into the cytoplasm of hepatic cancer cells with minimal side effects. 
However, this potential has not been completely been realized yet, primarily due to: 1) Low 
loading densities of targeting and drug moieties onto the nano-carrier, likely due to steric 
limitations of linear polymers like HPMA; 2) lack of “stealth” properties that lead to non-specific 
recognition by the RES; and 3) Lack of specificity to characteristics of the tumor tissue, such as 
targeting an enzyme that is present in all cells, not just tumor tissue, like the cathepsin enzymatic 
target of Gal-HPMA-DOX conjugates.53 Thus, there is an urgent need to address these issues with 
a novel molecular approach to polymer-drug conjugates. 
 
1.6 Thesis Structure 
This thesis describes our approach to develop a translational, efficacious, and synthetically-
feasible drug delivery system based on polymeric nanoparticles that is able to target HCC 
specifically and release a loaded drug within the cancer cell cytoplasm. The chapters to follow are 
broken down in the following manner:  
 
Chapter 2: Background 
This chapter descrbies initial results studying the potential of spherical, polymeric nanoparticles 
called dendrimers as the vehicle for targeted drug delivery to hepatic cancer, given their unique 
physiochemical and drug-loading properties. Dendrimers targeted to the ASGPR overexpressed 




biocompatible polymeric linkages achieved selective internalization into hepatic cancer cells. 
Further, chemotherapeutic drug (e.g. doxorubicin, DOX) molecules attached to dendrimers 
through an engineered chemical linkage susceptible to cleavage only by hepatic-specific enzymes 
led to controllable release of the drug within the cytoplasm of hepatic cancer cells. These results 
highlighted the potential of combining both targeting and enzyme-activated DOX linkages onto 
the same dendrimer in order to achieve a highly-targeted nanoparticle delivery system able to 
specifically kill hepatic cancer tissue.  
 
Chapter 3: Development and in vitro validation of P1 and P2 particles 
This chapter describes the development of N-acetylgalactosamine (NAcGal)-targeted, doxorubicin 
(DOX)-loaded, generation 5 (G5) poly-amidoamine dendrimers able to achieve cell-specific 
delivery and release of DOX into the cytoplasm of hepatic cancer cells. G5 is functionalized with 
16.6 PEG brushes displaying NAcGal ligands to target hepatic cancer cells. DOX is conjugated to 
G5 via two aromatic azo-linkages, L3 and L4, to achieve tunable hepatic cancer cell-specific 
release of the drug. The combination of PEGylated NAcGal ligands with similar loading of L3-
DOX and L4-DOX resulted in P1 ((NAcGal-PEGc)16.6-G5-(L3-DOX)11.6) and P2 ((NAcGal-
PEGc)16.6-G5-(L4-DOX)13.4) particles, respectively. After confirming the conjugates’ 
biocompatibility, flow cytometry studies show P1 and P2 achieve 100% uptake into hepatic cancer 
cells at 30-60 nM particle concentration. This internalization correlated with cytotoxic activity 
against HepG2 cells with IC50 values of 24.8, 1,414.0 and 237.8 nM for free DOX, P1, and P2, 
respectively. Differences in cytotoxic activity prompted the use of metabolomics to identify the 
intracellular release behavior of DOX. While treatment with free DOX results in intracellular 




metabolites, namely tetracenomycin-like analogues. The different metabolites induce different 
effects on metabolic cycles, as seen in studies using stable isotope tracers. Namely, free DOX 
significantly reduces glycolysis and increases fatty acid oxidation, while P1 and P2 particles 
increase glycolysis, likely as a response to high oxidative stress. Overall, P1 and P2 particles 
exhibit high potential as a platform drug delivery technology for improvement of hepatic cancer 
therapy. 
 
Chapter 4: in vivo efficacy of P1 and P2 particles 
Since DOX delivery through HAI is plagued by limited therapeutic efficacy and the occurrence of 
severe toxicities (e.g. cardiotoxicity), this chapter focuses on measuring the antitumor activity and 
cardiotoxicity induced by P1 and P2 particles in HCC-bearing mice. We demonstrate that while 
the intratumoral delivery of free DOX achieves a 2.5-fold inhibition of tumor growth compared to 
the saline group, P1 and P2 particles achieve a 5.1- and 4.4-fold inhibition, respectively. Magnetic 
resonance imaging revealed that P1- and P2-treated mice maintained cardiac function, unlike the 
free DOX group, suggesting that P1/P2 avoid DOX-induced cardiotoxicity. Taken together, these 
results highlight the ability of P1/P2 particles to improve the therapeutic index of DOX and offer 
a replacement therapy for clinical HCC treatment. 
 
Chapter 5: Effect of valency on targeting hepatic cancer cells  
Given the success of P1 and P2 particles to improve the therapeutic efficacy of DOX and its 
toxicity profile both in vitro and in vivo, we sought to investigate whether the affinity of P1 and 




density of targeting branches as well. In particular, we tested the ability of non-DOX-loaded G5 
dendrimers displaying either mono-valent NAcGal molecules (monoGal) or tri-valent NAcGal 
(triGal) at different densities to be internalized into hepatic cancer cells.  We therefore synthesized 
monoGal and a library of triGal particles, with either 2, 4, 6, 8, 11, or 14 targeting branches 
attached. Conventional flow cytometry studies showed that all particle formulations are able to 
label hepatic cancer cells in a concentration-dependent manner, reaching 90-100% of cells labeled 
at either 285 or 570 nM G5, but monoGal labeled more cells at lower concentrations. To elucidate 
the difference in internalization of monoGal versus triGal conjugates, we turned to multi-spectral 
imaging flow cytometry to determine the proportion of internalized versus surface-bound 
conjugates in all treatment groups. Results show that regardless of NAcGal valency or density of 
targeting branches, all particles achieve full internalization and diffuse localization throughout the 
cell, encouraging further work in molecular spacing to identify minor differences in NAcGal-
binding based on valency. Nevertheless, these results present a versatile library of targeted G5 
conjugates that can be used to target and deliver a variety of therapeutic payloads to hepatic cancer 
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Design of Targeted, Enzyme-Activated Nano-Conjugates 
 
2.1 Components of the Nano-Conjugate System 
The current research aims to develop a targeted, enzyme-activated nano-conjugate system that is 
able to home specifically to hepatic cancer tissue and release a loaded drug controllably within 
those cells through activation by liver-specific enzymes, while avoiding non-specific distribution 
and toxicity to healthy organs. 
 
 
Figure 5: Design of targeted, enzyme-activated nano-conjugates. The combination 
of targeted and enzyme-activated delivery of doxorubicin is hypothesized to overcome 




2.1.1 Dendrimers as the nano-carrier  
We employ dendrimers, which are spherical, hyper-branched polymers, as the nano-carriers for 
this system due to their high water-solubility, monodispersity, functionality, and controllable 
synthesis.1 Dendrimers have been more efficacious over their linear polymer counterparts as 
carriers of chemotherapeutic agents on account of their high monodispersity, higher functionality, 
and their ability to better stabilize and deliver drugs.1–3 Generation 5 (G5) poly(amido-amine) 
(PAMAM) dendrimers are chosen in order to exploit their high density of chemical surface groups 
(128) while maintaining a particle size (5.4 nm) 
that, after functionalizing with both drug and 
targeting linkages, is able to exploit the 
enhanced permeation and retention (EPR) 
effect in tumor tissue (Figure 6). The EPR 
effect is described by the ability for NPs 
between 10-100 nm to permeate into tumor tissue from the bloodstream due to leaky tumor 
vasculature. Once the NPs have localized inside the tumor tissue, the lack of proper lymphatic 














Figure 6: EPR effect. The enhanced permeation and 
retention (EPR) effect exploits the leaky vasculature 
and lack of proper lymphatic drainage, allowing the 




2.1.2 Enzyme-Activated DOX Linkage  
DOX is used as a model chemotherapeutic agent due to its well established clinical use in systemic 
and loco-regional HCC chemotherapy.6,7 DOX is covalently-linked to G5 dendrimers through an 
azobenzene linkage that is designed to exhibit tunable affinity for liver-specific azoreductase 
enzymes.8,9 The general chemical structure for this linkage can be seen in Figure 7, with varied 
oxygen or nitrogen substitutions in the electron-donating substituent positions (X and Y in Figure 
7) determining the electronegativity around the azo-bond and accordingly, azoreductase affinity 
to it. The enzymes are then able reduce to free amines in an NADPH-dependent manner, and a 
1,6-electron cascade eliminates the ring B attachment from DOX, resulting in the release of free 







Figure 7: Azo-DOX linkage structure. General structure of the chemical linkage 
conjugating DOX to the G5 dendrimer through azoreductase-cleavable azo-
linkages. The X and Y consitutents vary based on L(x) linkage composition. After 
reduction of the azo-bond to amines by azoreductase, a rapid electronic cascade 





2.1.3 NAcGal-PEG Targeting Branch  
In order to achieve selective delivery of DOX molecules to hepatic cancer cells, we also attach 
targeting ligands to the G5 dendrimers (Figure 8). NAcGal sugar residues that are specifically 
recognized by the ASGPR highly expressed on HCC are employed as the ligand. These moieties 
are attached to a poly(ethylene glycol) (PEG) spacer in order to impart hydrophilicity to the nano-
conjugate and increase plasma retention time.10–12 NAcGal-PEG molecules are then attached to 
the G5 surface through an acid-labile cis-aconitic (c) linkage that allows shedding of the NAcGal-
PEGc branch from the G5 surface in the acidic environment of the endosome after receptor-
mediated endocytosis.  
 
2.1.4 Targeted, Enzyme-Activated Nano-conjugates  
The DOX linkage and NAcGal targeting branch are combined onto the same G5 dendrimer to 
achieve targeted, enzyme-activated nano-conjugates (Figure 9). The number of NAcGal-PEGc 
 
Figure 8: NAcGal-PEG Targeting Branch. The targeting branch attached to a G5 
dendrimer. NAcGal ligands are attached through a PEG spacer and cis-aconityl linkage to 
achieve hepatic cancer cell-specific delivery.  
Acid-labile 
cis-aconityl linkage PEG brush
Targeting 
NAcGalβ ligand




targeting branches (m) and L(x)-DOX linkages (n) will vary batch to batch, but due to the robust 
chemistry we have incorporated in the nano-conjugate design, we can achieve reproducible loading 
of both branching structures for all batches of nano-conjugates created. 
 
2.2 Mechanism of Anticancer Activity 
The anticipated mechanism of activity is demonstrated in Figure 10. Briefly, the nano-conjugates 
will be injected intravenously and allowed to circulate through the systemic circulation. The stealth 
properties incorporated into the nano-conjugates prevent them from being rapidly cleared by the 
reticular endothelial system (RES) and allow them to circulate long enough to permeate and 
 
Figure 10: Mechanism of anticancer activity. The proposed mechanism of anticancer 
activity. Nano-conjugates bind to the ASGPR and undergo endocytosis before escaping the 
endosome. After release into the cytoplasm, azoreductase enzymes cleave the drug linkage 




localize in the tumor tissue due to the EPR effect. Once inside the tumor tissue, the NAcGal 
targeting ligands bind to the target receptor on the HCC and induce receptor-mediated endocytosis 
of the nano-conjugates. Within the endosome, the acid-labile linkage attaching the targeting ligand 
to the nano-carrier is cleaved due to the acidic nature of the endosome.13 The buffering capacity 
of dendrimers elicits the influx of charged ions into the endosome, causing it to swell and 
eventually burst, leading to release of the nano-conjugates into the cytoplasm.14 In the cytoplasm, 
azoreductase enzymes cleave the L(x)-DOX linkage, releasing the DOX and allowing it to induce 
its cytotoxic effects both in the cytoplasm and in the nucleus. Meanwhile, the urine is able to be 
cleared from the intracellular space and removed by the kidneys in the urine due to their low MW 
having shed their cargo. This proposed mechanism achieves hepatic cancer cell-specific 
localization of the nano-conjugates and selective delivery of the loaded drug within the cell, 













2.3 Preliminary Results 
2.3.1 Tunable DOX Release and Anticancer Activity of G5-L(x)-DOX Conjugates 
 
Our previous work published in Biomaterials5 showed the successful synthesis of four aromatic 
azo-linkages, L1-L4, that have increasing electronegativity around the azo-bond, which 
consequently led to a rank-order increase in azoreductase affinity and DOX release from the azo-
bond in the presence of liver-specific enzyme preparations. This rank-order correlated with 
anticancer activity of G5-L(x)-DOX conjugates towards HepG2 cells, with G5-L1-DOX and G5-
L4-DOX conjugates exhibiting the lowest and highest cytotoxic activities, respectively. Compared 
to the IC50 of free DOX in HepG2 of 10 nM, G5-L3-DOX and G5-L4-DOX were the most active 
conjugates, exhibiting IC50 values of 158 nM and 13 nM, respectively (Figure 11). We visualized 
the DOX release from G5-L(x)-DOX conjugates through confocal microscopy to confirm the 
 
Figure 11: Established azo-DOX linkages. The four linkers, L1-L4, that were synthesized in G5-L(x)-DOX 
conjugates, and their associated anticancer activity towards HepG2 cells. Those not noted in the legend are 




diffuse release of DOX throughout the cell body (Figure 12). The work involved in this thesis 
investigates the L3-DOX and L4-DOX constructs as part of the complete nano-conjugate structure 
due to their higher DOX release rates and anticancer activity.  
 
Figure 12: Intracellular DOX localization. Confocal fluorescence microscopy results showing the intracellular 
localization of DOX delivered either freely, by G5-L3-DOX, or G5-L4-DOX. Cell nuclei are stained with DAPI 
(blue) and free DOX imaged by its intrinsic fluorescence. The co-localization of DAPI and DOX signals in the 




2.3.2 Selective Recognition of G5-PEG-NAcGal Particles by HCC 
Medina et al. recently showed the selective recognition and internalization of NAcGal-PEG-
targeted G5 dendrimers into hepatic cancer cells.15 Specifically, it was established that NAcGal 
sugar residues in the β conformation have selective affinity for the ASGPR on HCC, compared to 
NAcGal molecules in the α-conformation as well as a peptide, SP-94, established to be HCC-
specific (Figure 13).16 Further, it was confirmed that the PEGylation of G5 dendrimers reduced 
particle phagocytosis by isolated mouse liver macrophage Kupffer cells, due to a decrease in 
opsonization of the particles by serum proteins. Finally, minimal uptake of G5-PEG-NAcGal 
conjugates into normal rat hepatocytes confirmed that these carriers achieve cell-specific delivery 
to HCC while avoiding internalization into neighboring healthy liver cells.  
 
Figure 13: Uptake of targeted G5-PEG particles into HepG2 cells after 2 hours. These results confirm the 
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Hepatocellular carcinoma (HCC) is the 5th most commonly-occurring cancer worldwide and 
the 2nd highest cause for cancer-related deaths globally.1,2 The poor prognosis and treatment of 
HCC is highlighted by the 782,000 new cases that developed in 2012 and the 746,000 deaths 
that resulted from it in the same year2 leading to a global mortality-to-incidence ratio of 0.95.1–
3 In the US, the incidence rate of HCC has more than doubled in the last three decades and is 
anticipated to reach peak incidence rates before 2030,4,5 which emphasizes the need to develop 
an effective therapeutic strategy.  
 
Figure 14: in vitro strategy. Strategy for targeted, enzyme-activated delivery of 




Currently, the most common therapeutic strategy is the direct injection of chemotherapeutic 
agents (e.g. doxorubicin, DOX) into the hepatic artery through a process called hepatic arterial 
infusion (HAI).6 A common modification of this procedure is the co-delivery of an embolizing 
agent to restrict arterial bloodflow and induce ischemia in addition to the chemotherapeutic 
effect of DOX, a technique called transarterial chemoembolization (TACE).7–9 Unfortunately, 
HAI and TACE are severely hindered by high complication rates such as dose-limiting 
toxicities (e.g. cardiotoxicity, myelosuppression, and hepatic failure),10 high rates of tumor 
recurrence, and development of chemoresistance.7,11–13 Off-target toxicity arises mainly from 
the leakage of DOX into the systemic circulation leading to the unintended delivery of DOX 
to surrounding healthy tissue,10,14 while chemoresistance develops through upregulation of 
drug efflux pumps in response to xenobiotic compounds such as DOX.15  
 
Our strategy to address the limitations of HAI/TACE and the associated systemic toxicity of 
the administered chemotherapeutic agent is to engineer a targeted polymer-drug conjugate that 
can accumulate in the tumor tissue upon parenteral administration, get internalized by hepatic 
cancer cells via receptor-mediated endocytosis, and achieve selective release of the loaded 
chemotherapeutic cargo to trigger cancer cell death. Specifically, we utilize generation 5 (G5) 
of poly-amidoamine (PAMAM) dendrimers as the core carrier for DOX (as a model 
chemotherapeutic drug) and N-acetylgalactosamine (NAcGal) as a targeting ligand for hepatic 
cancer cells. G5 poly-amidoamine dendrimers are water-soluble, spherical polymers that have 
128 terminal amine groups, allowing the functionalization of the surface with compounds like 
drugs, imaging agents, or genetic material.16,17 We recently reported that G5 dendrimers 
displaying NAcGal ligands in the beta-conformation (NAcGal) on the end of a 2 kDa 
poly(ethylene glycol) (PEG) brush and attached to the G5 surface via an acid-labile cis-aconitic 




NAcGal-PEGc-G5 conjugates escaped recognition by healthy hepatocytes and liver 
macrophages18,19 by targeting the asialoglycoprotein receptor (ASGPR) overexpressed on 
hepatic cancer cells.20,21 Upon internalization via receptor-mediated endocytosis, the cis-
aconityl linkages are hydrolyzed in the acidic endosomes resulting in the shedding of the PEG 
brush and release of the G5 carrier into the cytoplasm via their endosomolytic activity mediated 
by the proton sponge effect.22 We reported the synthesis of aromatic azo-benzene linkers that 
incorporate a 1,6 self-eliminating electron cascade and utilized them to conjugate DOX to G5 
dendrimers.23 These aromatic azo-benzene linkers are substrates for azoreductase enzymes 
expressed by hepatic cancer cells, which mediates cancer cell-specific release of the conjugated 
cargo.23 We showed that changing the electron density surrounding the azo-linkage [L(x)] by 
modifying the substituents in X and Y positions allows us to modulate the affinity to 
azoreductase enzymes, tune DOX release, and impact the associated cytotoxicity.23 Namely, 
the L3 (X: N-CH3; Y: H) and L4 (X: N-CH3; Y: O-CH3) linkages exhibited amenable DOX 
release profiles that correlated with anticancer activity comparable to the toxicity of free DOX 
in hepatic cancer cells.23 
 
In this manuscript, we successfully conjugated DOX to G5 dendrimers via aromatic azo-linkers 
and grafted NAcGal-PEG via acid-labile cis-aconityl linkages to prepare two targeted G5-
DOX nano-conjugates. We conjugated DOX to G5 dendrimers via L3 and L4 aromatic azo-
linkers and attached NAcGal-PEGc chains to the G5 dendrimers to prepare P0 [(NAcGal-
PEGc)12.1-G5], P1 [(NAcGal-PEGc)16.6-G5-(L3-DOX)11.6], and P2 [(NAcGal-PEGc)16.6-G5-
(L4-DOX)13.4] (Figure 15). We investigated their biocompatibility to determine their potential 
as an intravenous therapy by quantifying their induction of hemolysis, platelet aggregation, and 
opsonization by serum proteins. We investigated their uptake by hepatic cancer cells, and the 




cytotoxicity of free DOX compared to P1 and P2, we employed metabolomics to quantify DOX 
release and identify the species released from P1 and P2 inside the cytoplasm. This 
investigation revealed a difference in intracellular species of DOX delivered by the three 
treatments, as well as a difference in the induced metabolic response (e.g. glycolysis, fatty acid 
oxidation, and tricarboxylic acid (TCA) cycle), as measured by targeted and untargeted 





conjugates will help evaluate their potential as a platform technology and as an alternative 




Figure 15. Strategy for targeted, enzyme-activated delivery of doxorubicin to hepatic cancer cells.  We 
functionalized G5 PAMAM dendrimers with N-acetylgalactosamine (NAcGal)-terminated PEG brushes 
attached to G5 via an acid-labile cis-aconitic (c) spacer to facilitate selective binding to the asialoglycoprotein 
receptor (ASGPR) overexpressed on hepatic cancer cells. We also attached doxorubicin (DOX) molecules via 
two different enzyme-sensitive linkages to form either (NAcGalβ-PEGc)16.6-G5-(L3-DOX)11.6 (P1) or 
(NAcGalβ-PEGc)16.6-G5-(L4-DOX)13.4 (P2) conjugates. After internalization into the cancer cell via receptor-
mediated endocytosis, P1/P2 conjugates shed the NAcGal-PEGc branches in the acidic endosome and 
undergo endosomal escape via the proton sponge effect. In the cytoplasm, the DOX linkages are selectively 
cleaved by hepatic azoreductase enzymes and release either DOX or DOX-related metabolites that are able to 




3.2 Materials and Methods 
3.2.1 Materials 
G5-(NH2)128 dendrimers with a diaminobutane core were purchased from Andrews 
ChemServices (Berrien Springs, MI) and purified by dialysis against deionized water using 
Slide-A-Lyzer dialysis cassettes (MWCO 10 kDa, Thermo Fisher Scientific, Rockford, IL) to 
remove imperfect dendrimers and debris. Doxorubicin-HCl was purchased from AvaChem 
Scientific (San Antonio, TX). N-acetylgalactosamine, 4-pentynoic acid, pyridine, 
trimethylphosphine solution (1.0 M in THF), triethylamine (TEA), acetic anhydride (Ac2O), 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloric acid (EDC.HCl), benzotriazol-1-
ol (HOBt), trifluoroacetic acid (TFA), bathophenonthroline sulfonated sodium salt (SBP), 
copper bromide (CuBr), anhydrous dimethylsulfoxide (DMSO), anhydrous dichloromethane 
(DCM), anhydrous dimethylformamide (DMF), anhydrous tetrahydrofuran (THF), cis-aconitic 
anhydride (cis-Ac), and bovine serum albumin (BSA) were purchased from Sigma-Aldrich Inc. 
(St. Louis, MO). Trimethylsilyl trifluoromethanesulfonate (TMSOTf), N,N-diisopropyl ethyl 
amine (DIPEA), camphor sulphonic acid (CSA), sodium azide (NaN3), sodium ascorbate,  and 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) were 
purchased from Across Organics Chemicals (Geel, Belgium). N-hydroxysuccinimide-
poly(ethylene glycol)-Boc (2 kDa) was purchased from JenKem Technology USA Inc (Plano, 
TX). 2-{2-(2-Chloroethoxy)ethoxy}ethanol was purchased from TCI America (Portland, OR). 
Dialysis cassettes (MWCO 1–10 kDa) were purchased from Thermo Fisher Scientific 
(Rockford, IL). Minimum essential medium (MEM), OPTI-MEM reduced serum medium, 
fetal bovine serum (FBS), 0.25% trypsin/0.20% ethylenediaminetetraacetic acid (EDTA) 
solution, phosphate buffered saline (PBS), penicillin/streptomycin/amphotericin solution, 
sodium pyruvate, minimum non-essential amino acid (NEAA) solution, and 0.4% trypan blue 




3.2.2 Spectra for Synthesis of Conjugates  
Complete NMR and time-of-flight matrix-assisted laser desorption/ionization (MALDI-TOF) 
spectra confirming the structural identity and composition of NAcGal-cPEG-G5-L(x)-DOX 
(P1 and P2) conjugates can be found in Appendix A. Control particles were either purchased 
commercially (unmodified, cationic G5-(NH2)128 dendrimers) or synthesized according to our 
established protocols18,24 (acetylated G5 (G5-(Ac)128) and non-DOX-loaded (NAcGal-
PEGc)12.1-G5 conjugates (P0)). 
 
3.2.3 Synthesis of NAcGal-cPEG-G5-(NH2)-alkyne 
We chose a similar approach to our previously published strategies in order to synthesize 
PEGylated, NAcGal-targeted G5 conjugates (Figure 16).19,23 Briefly, D-galactosamine was 
treated with Ac2 and Py to obtain D-galactopentaacetate (1), which was treated with TMSOT 
in DCM to obtain an oxazolidine derivative (compound 2). The oxazolidine was reacted with 
an alcohol (compound 3) in the presence of D-10-CSA in DMSO at 40 oC to yield compound 
4. The azide functional group of compound 4 was reduced to an amine with Me3P and THF to 
obtain compound 5, which facilitates coupling to the hetero bi-functional PEG with an NHS-
activated COOH group. This peptide coupling was facilitated by EDC.HCl, HOBt, and DIPEA 
in DMF to obtain a PEG derivative (6) having NAcGalβ at one end and on the other end a Boc-
protected NH2. The Boc group was deprotected by acid hydrolysis using TFA and DCM to 
unmask the terminal amine group (7), which was reacted with cis-aconitic anhydride to form 




methanol to deprotect the O-acetate groups from galactosamine to obtain acid 9. We attached 
NAcGal-functionalized NAcGalβ-PEG chains (9) to G5 by reacting the cis-aconitic acid at the 
PEG end with alkyne-G5-NH2 (10), which was synthesized via a peptide coupling reaction 
between G5-(NH2)128 dendrimers and 4-pentynoic acid in the presence of PyBOP and DIPEA 
in DMSO. The primary amine groups of G5 form peptide bonds with cis-aconityl acids in the 
presence of EDC.HCl and HOBt in 6.0 pH phosphate buffer solution to obtain conjugate 11 
(Figure 16).  
 
3.2.4 Click coupling of L(x)-DOX Conjugates 
We synthesized NAcGal-cPEG-G5-L(x)-DOX conjugates by using a modified version of a 
standard click coupling procedure between conjugate 11 and L3/L4-DOX linkages following 
published protocols (Figure 16).23 In brief, sodium ascorbate, bathophenonthroline sulfonate 
sodium salt (SBP), and Cu (I) were dissolved in 3 mL of a THF:water mixture (1:1) and bubbled 
with argon for 10 minutes to obtain an oxygen-free catalyst solution. This solution was heated 
to 75 °C for 3-4 minutes, resulting in a change in solution color to brick red, and then cooled 
to room temperature. In a separate flask, compound 11 (1 equivalent) and L3-DOX or L4-DOX 
(12 equivalents) were dissolved in a THF:water mixture (1:1) and bubbled with argon for 10 
minutes. The catalyst solution was then added to this flask by a syringe under argon gas. The 
whole mixture was stirred slowly (~400 rpm) in the dark for 48 hours at room temperature. The 
reaction mixture was then purified by dialysis against deionized water (10kDa MWCO) for 2 
days to obtain pure [(NAcGal-PEGc)16.6-G5-(L3-DOX)11.6] (P1) or [(NAcGal-PEGc)16.6-G5-
(L4-DOX)13.4] (P2) conjugates dispersed in DI water (Figure 16). To obtain the concentration 
of these conjugates, we lyophilized 1 mL of the particle solution and weighed the amount of 





i) Synthesis of (2R,3R,4R,5R,6R)-5-acetamido-2-(acetoxymethyl)-6-(2-(2-(2-
aminoethoxy)-ethoxy)-ethoxy)tetrahydro-2H-pyran-3,4-diyl diacetate (5) 
 
ii) Synthesis of NAc-Gal-PEG-CisAc (9) 
 
Figure 16. Synthesis of P1 and P2 conjugates. To achieve NAcGal-targeted, DOX-loaded nano-conjugates we 
first functionalized the G5 surface with 16.6 moles of NAcGal-targeted PEG brushes attached via an acid-labile 
cis-aconitic linkage. We then loaded either 11.6 moles of L3-DOX molecules or 13.4 moles of L4-DOX molecules 
via click-coupling to achieve P1 and P2, respectively. P1 and P2 particles have hydrodynamic diameters of 6.02 




iii) Synthesis of G5-alkyne and its coupling to NAcGal-PEG-CisAc 
 
 







3.2.5 Characterization of P1 and P2 Conjugates 
We measured the particle size of the nanoparticle formulations by dynamic light scattering 
(DLS) using a 90Plus particle size analyzer (Brookhaven Instruments, Holtsville, NY). The 
nanoparticle solution was diluted in DI water at 1:20 v/v with 10% tween 20 in order to limit 
nanoparticle aggregate formation. After sonication for 20 minutes, P1 and P2 conjugates were 
sterile-filtered through syringe filters with a pore size of 800 nm and warmed to 37 ℃ before 
measurements. Raw distribution data was plotted in Graphpad Prism software and fit using a 
Gaussian curve, with the mean being taken as the particle size for that replicate. The average 
of three separate replicates was taken to find the mean particle size ± standard error of the mean 
(SEM). We also determined the zeta potential of the conjugates using a 90Plus Zeta Potential 
Analyzer (Brookhaven Instruments, Holtsville, NY). Particle formulations were dissolved in 
DI water at 1:20 v/v and warmed to 37 ℃ before analysis. The average of three separate 
replicates was taken to find the mean zeta potential ± SEM. 
 
3.2.6 Hemolysis Assay 
We measured the extent of erythrocyte lysis caused by P1 and P2 conjugates using the RBCs 
hemolysis assay.25,26 Briefly, we collected fresh blood from healthy human volunteers 
following IRB-approved protocols into EDTA-coated tubes and immediately centrifuged them 
at 3000 RPM for 5 minutes to precipitate out the red blood cells (RBCs). The supernatant was 
removed, and a 0.15 M NaCl wash solution was used to bring the RBCs up to the initial volume 
of blood. The sample was spun again at 3000 RPM for 5 minutes, the supernatant removed, 
and the RBCs resuspended to the original volume. This cycle was repeated a third time before 
splitting the resuspended RBCs into three different EDTA-coated centrifuge tubes. These tubes 
were centrifuged at 3000 RPM for 5 minutes, and the level of the fluid was marked before 




solution was diluted 1:9 (v/v) in PBS to create the working stock solution. 200 µL of this 
working stock solution was added to each test tube, and treatment solutions of 1x PBS (negative 
control), DI water (positive control), 240 nM naked G5-(NH2)128 dendrimers, or 240 nM G5-
equivalent of either P1 (2.78 µM DOX) or P2 (3.22 µM DOX) conjugates were added to the 
wells to achieve a final volume of 1mL. The samples were incubated for 1 hour at 37 ℃ and 
then mixed by inversion and centrifuged at maximum speed for 5 minutes. Finally, 200 µL of 
the supernatant was collected and added to 96-well plates, and the excitation of hemoglobin 
was measured by UV (λex=541 nm). The raw data was normalized to PBS values (which is 
non-hemolytic due to its buffering capacity27) and presented as a percentage of hemolysis 
caused by DI water (which causes hemolysis through osmotic swelling and rupture of RBCs27). 
Results are presented as the mean of three replicates ± SEM.  
 
3.2.7 Platelet Aggregation  
We evaluated the interaction of platelets with P1 and P2 conjugates using light transmission 
platelet aggregometry according to published protocols.26 Briefly, fresh blood was isolated 
from anesthetized C57BL/6 mice via cardiac puncture using 20 gauge needles flushed with 
3.2% sodium citrate and was diluted 1:1 v/v with HEPES Tyrode (HT) buffer and centrifuged 
at 50xg for 10 minutes at room temperature. The supernatant was collected as platelet rich 
plasma (PRP), and the precipitate was resuspended in HT buffer up to the original volume and 
spun again at 50xg for 10 minutes at room temperature. The supernatant was collected and 
added to the original PRP fraction, while the precipitate was resuspended with HT buffer to the 
original volume. After spinning the suspension at 1200xg for 10 minutes at room temperature, 
the supernatant was collected into a separate tube as the platelet poor plasma (PPP) fraction. 
We mixed either naked G5-(NH2)128 dendrimers, P0, P1, or P2 conjugates with 500 µL of PRP 




monitored platelet aggregation over 10 minutes using the Aggro-Link data reduction system 
(Chrono-log Corporation, Havertown, PA). We also measured the platelet aggregation of 500 
µL PRP incubated with PBS or 10 µM adenosine diphosphate (ADP) as negative or positive 
controls, respectively. Results are presented as the mean of three replicates ± SEM. 
 
3.2.8 Opsonization by Serum Proteins  
We also assessed the extent of particle opsonization by measuring the binding of bovine serum 
albumin (BSA) as a model protein to P1 and P2 conjugates as a function of particle composition 
and time, based on our published protocols.18 Briefly, we prepared G5-(NH2)128, (NAcGal-
PEGc)12.1-G5 (P0), P1, and P2 conjugates in warmed PBS (pH 7.4) at a particle concentration 
of 241 nM. Conjugates were mixed with BSA (0.2 mg/mL) in a quartz cuvette and incubated 
at 37 ℃ for 60 minutes. The fluorescence of BSA tryptophan residues (λex: 280 nm; λem scanned 
between 300-400 nm) was measured at time zero (I0) and at different incubation times (I) up 
to 60 minutes in a QM4 fluorescence spectrophotometer (Perkin-Elmer, Waltham, MA). We 
divided the initial BSA fluorescence (I0) by the measured fluorescence at different timepoints 
(I) to evaluate the extent of BSA quenching, as an indication of BSA binding to the particle’s 
surface, indicated by I0/I > 1. BSA adsorption to each particle was measured in triplicates and 
presented as the mean I0/I ± SEM. Statistical comparisons were made between the I0/I values 
measured for conjugates and that observed with BSA alone using student’s t-test. 
 
3.2.9 Cell Culture  
HepG2 and Hep3B cells were cultured in T-75 flasks using MEM supplemented with 10% 
FBS, 1% antibiotic-antimycotic, 1% sodium pyruvate, 1% non-essential amino acids, and 1 




humidity and medium was changed every 48 hours. The cells were passaged at 80-90% 
confluency using a 0.25% trypsin/0.20% EDTA solution.  
 
3.2.10 Uptake of P1 and P2 conjugates into Hepatic Cancer cells  
The internalization of P1 and P2 conjugates into HepG2 and Hep3B cells was measured as a 
function of particle composition and concentration via flow cytometry. Briefly, 250,000 
HepG2 or Hep3B cells were seeded in 24-well plates and allowed to adhere overnight. 
Treatment solutions of P1 or P2 conjugates (7-285 nM G5 concentration; 100-4000 nM 
NAcGal concentration) were prepared in OPTI-MEM and then incubated with the cells for 2 
hours at 37 ℃. We used free DOX treatments for comparison and included them at 
concentrations equivalent to the DOX loaded onto either P1 or P2 conjugates. We also used 
cells treated only with OPTI-MEM as a control. After removing the treatment medium and 
washing the cells with warmed PBS twice, the adherent cells were removed from the plates 
using a 0.25% trypsin/0.20% EDTA solution and then suspended in fresh culture medium. The 
cells were then transferred to flow cytometry tubes, centrifuged at 1000 RPM for 5 minutes at 
4℃, kept on ice, and then resuspended immediately before analysis. Samples were analyzed 
by flow cytometry using the intrinsic fluorescence of DOX (λex: 488 nm; λem: 613 nm) on a 
Beckman Coulter Cyan ADP instrument provided by the Flow Cytometry Core at the 
University of Michigan (Ann Arbor, MI). Data is presented as the mean ± SEM for n=4 
replicates, and we used untreated cells in blank OPTI-MEM as our negative control.  
 
3.2.11 Cytotoxicity of P1 and P2 conjugates  
The cytotoxicity of P1 and P2 conjugates against HepG2 and Hep3B cells was measured as a 
function of DOX concentration via the clonogenic survival assay.23 Briefly, 250,000 HepG2 or 




DOX, P1, or P2 conjugates were prepared at equivalent DOX concentrations (1-10,000 nM 
DOX) in OPTI-MEM at a total volume of 5 mL and incubated with the cells for 72 hours. After 
the treatment period, the cells were washed twice with PBS, trypsinized with 0.25% 
trypsin/0.20% EDTA solution, collected into tubes, and centrifuged at 1000 RPM for 5 
minutes. The supernatant was then aspirated and the cells were resuspended in 1 mL of fresh 
medium and kept on ice during counting. The cell count was established manually using a 
hemocytometer and were seeded into 6-well plates at either 1000 or 2000 cells per well in 3 
mL of medium, with three replicates for each cell count. The cells were allowed to sit 
undisturbed for 14 days at 37 ℃ and 5% CO2. The medium was then removed and the cells 
were washed with PBS once. The colonies were fixed and stained using 1 mL of a 
methanol/glacial acetic acid (75/25 v/v) solution with 0.04% w/v trypan blue and incubated for 
15-30 minutes. The stain was then aspirated and the plates were allowed to dry uncovered for 
20 minutes. The stained colonies were counted by visual inspection. Plating efficiency (PE) 
was determined by dividing the number of control untreated colonies resulting from the known 
number seeded cells (1000 or 2000). The surviving fraction of treated cells was then determined 
by dividing the number of counted colonies by the PE. The surviving fraction across all six 





3.2.12 Metabolomics analysis  
To measure the intracellular release of either free DOX or P1/P2 conjugates as well as the 
associated metabolic response upon treatment, we applied metabolomics analysis on treated 
cells, as described previously.28–30 For treatment, 1x106 HepG2 cells were seeded in 6-well 
plates and allowed to adhere and double in population over 24 hours. Treatment solutions of 
free DOX (10 µM) or P1 and P2 (10 µM DOX-equivalent) in OPTI-MEM were incubated with 
the cells for 12 hours. After treatment, cell plates were rinsed with 200 mM ammonium acetate 
and quenched with liquid nitrogen. Metabolites were extracted with ice cold 8:1:1 
methanol:chloroform:water and assayed by high performance liquid chromatography coupled 
to time-of-flight mass spectrometry (HPLC-TOF-MS). For polar metabolites, chromatographic 
separation was performed using an Agilent Technologies (Santa Clara, CA) 1200 HPLC system 
equipped with a Phenomenex (Torrance, CA) Luna NH2 HPLC column (1.0 mm inner bore × 
150 mm long and packed with 3 μm particles). Mobile phase A was 100% acetonitrile (ACN) 
and mobile phase B (MPB) was 100% 5 mM ammonium acetate adjusted to pH 9.9 with 
ammonium hydroxide. The gradient started at 20% MPB and was ramped to 100 % MPB over 
20 minutes, held for 5 minutes, and returned to 20% MPB for an additional 7 minutes. 
Doxorubicin and its metabolites were separated using an Acquity UPLC® BEH C18 column 
(2.1 × 100 mm, 1.7 μm) and a 2.1 × 5 mm VanGuard™ pre-column using the following 
conditions: mobile phase A of 0.1 % formic acid and mobile phase B of acetonitrile with 0.1% 
formic acid. The gradient was started at 5% B and progressed to 100% B in 25 minutes followed 
by being held at 100% B for 10 minutes before reconditioning the column back to 5% B for 10 
more minutes.   
 
For isotope tracer studies, after the same treatment for 12 hours by either free DOX, P1, or P2, 




contained 10 mM U-13C glucose and 100 µM oleate while the other contained 10 mM glucose 
and 100 µM U-13C oleate. Cells were incubated for 4 hours before being quenched and 
analyzed for metabolites as described above.  
 
3.2.13 Data analysis and statistics  
Targeted analysis was performed to measure specific metabolites involved in central carbon 
metabolism such as glycolysis and TCA cycle intermediates. Untargeted analysis was 
performed using XCMS online.31 Features that showed substantial differences were manually 






3.3 Results and Discussion 
 
3.3.1. Synthesis and Characterization of P1 and P2 Conjugates 
We synthesized G5 dendrimers functionalized with both NAcGal-PEGc targeting moieties as 
well as L(x)-DOX linkages by combining our previous synthetic methodologies18,23 with minor 
modifications (Figure 16). We confirmed that conjugation of 16.6 NAcGal-PEGc units onto 
G5 surface by NMR and MALDI-TOF (Figure A1). This corresponds to 13.0 mole% 
PEGylation of the dendrimer surface, which provides sufficient packing (>5 mol%) to trigger 
PEG chains to adopt a “brush” conformation instead of the “mushroom” regime.32,33 This brush 
conformation enables PEG chains to completely cover the particle’s surface and shield it from 
non-specific adsorption of serum proteins, which mediates the particle’s clearance by the 
reticuloendothelial system (RES) (i.e. liver, lungs, spleen).32–34 
 
The PEGylated G5 (compound 11) was coupled with L3-DOX or L4-DOX conjugates via click 
chemistry following published protocols.23 Starting with the same precursor molecule 
(compound 11) ensured equal density of NAcGal targeting ligands per G5 particle before 
loading of the chemotherapeutic agent (DOX). We achieved similar DOX loading in P1 
(compound 12) [(NAcGal-PEGc)16.6-G5-(L3-DOX)11.6] conjugates and P2 (compound 13) 
[(NAcGal-PEGc)16.6-G5-(L4-DOX)13.4] reaching 11.6 moles and 13.4 moles per G5, 
respectively (Figure 16). We previously established that loading of 16 DOX molecules per G5 
(i.e. 12.5 functionalization of surface amine groups) is the maximum capacity to maintain the 
aqueous solubility of G5-DOX conjugates.23 Similarly, P1 and P2 conjugates exhibited 





We measured the size of our conjugates using dynamic light scattering (DLS), identifying that 
P1 and P2 have hydrodynamic diameters (HD) of 6.02 ± 0.28 nm and 6.39 ± 0.40 nm, 
respectively (Table 2). This size places P1 and P2 conjugates in the ideal size range that will 
enable them to surpass renal filtration from the blood (HD < 5nm35,36), and thus extends their 
circulation time within the bloodstream. We also measured the particle size of acetylated G5 
(G5-(Ac)128) and non-DOX-loaded P0 conjugates to be used as controls (Table 2). We 
measured the molecular weights of P1 and P2 using MALDI-TOF, which are 84,572 and 
85,553 Da, respectively (Table 2; Figure A2 and A3). This range of MWs places P1 and P2 
conjugates well above the molecular weight cut-off of 40 kDa required to escape renal 
clearance. This MW range also allows them to exploit the enhanced permeation and retention 
(EPR) effect,37–40 indicating that during circulation they can extravasate into the tumor 
interstitium due to its leaky vasculature and be retained there due to the lack of a proper 
lymphatic drainage system. Finally, we measured the zeta potential of P1 and P2 conjugates 
which were -0.63 ± 0.28 mV and -0.46 ± 0.23 mV, respectively. The neutral surface charge is 
important to ensure biocompatibility of PAMAM dendrimers,41 and also guarantees that the 












G5-(Ac)128 G5-(Ac)128 34,200 5.59 ± 0.56 1.22 ± 1.44 
P0  (NAcGalβ-PEGc)12.1-G5 59,171 7.43 ± 0.34 -0.30 ± 0.21 
P1  (NAcGalβ-PEGc)16.6-G5-(L3-DOX)11.6 84,572 6.02 ± 0.28 -0.63 ± 0.28 




3.3.2 Biocompatibility of P1 and P2 Conjugates 
We measured the extent of hemolysis induced by P1 and P2 conjugates in the presence of 
freshly isolated red blood cells (RBCs) by quantifying the amount of released hemoglobin from 
ruptured RBCs after a 1 hour incubation at 37 ºC, and compared this behavior to naked, non-
PEGylated G5-(NH2)128 dendrimers (Figure 17, Panel A). Results are presented as a 
percentage of hemolysis caused by distilled (DI) water, which is considered to cause 100% 
hemolysis through osmotic swelling and rupture of RBCs.27 Unmodified G5-(NH2)128 
dendrimers exhibited complete hemolysis (98.7 ± 3.1%), which can be attributed to membrane 
destabilization caused by the cationic quaternary ammonium ions that develop at the amine-
terminated surfaces of PAMAM dendrimers.43,44 In comparison, P1 and P2 completely 
suppressed hemolysis, verifying the established ability of nanoparticle PEGylation45–47 and 
neutral surface charge48 to prevent membrane destabilization and rupture of RBCs. 
 
To ensure both P1 and P2 do not induce platelet aggregation in the bloodstream, we used light 
transmission aggregometry to measure the activation of platelets in the presence of either 
particle, following published protocols26 (Figure 17, Panel B). After drawing fresh blood and 
isolating the platelet rich plasma (PRP) and platelet poor plasma (PPP) fractions, we added 
either P1 or P2 to the PRP fraction and compared the resulting aggregation over 10 minutes to 
that caused by naked G5-(NH2)128 dendrimers or P0 conjugates at an equivalent G5 
concentration. Results show that the positive control of adenosine diphosphate (ADP) caused 
the highest amount of platelet aggregation (26.3 ± 5.36%), which is not surprising due to its 
established role in platelet activation.49,50 The effect of PEGylation and surface charge of G5 
dendrimers is evident when comparing the 9% platelet aggregation caused by unmodified, 
cationic G5-(NH2)128 dendrimers versus the 0% aggregation caused by the PEGylated P0 




despite the addition of L(x)-DOX molecules (thereby imparting hydrophobicity to the P0 
skeleton), PEGylation takes precedence and is able to protect the conjugates from activating 
platelets. 
 
The advantage of PEGylation and its precedence over the addition of hydrophobic L(x)-DOX 
linkages is further evident in the opsonization of P1 and P2 conjugates. Opsonization, or the 
fouling of a surface by nonspecific protein adsorption during plasma circulation, leads to rapid 
shuttling of nanoparticles to organs of the RES within minutes of intravenous delivery. As 
such, opsonization is one of the largest barriers facing nanomedicine strategies.51–53 To 
approximate the extent of opsonization of our NP formulations, we measured the binding of 
bovine serum albumin (BSA) to their surfaces using the change in intrinsic fluorescence of 
BSA, which is quenched when the protein binds to the NP surface.18 In particular, we 
investigated the adsorption of BSA to P1 and P2 conjugates in comparison to G5-(NH2)128 
dendrimers and P0 conjugates at equal G5 concentration (Figure 17, Panel C). Results show 
that the fluorescence intensity of free BSA remained relatively unchanged during the 60-minute 
incubation period and thus was used as the negative control. Cationic, G5-(NH2)128 dendrimers 
exhibit high (4-7 folds) fluorescence quenching, reaching an I0/I value of 7.18 ± 1.90 at the end 
of the incubation period. This is expected given the high surface charge of the particle due to 
the 128 free terminal amines on its surface. In comparison, P0 conjugates exhibit no 
fluorescence quenching, which is not surprising given its neutral surface charge imparted by 
the capping (acetylation) of the free amine groups as well as the hydrophilic nature of the PEG 
that is able to prevent protein adsorption to the particle surface.18 As mentioned, neither P1 nor 
P2 conjugates exhibited any fluorescence quenching, suggesting that they are able to escape 




acetylated nor functionalized, yet the 16.6 moles of 2 kDa PEG chains with hydrophilic 
NAcGal ligands are able to cover their surfaces and mask them from protein recognition.  
 
Taken together, the high in vitro biocompatibility observed in these results validates the utility 
of PEGylation, water-soluble polymers, neutral surface charge, and functionalization with 
hydrophilic NAcGal targeting ligands for intravenous drug delivery systems. Results suggest 
that P1 and P2 conjugates will be able to overcome rapid clearance from the bloodstream and 
can be retained long enough in circulation to exploit the EPR effect and achieve high 
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Figure 17. Biocompatibility of P1 and P2 conjugates. We evaluated the biocompatibility of P1 and P2 
conjugates by measuring the extent of hemolysis (A), platelet aggregation (B), and opsonization by serum proteins 
(C). Results show that P1 and P2 induce no hemolysis in red blood cells compared to PBS controls (A), and they 
also do not cause aggregation of platelets (B). Further, opsonization studies show that P1 and P2 are able to escape 
recognition by serum proteins due to their neutral charge and PEG corona (C). Results are presented as the means 
of at least three replicates ± SEM. Two-tailed Student’s t-tests were used to determine the statistical difference 
between each treatment and the positive control of the respective study (DI H20, ADP, or G5-(NH2)128, 
respectively), which is denoted by * for p<0.05, ** for p<0.01, and *** for p<0.001. 
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3.3.3 Uptake of P1 and P2 conjugates into hepatic cancer cells 
We were interested to see if the addition of L(x)-DOX molecules to NAcGal-targeted, 
PEGylated G5 dendrimers would be able to retain affinity for hepatic cancer cells. Therefore, 
we measured the internalization of P1 and P2 conjugates into HepG2 or Hep3B cells over 2 
and 24 hours as a function of concentration via flow cytometry. We previously established that 
the ideal concentration range of NAcGal ligands is 10-4000 nM in order to achieve 
controllable labeling and internalization of G5-based conjugates into HepG2 and Hep3B 
cells.18 Therefore, we incubated P1 and P2 conjugates over this NAcGal concentration range, 
which is equal to 0.6-240 nM of P1/P2 conjugates. We used the intrinsic fluorescence of DOX 
to measure the number of cells labeled by P1/P2 conjugates and we included equivalent 
concentrations of free DOX to compare the internalization of free DOX to that delivered by 
G5 carriers. It is important to note that we accounted for the slight difference in DOX-loading 
in P1 and P2 by adjusting the concentration of free DOX used in uptake studies to allow 
accurate assessment of the particle’s internalization (Figure 18).  
 
Results show P1 and P2 conjugates are internalized into hepatic cancer cells in a concentration-
dependent manner, which is higher than the internalization of equivalent concentrations of free 
DOX (Figure 18, Panels A & C). In HepG2 cells, at a NAcGal concentration of 100 nM, P1 
conjugates fluorescently-label 14% of cells and P2 conjugates label 39% (Figure 18, Panel 
A). Free DOX, on the other hand, at both equivalent concentrations (46 nM DOX for P1, or 61 
nM for P2) only labels 2% of HepG2 cells. As the NAcGal concentration increased to 500 
nM, P2 conjugates virtually label all cells, while free DOX only labels 2%. Similarly, P1 
reaches 97% labeling of cells at a NAcGal concentration of 1000 nM, while the equivalent 
incubation of free DOX only labels 43% of cells. At the highest concentration of 4000 nM, all 




folds more Hep3B cells than free DOX and P2 labeled up to 78-folds more cells (Figure 18, 
Panel C). We also investigated the uptake of P1 and P2 conjugates into a control cell line, SK-
Hep1, which is ASGPR-deficient.54–56 Results show that these cells do not bind or internalize 
P1/P2 conjugates, demonstrating that uptake of the conjugates into HepG2 and Hep3B cells is 
ASGPR-mediated (Figure A4). Further, we normalized the relative fluorescence intensity of 
fluorescently-labeled HepG2 and Hep3B cells to that of untreated cells in order to measure the 
difference of intracellular DOX concentration between different formulations (Figure 4, Panels 
B & D).18,57,58 P1 and P2 conjugates achieved up to 6-folds increase in intracellular DOX 
concentration over the free drug incubation in HepG2 cells (Figure 4, Panel B). In Hep3B cells, 
P1 achieved up to 4-folds increase over free DOX while P2 achieved a 19-fold increase at the 
highest particle concentration (Figure 18, Panel D).  
 
These results indicate that the higher fluorescent labeling and intracellular fluorescence of 
DOX mediated by P1 and P2 conjugates in both HepG2 and Hep3B cells highlights the 
advantage of active targeting through NAcGal-facilitated receptor endocytosis. We previously 
established that the display of NAcGal ligands at the end of a PEG brush was able to achieve 
selective internalization of G5 dendrimers into hepatic cancer cells, and escaped recognition 
by non-target cells, namely healthy hepatocytes and liver macrophages (i.e. Kupffer cells).18 It 
is evident that P1 and P2 conjugates maintain uptake capability into hepatic cancer cells, 
despite the addition of L(x)-DOX molecules, and in terms of percentage of cells labeled and 
intracellular DOX fluorescence, they exhibit a clear advantage over passive diffusion of free 
DOX.  In addition, it is important to note that P1 and P2 conjugates exhibit higher cell labeling 
and higher intracellular concentration in Hep3B cells than HepG2 cells almost universally, 
achieving a maximum of 5.4-folds higher intracellular fluorescence for P2 conjugates at the 




in expression of ASGPR between cell lines, which has been confirmed to be greater for Hep3B 

















































































Figure 18. Uptake of P1 and P2 conjugates into HepG2 and Hep3B cells. We measured the internalization of 
P1 and P2 conjugates into hepatic cancer cells in comparison to free DOX via flow cytometry. P1 and P2 were 
incubated at NAcGal concentrations of 10-4,000 nM for 2 hours at 37ºC, and their equivalent DOX-loaded 
concentrations were used for free DOX incubations, as shown in the table. Results show that both P1 and P2 label 
a significantly higher number of cells than their free DOX counterparts (A, C), and this leads to as high as a 38-
fold increase in intracellular fluorescence (B, D). Results are presented as the means of three replicates ± SEM. 
Two-tailed Student’s t-tests were used to determine the statistical difference between each treatment and is 




3.3.4 Cytotoxic Activity of P1 and P2 conjugates 
We incubated free DOX, P1, and P2 conjugates with HepG2 and Hep3B cells over 72 hours 
and used the clonogenic survival assay to measure cell survival following our published 
protocols.23 As expected, free DOX induced an exponential decrease in HepG2 cell survival 
with increasing DOX concentration, achieving an IC50 (median concentration of drug required 
to inhibit cell growth by 50%) of 24.8 ± 1.2 nM (Figure 19, Panel A). This IC50 is comparable 
to our established results and falls in the expected range of DOX toxicity in HepG2 cells for 
these treatment conditions.61,62 We measured the intrinsic toxicity of P0 and results show that 
it has insignificant toxicity within the investigated concentration range with IC50 > 10,000 nM 
(Figure 19, Panel A). P1 and P2 conjugates exhibited increasing toxicity with increasing DOX 
concentration achieving IC50 values of 1414.0 ± 1.4 and 237.8 ± 1.2 nM, respectively (Figure 
19, Panel A). It is evident that P2 has a higher activity than P1 indicated by its IC50 value that 
is 6-folds lower than that of P1. This is expected given that it has 1.8 more DOX moles/G5 
carrier and the higher affinity for azoreductase enzymes responsible for cleavage of the linkage 
and release of DOX as established in previous reports.23 Results in Hep3B cells follow similar 
trends (Figure 19, Panel B) with toxicity increasing exponentially with DOX concentration, 
while the carrier P0 again shows insignificant toxicity with an IC50 ~ 10,000 nM (Figure 19, 
Panel B). Consistent with previous results,23,61 Hep3B cells are more sensitive to treatment 
than HepG2 cells, with free DOX, P1, and P2 having lower IC50 values of 18.6 ± 1.3, 78.5 ± 
1.1, and 145.5 ± 1.25 nM, respectively. In addition to the higher intrinsic sensitivity to 
treatment, our internalization results (Figure 19, Panels B and D) also showed that P1 and P2 
conjugates achieve higher intracellular concentrations in Hep3B over HepG2 cells, and thus 
higher intracellular DOX concentrations may be contributing to the higher toxicity. Further, 
similar to what we observed in our previous results,23 P1 particles are more cytotoxic than P2 




azoreductase identity and expression between cell lines, but further studies are required to test 
this hypothesis. Nevertheless, these results verify that P1 and P2 conjugates are able to exhibit 
toxicity towards hepatic cancer cells that is comparable to free DOX and this toxicity can be 































































































































Figure 19. Anticancer activity of P1 and P2 conjugates against HepG2 and Hep3B cells. 
We measured the cytotoxicity profiles of P1 and P2 compared to free DOX against hepatic 
cancer cells after a 72-hour treatment via the clonogenic survival assay. Results show that in 
HepG2 cells (A), free DOX, P1, and P2 exhibit IC50 values of 24.8 ± 1.19, 1414.0 ± 1.42, and 
237.8 ± 1.20 nM, respectively. In Hep3B cells (B), IC50 values were 18.6 ± 1.26, 78.5 ± 1.1, 
145.5 ± 1.3 nM, respectively. The non DOX-loaded P0 carrier showed no (≥10,000 nM) 
toxicity in either cell line. Results are presented as the means of three replicates ± SEM. 
 
3.3.5 Intracellular release of DOX from P1 and P2 conjugates via metabolomics studies 
The differences in cytotoxicity between free DOX, P1, and P2 particles prompted us to 
elucidate the intracellular fate of DOX being delivered by each treatment. We employed 
metabolomics to determine the chemical fingerprints of DOX delivered by P1 and P2 
conjugates intracellularly in comparison to DOX delivered freely in solution. We chose a 
treatment time of 12 hours to provide a snapshot of metabolic alteration induced by the DOX-
loaded conjugates without causing substantial cell death commonly observed after 24 
hours.63,64 Both intracellular and extracellular metabolites were analyzed by LC-MS (Figure 
20).  Results show that treatment of HepG2 cells for 12 hours with free DOX results in detection 
of the parent DOX ([M-H]‾: 542.1710) and 7-deoxydoxorubicinone ([M-H]‾: 395.0587), which 
is its deglycosylated form (Figure 20, Panel A). This conversion has been shown to be 
mediated by a combination of cytochrome P450s and NADH dehydrogenase,65,66 which are 
both cytosolic enzymes. 
 
Although P1 and P2 conjugates exhibited significant cytotoxicity towards HepG2 cells (Figure 
19), results show a significantly lower amount of the parent DOX present intracellularly from 
these treatments (Figure 20, Panel A). This can be attributed to slow release of DOX molecules 
from P1 and P2 conjugates, which dramatically minimized intracellular concentration of parent 
DOX at this 12-hour time point. Using untargeted metabolomics, we found both P1 and P2 




backbone of DOX but only one that matched the exact mass ([M-H]‾: 335.0561) of a known 
DOX metabolite recently described by Kaushik et al.67 (Figure 20, Panel B). These molecules 
are similar in exact mass to tetracenomycin (TCM) compounds, which are structural isomers 
of DOX metabolites67 that are known to exhibit similar cytotoxicity via DNA intercalation, 
topoisomerase II inhibition, and generation of reactive oxygen species (ROS).68–70 Therefore, 
we chose TCM nomenclature to identify these metabolites. However, it is important to note 
that TCM compounds are less potent than the parent DOX, which is indicated by their higher 
IC50 values.
69 For example, Gan et al. reported an IC50 of 7.5 µM for TCM X in HepG2 cells 
compared to an IC50 of 1.6 µM for DOX.
69 The TCM F1 methylester analogue ([M-H]‾: 
379.0823) appeared in the intracellular extracts of P1- and P2-treated cells at similar quantities 
(Figure 20, Panel B), which indicates that this metabolite is generated from the P1/P2 
conjugates by intracellular enzymes. The second and most prominent metabolite identified 
from P1- ad P2-treated cells is TCM D1 ([M-H]‾: 335.0561), which results from the loss of an 
acetaldehyde group from TCM F1 methylester (Figure 20, Panel B). Free DOX treatments 
also generated the TCM D1 metabolite, which is not surprising given that it is a downstream 
metabolite of parent DOX after the loss of a glycoaldehyde group from 7-
deoxydoxorubicinone.67 However, the quantity of intracellular TCM D1 in free DOX-treated 
cells, is 9- and 4-folds lower than that observed in P1 (P<0.05) and P2 (P<0.01) treated cells, 
respectively (Figure 6, Panel B). Interestingly, the levels of TCM D1 inside HepG2 cells are 
significantly higher for P1 treated cells compared to those incubated with P2 (P<0.05) while 
the extracellular concentration of the same metabolite is reversed (i.e higher for P2 than P1, 
P<0.01). It is also important to note that TCM D1 molecules were generated when P1 and P2 
conjugates were incubated with PBS alone (data not shown), albeit at lower levels than those 
detected inside HepG2 cells. This suggests that introducing the drug with a nanoparticle might 




Additionally, since it is also common to see non-specific degradation pathways for free DOX 
molecules in buffers,71 it is possible that P1 and P2 conjugates are not completely devoid of 
this degradation either.  
 
The exact mechanism of intracellular release and metabolism of DOX delivered by P1 and P2 
conjugates that result in generation of TCM F1 and D1 molecules is still unclear. Earlier reports 
show that changing the enzyme responsible for releasing a therapeutic cargo from a polymer-
drug conjugate leads to recognizable difference in kinetics of drug release, drug metabolism, 
and associated intracellular activity. For example, Greco et al. observed stark differences in the 
release and activity of DOX against breast cancer cells when singly loaded onto a HPMA 
polymer or loaded in combination with aminoglutethimide (AMG) due to differences in the 
enzymes involved in drug release between the two HPMA-DOX conjugates.72 Similarly, we 
hypothesize that azoreductase enzymes responsible for DOX release from P1 and P2 
conjugates may impact not only the release kinetics but also intracellular metabolism of the 
released DOX molecules. Our current focus is on elucidating the mechanism of DOX 







Figure 20. Metabolomics identifies different DOX-related metabolites delivered by P1 and 
P2 conjugates. We employed metabolomics to determine the chemical fingerprints of DOX 
delivered by P1 and P2 conjugates in comparison to DOX delivered freely in solution after a 
12 hour treatment of HepG2 cells. Results show that free DOX generates two different 
metabolites: parent DOX ([M-H]‾: 542.1710) and its deglycosylated form, 7-
deoxydoxorubicinone ([M-H]‾: 395.0587) (A). P1 and P2 conjugates deliver other DOX-related 
metabolites, namely tetracenomycin analogues F1 methylester ([M-H]‾: 379.0823) and D1 ([M-
H]‾: 335.0561) (B). Intracellular and extracellular abundance of each metabolite is presented as 
the mean of three replicates ± SEM. Two-tailed Student’s t-tests were used to determine the 
statistical difference between P1 or P2 compared to free DOX (*) or between P1 and P2 (#), 




3.3.6 Effect of P1 and P2 conjugates on HepG2 metabolic pathways 
We extended our metabolomics analysis to measure the metabolic response induced by P1 and 
P2 conjugates compared to free DOX treatment using an untargeted metabolomics approach 
and also by determining relative flux using stable isotope tracers. Principle component analysis 
(PCA) of all features detected by untargeted analysis showed clear clustering within each 
treatment type and clear distinctions between each group, which indicates different metabolic 
profiles induced by each treatment (Figure 21, Panel A). Targeted analysis of major 
biochemical pathways such as central carbon metabolism showed clear distinctions between 
DOX-treated and P1/P2-treated cells (Figure 21, Panels B and C). Figure 21 Panel B 
identifies the differences in the presence of key markers of glycolysis and the tricarboxylic acid 
(TCA) cycle based on either DOX or P1/P2 treatment. Most notably, metabolites involved in 
glycolysis and the TCA cycle are reduced 2-4 folds in DOX-treated cells while they are almost 
all upregulated up to 2-folds greater in P1- and P2-treated cells. Similar metabolic changes 
induced by free DOX have been described before73,74 where glycolysis was reduced as well as 
protein, purine, pyrimidine, and glutathione biosynthesis. The inhibition of glycolysis most 
probably increased the oxidation of substrates other than glucose to increase ATP generation 
for cell survival after DOX damage.75 In comparison, P1 and P2 conjugates induced increases 
in markers of glycolysis such as fructose 1,6-bisphosphate and the TCA cycle intermediates 
such as citrate (Figure 21, Panel B). We hypothesize that the increase in glycolysis is a 
response to oxidative stress caused by the generation of ROS, a primary mechanism of DOX 
and DOX-metabolite toxicity.76,77 This is supported by several studies correlating increased 
glycolysis with oxidative stress and mitochondrial dysfunction.78–80 Wu and Wei in their work 
showed increased glycolytic flux was a result of oxidative stress in skin fibroblasts from 
patients with myoclonic epilepsy and ragged-red fiber (MERRF) syndrome, in an attempt to 




glycolysis and TCA cycle was a result of poor adaptation to ROS generated in amyotrophic 
lateral sclerosis (ALS) neuronal cells, and was a sign of neuronal death.79 Further, plasma from 
patients with Alzheimer’s disease, a neurodegenerative disorder associated with increased 
oxidative stress, caused mitochondrial dysfunction and increased glycolysis as a compensatory 
action, ultimately leading to a loss of cell viability, as studied by Jayasena et al.80 Therefore, 
our data may suggest that the delivery of TCM F1 and D1 moieties causes high oxidative stress 
leading to upregulation of glycolysis and the TCA cycle and may be the primary mechanism 
of toxicity observed with P1 and P2 conjugates. This also explains the 3- to 5-fold increase in 
oxidized glutathione (GSSG) present in P1/P2-treated cells (Figure 21, Panel B), which is 
normally upregulated to scavenge ROS.77 Further examination of ROS presence and 
mitochondrial function will elucidate whether this is indeed the phenomenon at play. 
 
To compensate for reduced glycolysis, it has been established that DOX-treated cells increase 
fatty acid oxidation upon treatment.81 To further investigate the effect of different substrates 
on the relative utilization of fatty acid and glucose, we applied the stable isotope tracer strategy. 
We treated cells with DOX, P1, or P2 for 12 hours, followed by a 4-hour incubation with 10 
mM U-13C glucose and 100 uM oleate or 10 mM unlabeled glucose with 100 uM U-13C oleate. 
We found reduced incorporation of 13C glucose in citrate and glutamate metabolites for free 
DOX-treated cells (Figure 21, Panel D), confirming the reduced glucose flux through 
glycolysis. On the other hand, citrate and glutamate enrichment was not altered by P1 and P2 
conjugates compared to control cells upon adding U-13C glucose. This suggests that P1/P2 
achieved minimal inhibition on glucose utilization. Further, free DOX shifted the TCA cycle 
substrate utilization towards fatty acid oxidation instead of glucose oxidation, as expected. This 
is evident by the increased incorporation of 13C carbons from oleate in citrate and glutamate 




the control or P2 conjugates but less than free DOX (Figure 21, Panel E). While the reason 
for the differences in fatty acid oxidation caused by either P1 or P2 remains to be identified, it 
is evident that the metabolic response induced by the conjugates is significantly different from 
that caused by free DOX, particularly in terms of the effect on glucose and fatty acid oxidation.   
 
These results suggest that G5-mediated delivery of DOX alters both its intracellular release and 
the associated cellular response. To the best of our knowledge, this is the first report 
establishing a relationship between the mode of delivery of a chemotherapeutic cargo using a 
polymeric carrier and the associated intracellular release, metabolism, and effect on metabolic 
pathways. We believe this warrants more attention and analysis of the intracellular fate of the 
therapeutic cargo delivered using different carriers (e.g. nanoparticles, antibodies) to establish 
a robust correlation between intracellular concentration-versus-time profiles. Such insight 
would allow accurate determination of the anticipated therapeutic response in vitro and in 













Figure 21. Metabolic response of cells treated by P1/P2 versus free DOX. Untargeted metabolomics analysis 
and relative flux using stable isotope tracers were used to assess metabolic changes associated with either free 
DOX or P1/P2 treatment. Targeted analysis shows distinct differences between metabolites of key pathways based 
on treatment type, as indicated by principle component analysis (A), changes within glycolysis and the TCA cycle 
(B), and in the heatmap of various metabolic markers (C). Further, using 13C-glucose or 13C-oleate media, we 
found that free DOX reduces glycolysis while P1 and P2 cause an increase in glycolysis, as shown in the 
normalized enrichment levels of citrate and glutamate in the presence of U-13C glucose media (D). Results also 
show that free DOX increases fatty acid oxidation while P1 and P2 have little to no effect on it, as seen by the 
normalized enrichment of citrate and glutamate in the presence of U-13C oleate media (E). Targeted analysis and 
flux tracing results are presented as the mean of three replicates ± SEM. Two-tailed Student’s t-tests were used to 
determine the statistical difference between DOX-, P1-, or P2-treated cells compared to untreated (control) cells 
and are denoted by * for P<0.05, ** for P<0.01, and *** for P<0.001.  
 
3.4 Conclusion 
We report the synthesis and in vitro validation of a nanoparticle-based drug delivery method 
aimed at improving the treatment of hepatocellular carcinoma. We synthesized NAcGal-
targeted, DOX-loaded G5 PAMAM dendrimers (e.g. NAcGal-PEGc-G5-L(x)-DOX 
conjugates) in two different formulations based on our previous work, P1 or P2. We verified 
the biocompatibility of the two conjugates and showed that they achieved efficient 
internalization into hepatic cancer cells, which corresponded with controllable anticancer 
activity comparable to free DOX. We employed metabolomics to identify that P1 and P2 
conjugates deliver DOX metabolites different than DOX delivered freely in solution, indicating 
differences in intracellular release of the drug based on the delivery method. Further, we 
established that the difference in delivered DOX metabolites also induced different metabolic 
responses within the treated cells. Despite alternate metabolomics profiles, our results indicate 
that P1 and P2 conjugates present viable nanoparticle-based delivery systems that can be used 
for controllable doxorubicin delivery to hepatic cancer tissue. 
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1. Synthesis of NAcGal-PEGc-G5-L(x)-DOX Particles: 
General Experimental Procedures: All reactions were carried out under nitrogen with 
anhydrous solvents in flame-dried glassware, unless otherwise noted. All glycosylation 
reactions were performed in the presence of molecular sieves, which were flame-dried right 
before the reaction under high vacuum. Solvents were dried using a solvent purification system 
and used directly without further drying. Chemicals used were reagent grade as supplied except 
where noted. Analytical thin-layer chromatography was performed using silica gel 60 F254 
glass plates. Compound spots were visualized by UV light (254 nm) and by staining with a 
yellow solution containing Ce(NH4)2(NO3)6 (0.5 g) and (NH4)6Mo7O24·4H2O (24.0 g) in 6% 
H2SO4 (500 mL). Flash column chromatography was performed on silica gel 60 (230–
400Mesh). NMR spectra were referenced using Me4Si (0 ppm), residual CHCl3 (δ 
1H-NMR 
7.26 ppm, 13C-NMR 77.0 ppm, CD3OD (δ 
1H-NMR 3.30 ppm, 13C-NMR 49.00 ppm, 
CD3SOCD3 (δ 
1H-NMR 2.49 ppm, 13C-NMR 39.5 ppm and D2O (δ 
1H-NMR 4.56 ppm). Peak 
and coupling constant assignments are based on 1H-NMR.  
Characterization of anomeric stereochemistry: The stereochemistry of the newly formed 
glycosidic linkages in N-acetyl galactosamine derivative was determined by JH1,H2 through 
1H-
NMR. Smaller coupling constants of JH1,H2 (below 4 Hz) indicate α linkages and larger coupling 
constants JH1,H2 (6.0 Hz or larger) indicate β linkages.  
Mass spectrometry (MS) analysis: ESI-MS measurements were performed according to the 
published protocols on a Q-TOF Ultima API LC-MS instrument with Waters 2795 Separation 
Module (Waters Corporation, Milford, MA). All samples passed through an EagleEye HPLC 
C18 column, 3 mm × 150 mm, 5 μm at a flow rate of 0.5 mL/min with a linear gradient from 
10% eluent B to 26% eluent B over eight minutes with the column temperature maintained at 
45 °C. All injections were performed in the full-loop injection mode using a 10 μL sample loop. 
Eluent A consisted of a pure aqueous solution and eluent B contained 75% acetonitrile/25% 
aqueous solution (v/v).  The following instrument settings were common for analyses S16 
performed in both positive and negative ion modes: source temperature 120 °C, desolvation 
temperature 400 °C, collision energy 10 eV. When operated in negative ion mode, the mass 
spectrometer used the following instrument settings: capillary voltage 2.0 kV, cone voltage 35 




in positive ion mode: capillary voltage 3.5 kV, cone voltage 35 V. Sample concentrations were 
1mg/mL. MALDI mass spectra were recorded on a Shimadzu Axima-CFR plus MALDI-TOF. 
The matrix used was 2,5-dihydroxy-benzoic acid (DHB) and Melittin from honeybee venom 
(M2272 from Sigma-Aldrich) as the calibration compound.  
 
We have reported the synthesis and analytical data for L3-DOX, L4-DOX linkers and 
compounds 1-8 in our previous work18. Below, we describe the synthesis and analytical 
data for compounds 9-13. 
1.1 N-((2R,3R,4R,5R,6R)-2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-4,5-dihydroxy-6-
(hydroxymethyl) tetrahydro-2H-pyran-3-yl)acetamide-PEG-NH-Cis-Ac-COOH (9):  
Compound 8 (0.195 g, 0.074 mmol) was dissolved in MeOH (6 mL) followed by addition of 
K2CO3 (0.102 g, 0.74 mmol), 1 M NaOMe solution (1 mL, pH was adjusted to 9.0-9.7 by drop 
wise addition) and stirred for 1 h at  0 oC then for 12 h at room temperature. The reaction 
solution was gradually acidified by adding ice-cold 1N HCl solution while stirring the mixture 
at 0 °C till the pH dropped to 3.0. The reaction mixture was dialyzed (MWCO 1kDa) against 
deionized water for 36 hours and lyophilized to obtain compound 9 as an off-white solid (175 
mg) in 94.5% yield. 
1H NMR (500 MHz, CDCl3): δ 1.85 (s, 3H, CH3, OAc), 2.02 (s, 3H, CH3, OAc), 2.04 (s, 3H, 
CH3, OAc), 2.16 (s, 3H, CH3, OAc), 3.08-3.20 (m, 6H), 3.26-3.44 (m, 4H,CH2-COOH), 3.46-
3.56 (m, 8H, Ha,b.c.d.e.), 3.58-3.3.72 (m, 180H, PEG-H), 3.72-3.86 (m, 4H, Hf, Ha’), 3.94-4.02 
(m, 2H, Ha), 4.04-4.16 (m, 3H, H2, H6,6’), 4.32-4.38 (m, 1H, H3), 4.41 (dd, 1H, J = 1.6 & 1.0 
Hz, H5), 5.31 (d, 1H, J = 1.6 Hz, H4), 6.36 (d, 1H, J = 6.8 Hz, H1),  6.78 (s, 1H, olefin), 7.70-
7.72 (2bs, 2H, COOH). ESI-MS: [M+H]- calculated for C14H28N2O8-PEG-NH-cis-Ac is 
2508.30, found 2507.20. 
 
1.2 Dendrimer coupled-4-pentynoic acid to form G5- pent-4-ynamide compound (G5-
(alkyne)15 or 10): 
Commercially available G5-Dendrimer (0.2 g, 0.00693 mmol) and 1-pentynoic acid (13.6 mg, 
0.138 mmol) were dissolved in anhydrous DMSO (7 mL) and added PyBOP (108 mg, 0.208 
mmol), DIPEA (base, 0.12 mL, 0.693 mmol) and stirred at RT for 36 h. Reaction mixture was 
transferred in to dialysis cassette (7KDa) and dialyszed for 2 days followed by lyophilization 




1H-NMR (500 MHz, D2O): δ 2.18-2.34 (m, 240H, G5-H), 2.40-2.50 (m, 120H, G5-H), 2.56 
(s, 14H, pentyne-H), 2.58-2.74 (m, 290H, 240 G5-H + 50 H from CH2 of 4-pentynoic acid), 
2.97(t, 10H, J = 6.0 Hz, pentyne-H), 3.03-3.24 (m, 240H, G5-H), 3.44 (bs, 240H). 
 MALDI analysis: The molecular weight of parent G5-(NH2)128 is 28, 826, and the molecular 
weight observed for G5-alkyne is 30,033, which has 1,207 daltons more than its parent 
dendrimer. This is attributed to alkyne units; each 4-pentynoic acid contributes 81 daltons. 





Compound 9 (112 mg, 0.0449 mmol, 18 eq) was dissolved in 7.5 mL of 0.1 M potassium 
phosphate buffer (pH 6.0) followed by addition of EDC.HCl (34 mg, 0.178 mmol, 1:4 eq with 
acid), catalytic  amount of HOBt (4 mg) and the reaction mixture was stirred at room 
temperature for 30 minutes. G5-(alkyne)15-(NH2)115 dendrimer 10 (75 mg, 0.00249 mmol, 1 eq) 
was dissolved in 5 mL of MeOH and added to the reaction mixture followed by pH adjustment 
to 8.0, by drop wise addition of 0.5 M NaOH solution. The reaction mixture was stirred for 36 
hours at room temperature before dialyzing (MWCO 10kDa) the reaction solution against 
deionized water for 36 hours followed by lyophilization to obtain compound 11 as a light orange 
fluffy solid (140 mg) in 93% yield.  
1H NMR (500 MHz, D2O): δ 1.82-1.88 (m, 31H, CH3, NHAc), 2.15-2.36 (m, 316H, G5-H, 
along with other ethylene dioxide protons), 2.40-2.52 (m, 120H, G5-H, un-overlapped G5 
protons), 2.54-2.76 (m, G5-H, along with other ethylene dioxide protons), 2.76 (bs, 9H, -OH), 
2.82 (bs, 8H, -OH), 2.86 (bs, 27H), 2.92-3.00 (m, 42H), 3.02-3.26 (m, 361H, G5-H, along with 
other ethylene dioxide protons), 3.26-3.38 (m, 62H), 3.40-3.72 (m, 2795H, PEG-protons); 3.78 
(bs 13H), 3.90 (bs 14H), 3.92 (bs 16.4H), 4.20 (bs 12H), 4.36 (bs 14H), 5.42 (d, 12H, J = 4.4 
Hz), 5.78 (d, 1H, J = 7.4 Hz, H1), 7.22 (bs, NH protons), 7.52 (bs, NH protons), 7.62 (bs, NH 
protons), 7.94 (bs, NH protons).  
NMR analysis: We took un-overlapped G5-protons as standard G5-120 protons at 2.40-2.52 
ppm, and we obtained 2795 PEG- protons at3.40-3.72 ppm. Each 2KDa PEG unit contains 
approximately 172 protons, and then we were able to attach 16.25 cis-Ac-PEG-NAcGAL units 




MALDI analysis: The molecular weight of the compound 9 is 2508, and compound 10 is 30033. 
The molecular weight observed for (alkyne)15-G5-(cis-Ac-PEG-NAcGAL) is 71,922 which has 
41,889 daltons more than its parent dendrimer. This is attributed to cis-Ac-PEG-NAcGAL 
units; each cis-Ac-PEG-NAcGAL contributes 2508.2 daltons. Therefore obtained cis-Ac-PEG-





First Flask: Sodium ascorbate (2 mg g, 0.002 mmol), bathophenonthroline sulfonated sodium 
salt (SBP, 5.5 mg, 0.002 mmol) and Cu(I) 1 mg, 0.001 mmol) was dissolved THF:H2O, 1:1= 3 
mL) and bubbled the nitrogen for 10 min. 
Second Flask: L3-Dox-azide (3.7 mg, 0.0042 mmol) was dissolved in THF and (N-Ac-
Gal)16.6-G5-(alkyne)15 (11, 0.021 g, 0.00035 mmol) in H2O and bubbled the nitrogen for 10 
min. The catalyst flask was heated to 75 oC for 3-4 min (during this time the solution becomes 
red in color), cool down to RT, and syringe out the catalyst solution while bubbling the 
nitrogen and added to L3-dox-azide flask carefully (drop wisely), flushed the nitrogen one 
more time and closed the flask and covered with aluminum foil and stirred for 48 h. Stirring 
should be slow and constant around 350 rpm. After 2 days, the reaction mixture was 
transferred into dialysis cassette (10KDa) and dialyzed for 2 days followed by lyphilization 
afforded 12, approximately (19 mL, 1 mg/mL, 19 mg, 77% yield).  
1H NMR (500 MHz, CD3OD + 4 drops of D2O): δ 0.62-0.82 (m, aliphatic protons), 0.86-1.32 
(m, G5-protons),  1.52-1.62 (m, G5-protons), 1.72-2.12 (m, including NHAc protons), 2.26-
2.46 (m, G5-H, along with other ethylene dioxide protons), 2.52-2.72 (m, G5-H), 3.40-3.72 
(m, G5-protons, PEG-protons merged with CD3OD peak), 3.78-4.12 (m, G5-H), 6.50-8.80 
(m, L3 linker and doxorubicin protons), 9.12 (bs, Doxorubicin protons).   
MALDI analysis: The molecular weight of parent particle (alkyne)15-G5-(cis-Ac-PEG-
NAcGAL)16.6 is 71,922. The molecular weight observed for (alkyne)15-(cis-Ac-PEG-
NAcGAL)16.6-G5-L3-DOX is 82,254 which has 10,332 daltons more than its parent 
dendrimer. This is attributed to L3-DOX units; each L3-DOX contributes 893.2 daltons. 








First Flask: Sodium ascorbate (2 mg g, 0.002 mmol), bathophenonthroline sulfonated sodium 
salt (SBP, 5.5 mg, 0.002 mmol) and Cu(I) 1 mg, 0.001 mmol) was dissolved THF:H2O, 1:1= 
3 mL) and bubbled the nitrogen for 10 min. 
Second Flask: L4-Dox-azide (3.8 mg, 0.0042 mmol) was dissolved in THF and (N-Ac-
Gal)16.6-G5-(alkyne)15 (11, 0.021 g, 0.00035 mmol) in H2O and bubbled the nitrogen for 10 
min. The catalyst flask was heated to 75 oC for 3-4 min (during this time the solution becomes 
red in color), cool down to RT, and syringe out the catalyst solution while bubbling the 
nitrogen and added to L3-dox-azide flask carefully (drop wisely), flushed the nitrogen one 
more time and closed the flask and covered with aluminum foil and stirred for 48 h. Stirring 
should be slow and constant around 350 rpm. After 2 days, the reaction mixture was 
transferred into dialysis cassette (10KDa) and dialyzed for 2 days followed by lyphilization 
afforded 13, approximately (17 mL, 1.25 mg/mL, 21.25 mg) in 85% yield.  
1H NMR (500 MHz, CD3OD + 4 drops of D2O): δ 0.68-0.88 (m, aliphatic protons), 1.02-1.52 
(m, G5-protons),  1.54-1.64 (m, G5-protons), 1.80-2.12 (m, including NHAc protons), 2.14-
2.50 (m, G5-H, along with other ethylene dioxide protons), 2.52-2.82 (m, G5-H), 3.40-3.92 
(m, G5-protons, PEG-protons merged with CD3OD peak), 3.92-4.12 (m, G5-H), 6.60-8.50 
(m, L3 linker and doxorubicin protons), 9.20 (bs, Doxorubicin protons).   
MALDI analysis: The molecular weight of parent particle (alkyne)15-G5--(cis-Ac-PEG-
NAcGAL)16.6 is 71922. The molecular weight observed for (alkyne)15-(cis-Ac-PEG-
NAcGAL)16.6-G5-L4-DOX is 84,313 which has 12,391 daltons more than its parent 
dendrimer. This is attributed to L4-DOX units; each L4-DOX contributes 923.2 daltons. 
Therefore obtained L4-DOX functionality is 13.4 units. 
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Figure A1. Compound 11 Spectra.  
A: Compound 11 1H NMR in D2O, 500 MHz 
B: Compound 11 1H NMR in D2O (expanded region 0.0-4.0 ppm region) 
C: Compound 11 MALDI spectrum: 
Analysis:  
1. The molecular weight of parent particle G5-(alkyne)15 is 30,033. 
2. The molecular weight observed for m(NAcGal-PEGc)-G5-(alkyne)15 is 71,922 
which has 41,889 daltons more than its parent dendrimer. This is attributed to 
NAcGal-PEGc units; each NAcGal-PEGc contributes 2508.2 daltons. Therefore the 

















Figure A2. Compound 12 Spectra. 
A: Compound 12 1H NMR in CD3OD + 4 drops of D2O, 500 MHz 
B: Compound 12 MALDI spectrum: 
Analysis:  
1. The molecular weight of parent particle 16.6(NAcGal-PEGc)-G5-(alkyne)15 is 71,922. 
2. The molecular weight observed for 16.6(NAcGal-PEGc)-G5-L3-DOX is 82,254 which has 
10,332 daltons more than its parent dendrimer. This is attributed to L3-DOX units; each L3-

















Figure A3. Compound 13 Spectra. 
A: Compound 13 1H NMR in CD3OD + 4 drops of D2O, 500 MHz 
B: Compound 13 MALDI spectrum: 
Analysis:  
1. The molecular weight of parent particle 16.6(NAcGal-PEGc)-G5-(alkyne)15 is 
71922. 
2. The molecular weight observed for 16.6(NAcGal-PEGc)-G5-L4-DOX is 84,313 
which has 12,391 daltons more than its parent dendrimer. This is attributed to L4-
DOX units; each L4-DOX contributes 923.2 daltons. Therefore the obtained L4-DOX 






Figure A4: Uptake of P1 and P2 particles into a control cell line, SK-Hep1.   
SK-Hep1 is known to be an ASGPR-deficient cell line, and flow cytometry results show that 
P1 and P2 conjugates are not internalized into these cells. Meanwhile, free DOX is 
internalized in SK-Hep1 cells at similar levels to HepG2 and Hep3B cells, presumably by 
passive diffusion. These results support that P1 and P2 internalization into HepG2 and Hep3B 
cells is mediated by the ASGPR. Values are presented as the mean of four replicates  SEM. 
A student’s t-test was used to compare the statistical significance between different treatment 
groups, with *P<0.05, **P<0.01, and ***P<0.001. 
DOX
Concentration (nM)
for P1 7.0 349 2795
for P2 8.1 404 3229
Particle Concentration (nM) 0.6 30 240










































Figure A6. Compound 10 Spectra. 
A: Compound 10 1H NMR in D2O, 500 MHz. 
B: Compound 10 MALDI spectrum: 
Analysis:  
1. The molecular weight of parent G5-(NH2)128 is 28,826 Da.  
2. The molecular weight observed for G5-alkyne is 30,033, which is 1,207 daltons more than 
its parent dendrimer. This is attributed to alkyne units; each 4-pentynoic acid contributes 81 














Currently, due to the low percentage of HCC patients that are eligible for surgery (9-29%)1 and 
the high rates of tumor recurrence after resection (60%),2 loco-regional chemotherapy delivered 
through hepatic arterial infusion (HAI) or transarterial chemoembolization (TACE) is the first-line 












Figure 22. in vivo delivery of P1 and P2 
conjugates. We investigated the in vivo efficacy 




doxorubicin; DOX) into the hepatic artery (Figure 23), given that the hepatic artery is the primary 
tumor-feeding vessel in clinical HCC. TACE is a modification of HAI in which DOX is delivered 
as a suspension in an embolizing agent (e.g. lipiodol) to simultaneously induce ischemia in the 
tumor. Unfortunately, however, HAI procedures have experienced limited antitumor activity in 
several clinical trials delivering DOX by itself or as part of a cocktail (e.g. drug-eluting 
microbeads).3,4 In fact, HAI response rates do not exceed 15% for the most advanced HCC stages 
(Child-Pugh score B/C),5,6 and the survival advantage over supportive care alone has been small 
(3.1 to 4.8 weeks).3,7  
 
One primary driver of the limited therapeutic response of DOX delivered by HAI is the expression 
of p-glycoprotein (P-gp) in hepatocellular carcinoma.8,9 The reliance on free diffusion to achieve 
high intracellular concentrations of DOX creates a large gradient within the cell of DOX, with the 
highest concentration being at or near the cell surface where P-gp is located. The basal expression 
of P-gp facilitates efflux of DOX out of the cell, minimizing its intracellular concentration (Figure 
23).10 Further, repeated DOX exposure leads to the upregulation of P-gp, conferring resistance to 







Figure 23:  Strategy for improving loco-regional therapy for hepatocellular carcinoma. (A) Conventional 
therapies for hepatocellular carcinoma (HCC), such as hepatic arterial infusion (HAI) or trans-arterial 
chemoembolization (TACE), involve the direct injection of doxorubicin (DOX) into the hepatic artery. (B) The 
delivery of free doxorubicin in solution through HAI/TACE is limited by minimal therapeutic response, due to p-
glycoprotein-mediated efflux of the drug, and severe cardiotoxicity as a result of I) mitochondrial iron accumulation, 
II) topoisomerase II inhibition, and III) generation of reactive oxygen species (ROS). (C) Our strategy involves the 
delivery of DOX via enzyme-activated nanoparticles targeted to hepatic cancer cells to achieve antitumor activity 
while avoiding DOX-induced cardiotoxicity. Specifically, NAcGal ligands displayed on the particle target hepatic 
cancer cells via the asialoglycoprotein receptor (ASGPR) and are internalized by receptor-mediated endocytosis. The 
particles are then able to escape the endosome into the cytoplasm where hepatic azoreductase enzymes cleave DOX 
from the particle, allowing it to induce its cytotoxic behavior through mechanisms I, II, and III.  The combination of 
receptor-mediated targeting and hepatic enzyme-mediated DOX release prevent distribution and toxicity from 




Despite the local administration of DOX through HAI, P-gp efflux combined with the need to 
deliver high doses of DOX leads to high systemic concentrations of the drug. This systemic 
concentration leads to off-target toxicities, namely cardiotoxicity,7,13,14 hepatic dysfunction,4,15 
myelosuppression,4 and portal vein thrombosis.16 The severity of toxicities developing from DOX 
administration limits the dosage that can be used, further incapacitating the efficacy of DOX by 
lowering its cumulative dose against the tumor.2 The primary reason for high rates of hepatic 
damage is the reliance on free diffusion for DOX penetration into the cell, leading to non-specific 
internalization and significant concentrations of DOX in healthy hepatic tissue that compromise 
the reserved liver function.17,18 Complementarily, ischemia of healthy hepatic tissue induced by 
lipiodol used in TACE further advances the hepatic damage.19 It is therefore not surprising that 
HAI/TACE procedures are not recommended for patients with Child-Pugh classification late B or 
C due to their already-compromised liver function and the intolerable hepatic dysfunction that 
would occur with DOX therapy.4,6,15  
 
The most severe clinical side effect of DOX administration, however, is cardiotoxicity. Release of 
DOX into the systemic circulation after injection by HAI enables DOX accumulation in the heart 
by free diffusion (Figure 23).17,18 Cardiomyocytes are a primary target of DOX-induced oxidative 
stress due to their high reliance on oxidative substrate metabolism, which makes them vulnerable 
to mitochondrial DOX-iron complexing and subsequently, reactive oxygen species (ROS) 
generation.13 On top of ROS, inhibition of topoisomerase II and mitochondrial iron accumulation 
contribute to cardiomyocyte damage, dysfunction, and apoptosis.13,14,20 The development of 
cardiotoxicity in patients receiving DOX ranges from 4-100% depending greatly on the cumulative 




100%.21–23 There is an urgent need to develop a drug delivery system that is able to specifically 
deliver DOX to hepatic cancer tissue to achieve comparable efficacy to the free drug, but avoid 
the systemic release that results in significant side effects like cardiotoxicity.  
 
We reported the development of enzyme-activated polymer-DOX nano-conjugates as a potential 
new therapy for HCC (Figure 23).24–27 Specifically, we conjugated DOX molecules to water-
soluble generation 5 (G5) of poly(amidoamine) (PAMAM) dendrimers via aromatic azo-linkages 
forming G5-DOX conjugates, which are selectively recognized and cleaved by azoreductase 
enzymes expressed by hepatic cancer cells (Figure 24).26 Targeting hepatic cancer cells was 
achieved by conjugating N-acetylgalactosamine (NAcGal) sugar molecules to the free tip of a 
PEG brush anchored to the G5 surface via acid-labile cis-aconityl (c) linkages (Figure 24), which 
proved to achieve rapid internalization into hepatic cancer cells while avoiding recognition and 
uptake by healthy hepatocytes.25,27 In these reports, we describe the synthesis of two NAcGal-
targeted nano-conjugates where DOX molecules are attached to the G5 surface via two different 
enzyme-sensitive azo-linkages (i.e. L3-DOX or L4-DOX) yielding NAcGal-PEGc-G5-L3-DOX 
or NAcGal-PEG-G5-L4-DOX, named P1 and P2, respectively (Figure 24). We hypothesize that 
P1 and P2 particles are able to avoid P-gp-mediated efflux of DOX due to receptor-mediated 
delivery instead of passive diffusion, achieving high intracellular concentrations within hepatic 
cancer cells and an associated antitumor activity. Further, the specific targeting combined with 
enzyme-mediated DOX release should mitigate the occurrence of systemic toxicities such as 
cardiac toxicity. In this manuscript, we report the antitumor activity of P1 and P2 particles after 
direct intratumoral (i.t.) injection into nod scid gamma (NSG) mice bearing ectopic HepG2 tumors. 




doses of free DOX after intraperitoneal (i.p.) administration in NSG mice. Quantifying the 
antitumor activity as well as the induced cardiotoxicity of P1 and P2 particles in vivo will elucidate 




Figure 24: Schematic of P1 and P2 particles. G5 PAMAM dendrimers are functionalized with N-
acetylgalactosamine (NAcGal)-terminated PEG brushes attached to G5 via an acid-labile cis-aconitic (c) spacer to 
facilitate selective binding to the asialoglycoprotein receptor (ASGPR) overexpressed on hepatic cancer cells. 
Doxorubicin (DOX) molecules are also attached via two different enzyme-sensitive linkages to form either P1 




4.2 Experimental Section  
4.2.1 Materials 
G5-(NH2)128 dendrimers with a diaminobutane core were purchased from Andrews ChemServices 
(Berrien Springs, MI) and purified by dialysis against deionized water using Slide-A-Lyzer 
dialysis cassettes (MWCO 10 kDa, Thermo Fisher Scientific, Rockford, IL) to remove imperfect 
dendrimers and debris. Doxorubicin-HCl was purchased from AvaChem Scientific (San Antonio, 
TX). N-acetylgalactosamine, 4-pentynoic acid, pyridine, trimethylphosphine solution (1.0 M in 
THF), triethylamine (TEA), acetic anhydride (Ac2O), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloric acid (EDC.HCl), benzotriazol-1-ol (HOBt), trifluoroacetic acid (TFA), 
bathophenonthroline sulfonated sodium salt (SBP), copper bromide (CuBr), anhydrous 
dimethylsulfoxide (DMSO), anhydrous dichloromethane (DCM), anhydrous dimethylformamide 
(DMF), anhydrous tetrahydrofuran (THF), cis-aconitic anhydride (cis-Ac), and bovine serum 
albumin (BSA) were purchased from Sigma-Aldrich Inc. (St. Louis, MO). Trimethylsilyl 
trifluoromethanesulfonate (TMSOTf), N,N-diisopropyl ethyl amine (DIPEA), camphor sulphonic 
acid (CSA), sodium azide (NaN3), sodium ascorbate,  and benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) were purchased from Across 
Organics Chemicals (Geel, Belgium). N-hydroxysuccinimide-poly(ethylene glycol)-Boc (2 kDa) 
was purchased from JenKem Technology USA Inc (Plano, TX). 2-{2-(2-
Chloroethoxy)ethoxy}ethanol was purchased from TCI America (Portland, OR). Dialysis cassettes 
(MWCO 1–10 kDa) were purchased from Thermo Fisher Scientific (Rockford, IL). Minimum 
essential medium (MEM), OPTI-MEM reduced serum medium, fetal bovine serum (FBS), 0.25% 
trypsin/0.20% ethylenediaminetetraacetic acid (EDTA) solution, phosphate buffered saline (PBS), 




acid (NEAA) solution, and 0.4% trypan blue solutions were purchased from Life Technologies 
(Thermo Fisher Scientific, Rockford, IL).  
 
4.2.2 Synthesis and Characterization of P1 and P2 particles 
We previously reported the synthetic techniques used to create P1 and P2 particles.27 We used 
similar techniques to fabricate the particles presented here, and the complete synthesis along with 
nuclear magnetic resonance (NMR) and time-of-flight matrix-assisted laser desorption/ionization 
(MALDI) spectra can be found in Appendix B. We relied on NMR and MALDI data to establish 
the molecular weights of P1 and P2 particles, as well as the density of loaded NAcGal-PEGc and 
L(x)-DOX linkages.  
 
We measured the particle size of P1 and P2 particles by dynamic light scattering (DLS) using a 
90Plus particle size analyzer (Brookhaven Instruments, Holtsville, NY). The particles were diluted 
in DI water at 1:20 v/v with 10% tween 20 in order to limit nanoparticle aggregate formation. After 
sonication for 20 minutes, P1 and P2 conjugates were sterile-filtered through syringe filters with a 
pore size of 800 nm and warmed to 37℃ before measurements. Raw distribution data was plotted 
in Graphpad Prism software and fit using a Gaussian curve, with the mean being taken as the 
particle size for that replicate. The average of three separate replicates was taken to find the mean 
particle size ± standard error of the mean (SEM). We also determined the zeta potential of the 
particles using a 90Plus Zeta Potential Analyzer (Brookhaven Instruments, Holtsville, NY). 
Particle formulations were dissolved in DI water at 1:20 v/v and warmed to 37℃ before analysis. 




4.2.3 Cell Culture 
HepG2 cells were cultured in T-75 flasks using MEM supplemented with 10% FBS, 1% antibiotic-
antimycotic, 1% sodium pyruvate, 1% non-essential amino acids, and 1 mL gentamicin. The cells 
were maintained at 37℃, 5% CO2, and 95% relative humidity and medium was changed every 48 
hours. Cells were passaged at 80-90% confluency using a 0.25% trypsin/0.20% EDTA solution.  
 
4.2.4 Development of ectopic HepG2 tumor model 
All animal procedures described in this work were reviewed and approved by the Institutional 
Animal Care and Use Committee (IACUC) at the University of Michigan. Mice were kept in 
specific pathogen-free (SPF) housing and were provided water and a regular diet ad libitum. 
 
Male and female NSG mice (Jackson Laboratory, Bar Harbor, ME, USA) (4-10 weeks old) were 
used to prepare ectopic HepG2 tumor models in the flank. Briefly, 24 hours before tumor 
inoculation the mice were injected with cyclophosphamide (100 mg/kg) i.p. in order to suppress 
the reserve immune system and prevent tumor cell rejection. The next day, 2.5 x 106 HepG2 cells 
were isolated and prepared 1:1 v:v in medium to Matrigel (Dow Corning, Midland, MI, USA) and 
kept on ice until the time of injection to prevent gelation of the Matrigel. We injected the cell 
suspension (150 µL volume) subcutaneously in the right flank of each mouse and placed a cotton 
swab on the site of injection after removal of the syringe to prevent leakage of cells. We monitored 
the health of the mice daily and measured the size of the tumor externally using digital calipers. 
The tumors were deemed ready for experiments once the tumor mass reached 50-100 mm3 




4.2.5 Intratumoral injection of P1 and P2 particles  
Mice bearing ectopic tumors in the flank (50-100 mm3) were divided randomly into n=5 per group 
for saline control, P1, P2, or free DOX treatments. Mice were anesthetized at 4-5% isoflurane for 
induction and reduced to 2-3% for maintenance during the procedure, with the carrier gas being 
oxygen. Anesthetized mice were given 0.5 mg/kg injections of free DOX or DOX-equivalent 
particle solutions in a final volume of 100 µL i.t. every 12 hours for 21 days using 27G insulin 
syringes (cumulative daily dose of DOX = 1 mg/kg). The injection site within the tumor was 
altered for each injection to create uniform distribution of the drug, and a cotton swab was placed 
on the injection site immediately upon removal of the syringe to prevent leakage of the 
drug/particles. Every other day, we measured body weight of the mice (data not shown) and used 
digital calipers to measure tumor volume using the formula 𝑉 (𝑚𝑚3) =
1
2
𝐿𝑊2, where 𝐿 and 𝑊 
are the longest and shortest diameters of the tumor, respectively. We normalized each tumor to its 
own volume at day 0 to account for differences in starting tumor volume. Results are presented as 
the mean percentage change in tumor volume every 2 days over the treatment period  SEM. Two-
way ANOVA with Tukey’s multiple comparison was used to determine statistical significance 
between the saline group compared to free DOX (*), P1 (#), and P2 ($) at each timepoint, and is 
denoted by *, #, or $ for p<0.05, **, ##, or $$ for p<0.01, and ***, ###, or $$$ for p<0.001. Linear 
regression was used to determine the best-fit slopes of tumor growth during three periods: Period 
I, during treatment (day 0 to 21); Period II, after treatment (day 21 to 30); Period III, throughout 
the entire course of treatment (day 0 to 30). For Period III we also individually compared the best-






4.2.6 Magnetic resonance imaging (MRI) to assess cardiac function 
Healthy, male and female NSG mice (6-10 weeks old) were randomly assigned to one of four 
treatment groups (saline control, P1, P2, or free DOX; n=3 per group). Personnel acquiring the 
MRI data (A.C.C.) were blinded to treatment groups. Before treatment, the mice underwent MR 
imaging as described above to assess baseline cardiac function (t=Week 0). The mice were then 
given i.p. injections of either P1, P2, or free DOX at 1 mg/kg DOX-equivalent dosing every 2 days 
for 21 days. The mice were imaged via MR once a week during treatment (t=Weeks 1, 2, and 3), 
and one final time one week after the last injection (t=Week 4). The outline of this study is 
illustrated in Figure 26A.  
 
Mice were anesthetized with 1.25-2% isoflurane in 1 L/min of oxygen. Animals were then placed 
in the supine position and imaged at 7T using a Direct Drive console (Agilent Technologies, Santa 
Clara, CA) and a 40 mm inner diameter transmit-receive volume coil (Morris Instruments, Ontario, 
Canada). Core temperature was controlled to 37ºC within +/- 0.2ºC using a custom-built PID 
controller (Labview, National Instruments, Austin TX) interfaced with a commercially available 
small animal system which includes a heater blowing warm air and a rectal temperature probe (SA 
Instruments, Stony Brook, NY). Respiration and ECG were also monitored.  
 
Coronal 2D acquisitions were used to plan the long axis slices of the heart. Long axis acquisitions 
of the heart at end-diastole and end-systole were obtained for each mouse undergoing treatment 
(representative images in Figure 26B). Five to six 2D contiguous slices were planned through the 




compensated 2D CINE acquisition with 12 frames was performed [TR/TE 180/2 ms, FOV (30 
mm)2, 30o, matrix 1282 zero-filled to 2562, slice thickness 1 mm, NEX 4, resolution (117µm)2]. 
The endocardial area of each frame was defined manually using Analyze. For each slice, the end-
diastolic and end-systolic areas were determined by selecting the maximum and minimum areas, 
respectively, as shown in Figure 26C. The left ventricle end-diastolic volume (LVEDV), left 
ventricle end-systolic volume (LVESV), stroke volume (SV), and cardiac output (CO) were 
calculated by using Equations 1-4: 
 
𝐿𝑉𝐸𝐷𝑉 (µ𝐿) = ∑ 𝑆𝑙𝑖𝑐𝑒 𝑎𝑟𝑒𝑎 𝑚𝑎𝑥𝑖 ∗ 𝑆𝑙𝑖𝑐𝑒 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠   
5−6
𝑖=1                     (1) 
𝐿𝑉𝐸𝑆𝑉 (µ𝐿) = ∑ 𝑆𝑙𝑖𝑐𝑒 𝑎𝑟𝑒𝑎 𝑚𝑖𝑛𝑖 ∗ 𝑆𝑙𝑖𝑐𝑒 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠
5−6








) = 𝑆𝑉 ∗ ℎ𝑒𝑎𝑟𝑡 𝑟𝑎𝑡𝑒                        (4) 
 
Results are presented as the mean of each treatment group  SEM.  Two-way ANOVA with 
Tukey’s multiple comparisons test was used to test the statistical significance between P1, P2, and 
free DOX compared to the saline group, except for the free DOX group at Week 2, where a t-test 
was used because replicate numbers did not match due to death (n=1) in the free DOX group. 




4.3 Results and Discussion 
4.3.1 Synthesis of P1 and P2 particles is reproducible 
We functionalized G5 dendrimers with NAcGal-PEGc targeting branches as well as L3-DOX or 
L4-DOX linkages using our previously reported synthetic strategies.27 We first conjugated 16.2 
NAcGal-PEGc units onto the G5 surface, as confirmed by NMR and MALDI spectra (Figure 
B1). This corresponds to 12.7 mole% PEGylation, which facilitates the PEG molecules to adopt a 
“brush” conformation. PEG in the brush conformation completely covers the G5 surface, 
preventing protein adsorption that would lead to clearance of the particles by the 
reticuloendothelial system (RES).27–29 Next, we conjugated L3-DOX or L4-DOX linkages onto 
PEGylated G5 using click chemistry26,27 to achieve P1 and P2 particles (Figure B2 and B3). We 
attained similar loading of DOX on P1 (compound 12) [16.2(NAcGal-PEGc)-G5-(L3-DOX)13.1] and 
P2 (compound 13) [16.2(NAcGal-PEGc)-G5-(L4-DOX)13.4], with 13.1 and 13.4 moles of DOX per 
G5, respectively (Table 3). As prepared, P1 and P2 particles maintained aqueous solubility at 
concentrations up to 1.30 mg/mL. Given the similarity in PEGylation, NAcGal-, and DOX-loading 
to our previously reported particles,25–27 it is important to highlight the batch-to-batch 
reproducibility of our system. The robust chemical practices we use allow the repeated synthesis 
of P1 and P2 particles with minimal variability, offering a strong advantage over other molecular 
therapeutics that are difficult to scale up due to batch-to-batch variation.30 
 
P1 and P2 particles had molecular weights (MW) of 82,577 and 83,277 dalton (Da), respectively 
(Table 3). Dynamic light scattering (DLS) results show P1 and P2 particles had hydrodynamic 




zeta potential measurements indicated that both particles had a neutral surface charge (Table 3). 
As we described previously,27 these physicochemical properties ensure the particles will be able 
to evade renal filtration and clearance by the reticuloendothelial system (RES). More importantly, 
they allow P1 and P2 particles to exploit the enhanced permeability and retention (EPR) effect,31,32 
which allows the particles to extravasate into the tumor interstitium through leaky vasculature and 
be retained there due to lack of a proper lymphatic drainage system.  
 
Table 3. Physicochemical properties of P1 and P2 particles  
 
4.3.2 Tumor Model Development 
The combination of immune-compromised NSG mice with an immunosuppressant given prior to 
HepG2 inoculation resulted in 100% tumor take in injected mice. By the third week after injection, 
tumors became palpable and volumes were measured at 23.8  1.9, 50.3  2.7, and 86.4  2.7 mm3 
at weeks 3, 4, and 5, respectively. As soon as a tumor volume reached 50-100 mm3, mice were 
randomly divided into a treatment group. The average tumor volume at day 0 was 58.9  4.8 mm3 





















4.3.3 P1 and P2 particles inhibit tumor growth earlier and to a greater degree than free DOX 
We were interested to see if P1 and P2 particles would exhibit antitumor activity comparable to 
free DOX in NSG mice bearing ectopic HepG2 tumors. Therefore, we measured the effect of i.t. 
injection of either P1, P2, or free DOX at an equivalent DOX dosage of 1 mg/kg per day for 21 
days, measuring tumor volume by digital caliper. It is important to note that the clinical dosage of 
DOX conventionally used is between 60-75 mg/m2,33–35 which equates to 1.6-2.0 mg/kg using 
accepted dose conversion methods for humans.36 Therefore, we tested a dose that is 37.5 to 50% 
lower than clinical doses and looked for a statistically significant inhibition of tumor growth as the 
key outcome to measure therapeutic efficacy of treatment, in comparison to saline-treated tumors 
(Figure 25). As such, P1-, P2-, and free DOX-treated tumors were not statistically different in 
tumor volume compared to saline-treated tumors through day 12 of treatment. After day 12, tumor 
growth was greater for the saline group than for any of the treatment groups. P1 and P2 particles 
induced an earlier onset of therapeutic activity, as seen by statistically significant inhibition of 
tumor growth compared to the saline control by day 15 (p<0.01, saline vs. P1; p<0.001, saline vs. 
P2; p=0.08, saline vs. DOX). At day 18, however, all three treatment groups reached statistically 
significant tumor growth inhibition, although the effect from P1 and P2 particles had stronger 
significance (p<0.0001, saline vs. P1 or P2; p=0.01, saline vs. free DOX). By the end of treatment 
at day 21, the mean change in tumor volume (MCTV) for saline-treated tumors was 771.1  87.3%, 
while for the P1, P2, and free DOX groups it was 190.7  35.4, 398.6  98.7, and 424.4  100.6%, 
respectively. Representative images of tumors at day 21 can be seen in Figure B8. Therefore, the 
treatments inhibited tumor growth by 75.3, 48.3, and 45.0%, respectively (p<0.0001, saline vs. P1; 
p<0.01, saline vs. P2; p<0.05, saline vs. free DOX). Upon the removal of treatment, saline-treated 




P1-, P2-, and free DOX-treated tumors reached 358.8  71.9, 406.8  85.9, and 622.0  70.0%, 
respectively. This equated to a 76.1, 72.9, and 58.6% reduction in tumor growth by the respective 
treatments at day 30 (p<0.0001 for P1, P2, and DOX vs. saline).  
 
Figure 25: Intratumoral delivery of P1 and P2 particles achieves antitumor activity comparable to free DOX. 
We measured the antitumor activity of P1 and P2 particles after intratumoral (i.t.) delivery to ectopic HepG2 tumors 
developed in nod scid gamma (NSG) mice, in order to mimic the clinical delivery of DOX through hepatic arterial 
infusion. (A) When tumors reached 50-100 mm3 in volume, animals were randomly divided into treatment groups of 
either saline, P1, P2, or free DOX, with each group receiving a DOX-equivalent dose of 1 mg/kg injected twice daily 
for 21 days. We monitored tumor volume every 3 days through day 30, and normalized tumor volumes to their starting 
volume at day 0. (B) Results show that saline-treated tumors reached a change in tumor volume of 1501  115% by 
day 30, while P1, P2, and free DOX treatments inhibited tumor growth by 76.1%, 72.9%, and 58.6%, respectively, 
compared to the saline controls. Linear regression results show that while free DOX inhibits tumor growth by 2.5-fold 
over the entire treatment period, P1 and P2 particles inhibit growth 5.1- and 4.4-fold, respectively. Results are 
presented as a mean of five replicates  standard error of the mean (SEM). Two-way ANOVA was used to determine 
statistical significance between the saline group compared to free DOX (*), P1 (#), or P2 ($) at each timepoint, and is 




We were interested to compare the inhibitory rates of P1, P2, and free DOX treatments during 
(Period I), after (Period II), and over the entire course of treatment (Period III) to identify the 
effect of presence or absence of treatment on antitumor activity between the groups. Results of the 
linear regression tests for Periods I, II, and III can be found in Table 4, with the slopes of each 
treatment group listed. During Period I, slopes of P1, P2, and free DOX treatment groups are 6.0-, 
4.4, and 2.4-fold smaller than that of the saline treatment group, with strong statistical difference 
between all groups. This indicates that not only were the treatments effective at tumor growth 
inhibition, but P1 and P2 exhibit stronger effects over free DOX. After the removal of treatment 
(Period II), tumor growth of the saline group increased substantially, indicated by a 2.1-fold 
increase compared to Period I. We hypothesize that the removal of injections using 27G needles 
improved the growth conditions of the tumor, particularly by allowing it to restore and maintain a 
high interstitial fluid pressure that is known to promote tumor cell proliferation.37 During this 
stage, slopes of P1 and free DOX treatment groups increased by 3.0 and 1.3-fold, respectively, 
suggesting that their activity was decreased upon treatment cessation and this effect was the largest 
for P1 particles. Interestingly, the slope of the P2 group reduced 1.6-folds compared to Period I. 
This suggests that P2 particles may have either a time-delay in initiating activity or a prolonged 
effect after ending treatment. Over the entire study (Period III), the slopes of P1, P2, and free 
DOX are different from the saline group with strong significance (p<0.0001 for all). While the 
slope of the free DOX group is 2.5-fold smaller than that of the saline group, P1 and P2 particles 






The therapeutic advantage of P1 and P2 over free DOX is exemplified by the strong significance 
when comparing the slopes between the respective groups over Period III (p=0.0021, P1 vs. free 
DOX; p=0.0212, P2 vs. free DOX). This advantage is surprising given that our in vitro cytotoxicity 
results showed free DOX concentrations required to inhibit 50% of tumor cell growth (i.e. IC50) 
was approximately 57- and 10-folds lower than P1 and P2, respectively.27 However, in tumor 
tissue, P1/P2 particles exhibited a therapeutic advantage over free DOX (Figure 25). We 
hypothesize that the EPR effect sequesters the nanoparticles within tumor tissue due to the lack of 
a proper lymphatic drainage system.38 Small molecules like free DOX (MW: 542 Da), however, 
can diffuse out of the tumor via capillaries in order to reach equilibrium throughout the body,39 
thereby decreasing the intratumoral DOX concentration and the antitumor activity it causes. 
 
4.3.4 Potential differences in tumor growth inhibition between P1 and P2 particles 
In our previous work,27  P2 particles exhibited a 5.9-fold higher cytotoxic activity than P1 in vitro, 
which we explained was due to the more labile linkage chemistry (e.g. L4) attaching DOX to the 
G5 surface. Our metabolomics analysis showed that two active DOX molecules released from both 
P1 and P2 – isomers of tetracenomycin (TCM), either F1 methylester or D1 – were in higher 
abundance intracellularly from P1 particles than those released from P2. Conversely, the 
extracellular abundance, particularly of TCM D1 metabolites, was higher for P2-treated cells 
compared to P1. We explained this phenomenon by considering the release kinetics of P1 vs. P2. 
We estimated that the lower intracellular concentrations of TCM molecules in P2-treated cells was 
a result of the quicker release (due to the more labile linkage chemistry), which subsequently 




hypothesized that the earlier release of TCM molecules led to higher initial intracellular 
concentrations and the higher observed toxicity.27  
 
Interestingly, the differences in slope of tumor growth between P1 and P2 over the entire treatment 
period, while not statistically significant (p=0.057), suggest that P1 particles may have an 
advantage in antitumor activity over P2 particles (Figure 25, Table 4). We explain this potential 
difference by considering the changes in the microenvironment between in vitro cell culture and 
an in vivo tumor model. In our in vitro cytotoxicity assays,27 after inducing toxicity in the host 
tumor cell, TCM D1 molecules from P2-treated cells were effluxed into the extracellular medium, 
where they would reside and potentially be internalized by other cells in culture via passive 
diffusion. We hypothesize that this cyclic shuffling between cells is what led to the increased 
toxicity in the midst of P2 particles, while for P1-treated cells, the released TCM D1 molecules 
were sequestered intracellularly and able to induce apoptosis in a smaller percentage of cells. 
However, in tumor tissue the same lymphatic and vascular drainage that reduces free DOX toxicity 
may also clear TCM D1 molecules once effluxed from treated cells due to its small size (MW: 336 
Da). In other words, if P2 particles do in fact exhibit reduced activity compared to P1, it may be 
because the cycling of TCM molecules from cell to cell is not as prominent in vivo due to drainage 
of the small molecule from tumor tissue. Contrarily, the intracellular sequestration of P1-derived 
TCM D1 molecules may allow for sustained therapeutic activity within the tumor, conferring the 
higher therapeutic activity observed for P1 particles. Further studies including metabolomics 
analysis of treated tumor tissue to measure the intratumoral and intracellular concentrations of P1- 
and P2-derived DOX metabolites will help elucidate the qualitative therapeutic differences 











4.3.5 P1 and P2 particles do not induce cardiotoxicity 
Results indicating that P1 and P2 inhibit tumor growth sooner and to a greater degree at earlier 
timepoints (Figure 25B), compared to free DOX prompted us to measure the cardiac function of 
mice undergoing treatment by all three treatments. We administered either saline, P1, P2, or free 
DOX at a DOX-equivalent dosage of 1 mg/kg (cumulative weekly dose of 3.5 mg/kg) i.p. and used 
MR imaging of the heart to assess cardiac function (Figure 26). Cardiac MR is a standard 
noninvasive practice to assess the effect of chemotherapy administration on cardiac function,14,40–
42 with decreases in LVEDV, LVESV, SV, and CO indicating cardiotoxicity after doxorubicin 
treatment, in humans and in mice.41–43 
 
Saline, P1, and P2 groups showed no signs of morbidity through Week 4, and accordingly had a 
100% survival rate. Qualitative visual assessment of the DOX group during treatment showed 
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Figure 26: Measurement of cardiac function by MR imaging. We measured the cardiac function of mice 
undergoing treatment by saline, P1, P2, or free DOX. (A) Treatment and imaging regimen used. Healthy, NSG mice 
were randomly divided into four groups and assessed for their baseline cardiac function using magnetic resonance 
imaging (MRI). Starting at day 0, mice were given intraperitoneal (i.p.) injections of one of the four treatment every 
48 hours for 21 days. We imaged the hearts weekly during treatment and also one week post-treatment. (B) 
Representative, long axis acquisitions at end-diastole and end-systole of mice treated by control, P1, P2, or free DOX 
at the final week of imaging possible. (C) For each 2D short-axis slice, a cardiac-gated and respiratory compensated 
2D CINE acquisition with 12 frames was performed and the endocardial area of each frame defined using Analyze. 
The end-diastolic and end-systolic areas were found in each slice and are represented by the highlighted region of 




100% of the free DOX group presented characteristics of palmar-plantar erythrodysesthesia (i.e. 
hand-foot syndrome), a common clinical side effect of DOX treatment,44 by day 11. The median 
survival time for DOX-treated mice was 14 days, with complete group mortality by day 15. While 
this is a low survival rate, the rate falls into the large range of median survival (2-14 weeks) 
observed in similar studies administering a cumulative weekly DOX dosage of 3-4 mg/kg  
DOX.45–47  
 
Mean LVEDV, LVESV, SV, and CO values at baseline between all animals were 46.9  1.6 µL, 
16.0  1.5 µL, 30.9  0.8 µL/beat, and 16.2  0.7 mL/min, respectively. These values are normal 
for mice48,49 and were similar between each treatment group (Figure 27A-D). By the end of the 
monitoring period (Week 4), the control group of mice exhibited no decrease in LVEDV, LVESV, 
SV, nor CO at Week 4 compared to baseline (p>>0.05 for all values). Similarly, P1 and P2 particles 
induced no changes in either LVEDV, LVESV, SV, or CO between their baseline and any 
timepoint (p>>0.05). There were also no differences between P1 and P2 groups at any timepoint 
(p>>0.05). For free DOX-treated mice, however, there was an obvious and significant decrease in 
cardiac function that is noticeable within the first week of treatment. By Week 2 (the last possible 
imaging time for the free DOX group), LVEDV, SV, and CO dropped by 39.8, 37.9, and 49.8%, 
respectively, to 25.3  2.7 µL, 18.1  1.5 µL/beat, and 8.0  0.2 mL/min (p<0.05, p<0.05, and 
p<0.001; Figure 27A, C, and D). Heart rate (HR) values were statistically not different from each 
other between all groups, allowing us to conclude that changes in CO (SV*HR) were solely 
dependent on changes in SV. While there was no statistical significance between LVESV at 
baseline compared to Week 2 (7.3  1.2 µL, p=0.2) (Figure 27B), there was a 44.1% decrease 




Our data supports the hypothesis that the combination of NAcGal-mediated targeting, PEGylation 
(which is known to limit distribution to off-target organs50,51), and a particle size profile that 
disables free diffusion across intact vasculature52 is able to spare P1 and P2 particles from cardiac 
distribution. Further, we have previously shown that the enzyme-dependent release of DOX from 
L3-DOX and L4-DOX linkages does not occur in cardiomyocytes, due to the enzymes being solely 
of hepatic origin,53–55 and as such we saw no resulting toxicity towards cardiomyocytes.26 This 
suggests that even if P1/P2 particles were to distribute to heart tissue in vivo, DOX release would 
not occur and therefore no decrease in cardiac function should be observed. A recent report by 
Zhang et al. established an MR protocol to assess DOX-induced cardiotoxicity after weekly IP 
injections of DOX,14 and we followed a similar protocol to assess P1-, P2-, or free DOX-induced 
toxicity in the present work. We chose not to assess the cardiotoxicity of mice undergoing i.t. 
therapy of ectopic tumors because it is well known that the clearance of subcutaneously-injected 
compounds depends on a complex interplay between the vascular network, lymphatic capillaries, 
and the hypodermal interstitium. In particular, for molecules larger than 20 kDa, diffusion into 
blood capillaries is inhibited and the lymphatic system dominates clearance.56 We predicted 
therefore that P1 and P2 particles would not achieve ample concentrations in the systemic 
circulation that are required to induce a representative cardiotoxic effect. Alternatively, given that 
i.p.-injected compounds are primarily cleared through the portal vein,57 i.p. injection of P1 and P2 
particles are a better predictor of cardiotoxicity given that they would have direct localization in 
the systemic circulation. Our results showing the maintenance of cardiac function after treatment 
suggest that P1 and P2 particles are equipped to avoid distribution to heart tissue and/or prevent 




will help identify whether it is the HCC-specific targeting or the enzyme-sensitive DOX release, 
or a combination of both, that confers the cardio-protective effect of P1/P2 particles.  
 
 
Figure 27: P1- and P2-mediated delivery of DOX escapes cardiotoxicity associated with free DOX 
administration. We measured the cardiac function of mice undergoing treatment by saline, P1, P2, or free DOX. 
Results show the effects of each treatment on the (A) left ventricular end diastolic volume (LVEDV), (B) left 
ventricular end systolic volume (LVESV), (C) stroke volume (SV = LVEDV – LVESV), and (D) cardiac output 
(SV*heart rate). The statistically significant decrease in cardiac function by all four metrics is obvious already after 
Week 1 of free DOX treatment, while P1 and P2 particles do not induce any toxicity compared to the control. 
Further, free DOX mice had a 100% death rate by day 15, while P1- and P2-treated had a 100% survival rate during 
the monitoring period. Results are presented as a mean of three replicates  SEM. Two-way ANOVA was used to 
test the statistical significance between P1, P2, and free DOX compared to the saline group, except for the free DOX 
group at Week 2, where a t-test was used because mice numbers did not match due to death in the free DOX group. 




Efforts to package DOX in a way that would improve therapeutic efficacy but minimize its cardiac 
distribution and toxicity have been made before. The use of liposomal DOX formulations, such as 
DOXIL or CAELYX, have proven their non-inferiority to DOX in therapeutic efficacy while also 
minimizing the occurrence of cardiotoxicity in patients with multiple myeloma23 and metastatic 
breast cancer.34 The decrease in toxicity has been credited to the ability of liposomes to prevent 
DOX diffusion through vascular junctions,23 as well as the ability of PEGylation to increase 
circulation half-life and thereby decrease off-target tissue distribution.34 Unfortunately, the 
extension of these novel DOX formulations has not seen the same clinical success when applied 
to HCC therapy. While patients were spared from cardiotoxicity, several clinical trials measuring 
the effect of liposomal DOX exhibited minimal therapeutic efficacy compared to DOX alone.58–60 
Valle et al. described a 0% response rate to PEGylated liposomal DOX for HCC patients, and in 
fact the trial was ended early because it did not reach the minimal threshold of activity at initial 
checkpoints.58 While the minimal therapeutic efficacy has yet to be mechanistically explained, it 
is postulated that the increased circulation time of liposomal DOX also prevents significant uptake 
into hepatic tissue, and without specific molecular targeting to HCC, the formulation is left with 
minute concentrations in hepatic tumor tissue.23,58 Our targeting strategy, however, equips P1/P2 
to overcome the minimal distribution to hepatic tumor tissue observed with its liposomal 
counterparts.  
 
The P1/P2 formulation could replace DOX in a multitude of procedures that it is used in currently. 
First and foremost, given that i.t. therapy is a good predictor of intra-arterial efficacy,61 the P1/P2 
formulation has high potential to be a viable replacement for free DOX in HAI procedures. Further, 




and/or targeted molecular therapies like sorafenib,62–65 P1/P2 particles could be an integral part of 
the new era of advanced HCC therapy. Sorafenib, due to its modest effect on survival benefit of 
HCC patients when delivered alone,62,66 has been combined with DOX (administered either 
systemically63 or through TACE64,65) and shown improved therapy over both agents given 
alone.64,65,67 However, patients experienced the expected DOX toxicities such as cardiotoxicity, 
myelosuppression, hand-foot syndrome, and neutropenia. In another interesting approach, DOX 
delivered by TACE is used as a predecessor to surgery in order to downsize the tumor.68 Not 
surprisingly, DOX morbidities developed for these patients as well. In both cases, P1/P2 particles 
offer an alternative DOX formulation that can either be used in combination with sorafenib or 
simply to reduce a large tumor before removing it surgically, potentially mitigating the observed 
toxicities while achieving comparable (if not better) therapeutic results. Another recent study 
showed that HAI of epirubicin and cisplatin combined with i.t. delivery of interferon-gamma and 
5-fluorouacil achieved a complete response in 66% of patients with advanced HCC.62 Despite this 
success, however, morbidities of myelosuppression and flu-like symptoms developed, likely due 
to the toxicities from one or several of the chemotherapy agents. These poorly-tolerated drugs 
could either be singly- or co-loaded onto the P1/P2 platform due to its synthetic versatility, and 
replace the cocktails used in approaches like this one to achieve comparable patient response while 
minimizing the co-morbidities that develop. Our ongoing studies are measuring the synthetic 









The results presented here clearly highlight the merit in using NAcGal-targeted G5 dendrimers to 
deliver DOX into hepatic cancer tissue. The cell-specific targeting combined with enzyme-
mediated drug release confers improved therapeutic efficacy against tumors in mice over free 
DOX. At the same time, P1/P2 particles exhibit a cardio-protective effect by maintaining complete 
cardiac function in treated mice. These findings suggest that P1 and P2 particles are promising 
nanoparticle formulations for improving the therapeutic index of DOX for advanced HCC patients 
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1. Synthesis of NAcGal-cPEG-G5-L(x)-DOX Particles: 
General Experimental Procedures: All reactions were carried out under nitrogen with anhydrous 
solvents in flame-dried glassware, unless otherwise noted. All glycosylation reactions were 
performed in the presence of molecular sieves, which were flame-dried right before the reaction 
under high vacuum. Solvents were dried using a solvent purification system and used directly 
without further drying. Chemicals used were reagent grade as supplied except where noted. 
Analytical thin-layer chromatography was performed using silica gel 60 F254 glass plates. 
Compound spots were visualized by UV light (254 nm) and by staining with a yellow solution 
containing Ce(NH4)2(NO3)6 (0.5 g) and (NH4)6Mo7O24·4H2O (24.0 g) in 6% H2SO4 (500 mL). 
Flash column chromatography was performed on silica gel 60 (230–400Mesh). NMR spectra were 
referenced using Me4Si (0 ppm), residual CHCl3 (δ 
1H-NMR 7.26 ppm, 13C-NMR 77.0 ppm, 
CD3SOCD3 (δ 
1H-NMR 2.49 ppm, 13C-NMR 39.5 ppm and D2O (δ 
1H-NMR 4.65 ppm). Peak and 
coupling constant assignments are based on 1H-NMR.  
Characterization of anomeric stereochemistry: The stereochemistry of the newly formed 
glycosidic linkages in N-acetyl galactosamine derivative was determined by JH1,H2 through 
1H-
NMR. Smaller coupling constants of JH1,H2 (below 4 Hz) indicate α linkages and larger coupling 
constants JH1,H2 (6.0 Hz or larger) indicate β linkages.  
Mass spectrometry (MS) analysis: ESI-MS measurements were performed according to the 
published protocols on a Q-TOF Ultima API LC-MS instrument with Waters 2795 Separation 
Module (Waters Corporation, Milford, MA). All samples passed through an EagleEye HPLC C18 
column, 3 mm × 150 mm, 5 μm at a flow rate of 0.5 mL/min with a linear gradient from 10% 
eluent B to 26% eluent B over eight minutes with the column temperature maintained at 45 °C. 
All injections were performed in the full-loop injection mode using a 10 μL sample loop. Eluent 
A consisted of a pure aqueous solution and eluent B contained 75% acetonitrile/25% aqueous 
solution (v/v).  The following instrument settings were common for analyses S16 performed in 
both positive and negative ion modes: source temperature 120 °C, desolvation temperature 400 
°C, collision energy 10 eV. When operated in negative ion mode, the mass spectrometer used the 
following instrument settings: capillary voltage 2.0 kV, cone voltage 35 V, extraction cone 4 V. 




capillary voltage 3.5 kV, cone voltage 35 V. Sample concentrations were 1mg/mL. MALDI mass 
spectra were recorded on a Shimadzu Axima-CFR plus MALDI-TOF. The matrix used was 2,5-
dihydroxy-benzoic acid (DHB) and Melittin from honeybee venom (M2272 from Sigma-Aldrich) 
as the calibration compound.  
 
We have reported the synthesis and analytical data for L3-DOX, L4-DOX linkers and 
compounds 1-10 in our previous work25. Below, we describe the synthesis and analytical 
data for compound 11, P1 & P2. 
1.1 (N-((2R,3R,4R,5R,6R)-2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-4,5-dihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide-PEG-NH-Cis-Ac)16.2-G5-(alkyne)15 (11):  
Compound 9 (202 mg, 8.05 x 10-2 mmol, 18 eq) was dissolved in 12 mL of 0.1 M potassium 
phosphate buffer (pH 6.0) followed by addition of EDC.HCl (61 mg, 3.18 x 10-1 mmol, 1:4 eq 
with acid), HOBt (10.8 mg, 8.05 x 10-2 mmol, 1:1 eq with acid) and the reaction mixture was 
stirred at room temperature for 30 minutes. G5-(alkyne)15-(NH2)115 dendrimer 10 (135 mg, 4.49 x 
10-3 mmol, 1 eq) was dissolved in 7 mL of MeOH and added to the reaction mixture followed by 
pH adjustment to 8.0, by drop wise addition of 0.5 M Na2CO3 solution. The reaction mixture was 
stirred for 36 hours at room temperature before dialyzing (MWCO 10kDa) the reaction solution 
against deionized water for 36 hours followed by lyophilization to obtain compound 11 as a light 
orange fluffy solid (305 mg) in 90% yield.  
1H NMR (500 MHz, D2O): δ 1.80-1.85 (m, 36H, CH3, NHAc), 2.12-2.38 (m, 316H, G5-H, along 
with other ethylene dioxide protons), 2.40-2.56 (m, 120H, G5-H, un-overlapped G5 protons), 2.56-
2.78 (m, 285H G5-H, along with other ethylene dioxide protons), 2.77 (bs, 9H, -OH), 2.83 (bs, 
9H, -OH), 2.87 (bs, 27H), 2.94-3.00 (m, 42H), 3.00-3.24 (m, 364H, G5-H, along with other 
ethylene dioxide protons), 3.26-3.38 (m, 62H), 3.39-3.74 (m, 2782H, PEG-protons); 3.78 (bs 13H), 
3.90 (bs 14H), 3.92 (bs 16.4H), 4.20 (bs 12H), 4.36 (bs 14H), 5.42 (d, 12H, J = 4.4 Hz), 5.77 (d, 
1H, J = 7.4 Hz, H1), 7.22 (bs, NH protons), 7.53 (bs, NH protons), 7.63 (bs, NH protons), 7.94 (bs, 
NH protons).  
NMR analysis: We took un-overlapped G5-protons as standard G5-120 protons at 2.40-2.56 ppm, 




approximately 172 protons, and then we were able to attach 16.17 cis-Ac-PEG-NAcGAL units on 
to the G5 surface.  
MALDI analysis: The molecular weight of the compound 9 is 2508, and compound 10 is 30033. 
The molecular weight observed for (alkyne)15-G5-(cis-Ac-PEG-NAcGAL) is 70,861 which has 
40,828 daltons more than its parent dendrimer. This is attributed to cis-Ac-PEG-NAcGAL units; 
each cis-Ac-PEG-NAcGAL contributes 2508.2 daltons. Therefore obtained cis-Ac-PEG-
NAcGAL functionality is 16.27 units. 
 
1.2(N-((2R,3R,4R,5R,6R)-2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)-4,5-dihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-3-yl)acetamide-PEG-NH-Cis-Ac)16.2-G5-(L3-Dox)13.1 (P1):  
First Flask: Sodium ascorbate (9.5 mg, 4.79 x 10-2 mmol), bathophenonthroline sulfonated sodium 
salt (SBP, 26.2 mg, 4.43 x 10-2 mmol) and Cu(I) 5 mg, 2.62 x 10-2 mmol) was dissolved THF:H2O, 
1:1= 15 mL) and bubbled the nitrogen for 10 min. 
Second Flask: L3-Dox-azide (17.6 mg, 1.97 x 10-2 mmol) was dissolved in THF (8 mL) and (N-
Ac-Gal)16.2-G5-(alkyne)15 (11, 100 mg, 1.41 x 10
-3 mmol) in H2O (7 mL) and bubbled the 
nitrogen for 10 min. The catalyst flask was heated to 75 oC for 3-4 min (during this time the 
solution becomes red in color), cool down to RT, and syringe out the catalyst solution while 
bubbling the nitrogen and added to L3-dox-azide flask carefully (drop wisely), flushed the 
nitrogen one more time and closed the flask and covered with aluminum foil and stirred for 48 h. 
Stirring should be slow and constant around 350 rpm. After 2 days, the reaction mixture was 
transferred into dialysis cassette (10KDa) and dialyzed for 2 days against DI water followed by 
lyphilization afforded P1, approximately (105 mL, 1 mg/mL, 105 mg, 89.2% yield).  
1H NMR (700 MHz, CD3SOCD3 + 2 drops of D2O): δ 0.72-0.85 (m, 80H, aliphatic protons), 
0.90-1.36 (m, 340H, G5-protons),  1.36-1.56 (m, 105 H,  G5-protons), 1.78-1.90 (m, 155H, G5-
protons), 1.92-2.02 (m, 65H, including NHAc protons), 2.05-2.40 (m, 240H, G5-H, along with 
other ethylene dioxide protons), 2.52-2.60 (m, 46H), 2.62-2.80 (m, 120H), 2.95-3.20 (m, 210H), 
3.20-4.40 (m, G5-protons, PEG-protons merged with DHO peak), 4.56 (s, 16H), 4.70 (s, 6H), 
4.82 (s, 6H), 4.94 (s, 6H), 5.00 (s, 12H), 5.20 (s, 8H), 5.30 (s, 6H), 5.46 (s, 10H), 5.78 (s, 16H), 




7.20 (s, 3H), 7.40 (s, 8H), 7.60-7.82 (m, 24H), 7.82-8.00 (m,10H), 13.24 (s, 2H, Dox-protons), 
14.06 (s, 2H, Dox-protons).   
MALDI analysis: The molecular weight of parent particle (alkyne)15-G5-(cis-Ac-PEG-
NAcGAL)16.2 is 70,861. The molecular weight observed for (alkyne)15-(cis-Ac-PEG-
NAcGAL)16.2-G5-L3-DOX is 82,577 which has 11,716 daltons more than its parent dendrimer. 
This is attributed to L3-DOX units; each L3-DOX contributes 893.2 daltons. Therefore obtained 




First Flask: Sodium ascorbate (10.5 mg, 5.3 x 10-2 mmol), bathophenonthroline sulfonated 
sodium salt (SBP, 28.8 mg, 4.87 x 10-2 mmol) and Cu(I) 5.2 mg, 2.73 x 10-2  mmol) was 
dissolved THF:H2O, 1:1= 15 mL) and bubbled the nitrogen for 10 min. 
Second Flask: L4-Dox-azide (20 mg, 2.17 x 10-2 mmol) was dissolved in THF (9 mL) and (N-
Ac-Gal)16.2-G5-(alkyne)15 (11, 110 mg, 1.55 x 10
-3 mmol) in H2O (8 mL) and bubbled the 
nitrogen for 10 min. The catalyst flask was heated to 75 oC for 3-4 min (during this time the 
solution becomes red in color), cool down to RT, and syringe out the catalyst solution while 
bubbling the nitrogen and added to L4-dox-azide flask carefully (drop wisely), flushed the 
nitrogen one more time and closed the flask and covered with aluminum foil and stirred for 48 h. 
Stirring should be slow and constant around 350 rpm. After 2 days, the reaction mixture was 
transferred into dialysis cassette (10KDa) and dialyzed for 2 days against DI water followed by 
lyphilization afforded P2, approximately (115 mL, 1.0 mg/mL, 115 mg) in 88% yield.  
1H NMR (700 MHz, CDCl3 + 3 drops of D2O): δ -1.50-0.4 (m, 320H, G5-H & aliphatic protons), 
0.78-0.98 (m, 80H),  1.00-1.40 (m, 240 H,  G5-protons), 1.40-2.10 (m, 440H, G5-protons), 2.05-
2.15 (m, 24H, extended arm ethylene dioxide protons), 2.32-2.42 (m, 12H), 2.40 (m, 6H), 2.95-
3.10 (m, 110H), 3.20-4.40 (m, G5-protons, PEG-protons merged with DHO peak), 4.56 (s, 16H), 
4.78 (s, 6H), 5.00-5.18 (m, 24H), 5.20 (bs, 6H), 5.30-5.40 (m, 24H), 5.56 (s, 8H), 6.24 (s, 4H), 
6.30 (s, 2H), 6.78 (s, 8H), 7.02 (s, 6H), 7.40 (s, 10H), 7.78 (s, 10H), 7.82 (s, 6H), 8.06 (s, 6H), 




MALDI analysis: The molecular weight of parent particle (alkyne)15-G5--(cis-Ac-PEG-
NAcGAL)16.2 is 710861. The molecular weight observed for (alkyne)15-(cis-Ac-PEG-
NAcGAL)16.2-G5-L4-DOX is 83,277 which has 12,416 daltons more than its parent dendrimer. 
This is attributed to L4-DOX units; each L4-DOX contributes 923.2 daltons. Therefore obtained 
L4-DOX functionality is 13.4 units. 
References: 
2. (a) G. Tiruchinapally, Scott H. Medina, Maxim V. Chevliakov, Yasemin Y. Durmaz, Rachell 
N. Stender, William D. Ensminger, Donna S. Shewach, and Mohamed E.H. ElSayed, 
"Targeting hepatic cancer cells with PEGylated dendrimers displaying N-acetylgalactosamine 
and SP94 peptide ligands", Advanced Healthcare Materials, (2013) 2, 1337-1350. (b) S. H. 
Medina, Maxim V. Chevliakov, Gopinath Tiruchinapally, Yasemin Y. Durmaz, Sibu Kuruvilla, 
and Mohamed E.H. ElSayed, "Enzyme-activated nanoconjugates for tunable release of 
















Spectral data for compound 11-13 
 











Figure B2. Compound 11 MALDI spectrum: 
Analysis:  
1. The molecular weight of parent particle G5-(alkyne)15 is 30,033. 
2. The molecular weight observed for m(NAcGal-PEGc)-G5-(alkyne)15 is 70,861 which has 
40,828 daltons more than its parent dendrimer. This is attributed to NAcGal-PEGc units; 
each NAcGal-PEGc contributes 2508.2 daltons. Therefore the obtained NAcGal-PEGc 















Figure B4. Compound 12 MALDI spectrum: 
Analysis:  
1. The molecular weight of parent particle 16.2(NAcGal-PEGc)-G5-(alkyne)15 is 
70,861. 
2. The molecular weight observed for 16.2(NAcGal-PEGc)-G5-L3-DOX is 82,577 
which has 11,716 daltons more than its parent dendrimer. This is attributed to L3-
DOX units; each L3-DOX contributes 893.2 daltons. Therefore the obtained L3-



















Figure B6. Compound 13 MALDI spectrum: 
Analysis:  
1. The molecular weight of parent particle 16.2(NAcGal-PEGc)-G5-(alkyne)15 is 
70,861. 
2. The molecular weight observed for 16.2(NAcGal-PEGc)-G5-L4-DOX is 83,277 
which has 12,416 daltons more than its parent dendrimer. This is attributed to L4-
DOX units; each L4-DOX contributes 923.2 daltons. Therefore the obtained L4-





























Hepatocellular carcinoma (HCC) is the fifth-most commonly occurring tumor worldwide and is 
the 2nd highest cause for cancer-related deaths1. Current treatment procedures involving the 
delivery of chemotherapy and other small molecule therapies suffer from minimal efficacy and 
high systemic toxicity due to the lack of targeted drug delivery. Nanotechnology has shown great 
promise recently to overcome the delivery limitations to localize therapeutic molecules within 










Figure 28. Tri-valent targeting strategy. 
Schematic of G5-dendrimers targeted by tri-




materials5, and silica6 have all been used to improve the delivery of a variety of payloads to hepatic 
cancer cells both in vitro and in vivo, such as siRNA7, imaging dyes8, and small molecule 
drugs5,9,10. The size characteristics of NPs allow them to passively target tumor tissue by exploiting 
the enhanced permeation and retention (EPR) effect11–13. Once inside tumor tissue, active targeting 
of specific molecules improves cellular trafficking of NPs11,14.  
 
Targeting of the asialogycoprotein receptor (ASGPR) specifically overexpressed on hepatic cancer 
cells5,15,16 has shown great promise due to its high binding affinity to glycoproteins, which can be 
synthetically immobilized on a NP surface to promote highly-efficient binding. We9,17,18 and 
others19–21 have shown that the display of N-acetylgalactosamine (NAcGal) ligands on a NP 
surface achieves selective internalization into hepatic cancer cells. We showed that mono-valent 
NAcGal ligands in the  conformation displayed on the tip of a PEG brush attached to generation 
5 (G5) poly(amidoamine) (PAMAM) dendrimers (i.e. G5-PEG-NAcGal particles) achieve 
controllable targeting of hepatic cancer cells17. The display of 12-16 moles of PEG-NAcGal 
branches on the G5 surface (i.e. G5-(PEG-NAcGal)12-16) enabled efficient delivery of co-loaded 
drug molecules into the cytoplasm of hepatic cancer cells, improving the therapeutic efficacy of 
the drug9.  
 
Interestingly, many studies have shown that the display of multi-valent NAcGal ligands, 
particularly tri-valent NAcGal (i.e. NAcGal3), improves the ability to target and bind the ASGPR 
in comparison to mono-valent NAcGal22–24. Accordingly, NAcGal3-targeting has successfully 
been used to deliver molecules like siRNA24 and imaging dyes22 to hepatic cancer cells, achieving 




or with improved internalization kinetics. To the best of our knowledge, the efficacy of NAcGal3 
targeting has only been studied on small molecules (<10 kDa), and has yet to be investigated for 
larger molecules such as nanoparticles (>20 kDa). It is important to identify whether the display 
of NAcGal3 ligands on nanoparticle surfaces can improve their distribution to hepatic cancer cells 
over mono-valent targeting, similar to what is observed with small molecules.  
 
In this study, we synthesized G5 dendrimers targeted by NAcGal3 ligands attached to the surface 
through a PEG brush (i.e. G5-[PEG-(NAcGal)3]n; triGal) and measured their ability to target 
hepatic cancer cells in comparison to mono-valent G5-(PEG-NAcGal)12.1 conjugates (Figure 29). 
We created a library of triGal conjugates with varying density of targeting branches attached, 
namely with n=2, 4, 6, 8, 11, or 14 moles of PEG-(NAcGal)3 branches, to achieve T2, T4, T6, T8, 
T11, and T14 conjugates, respectively. We compared the internalization of these particles to that of 
mono-valent G5-(PEG-NAcGal)12.1 (monoGal; M12) conjugates via conventional and multi-
spectral imaging flow cytometry methods. Results from this study are useful to understand whether 
NAcGal3-targeted dendrimers are a viable option to improve nanoparticle-mediated delivery of 






Figure 29: Strategy for multi-valent targeting of G5 dendrimers to hepatic cancer cells. We developed a 
library of G5 PAMAM dendrimers functionalized by a varying density of tri-valent NAcGal branches on the 
tip of a PEG brush to establish G5-[cPEG-(NAcGal)3]n, or triGal, conjugates. We measured the ability for 
triGal conjugates to target the asialoglycoprotein receptor (ASGPR) overexpressed on hepatic cancer cells in 
comparison to mono-valent, NAcGal-targeted G5 dendrimers (monoGal). Results from this study offers insight 
into the effect of multi-valent targeting for nanoparticle-mediated delivery of therapeutic cargo to hepatic 




5.2 Materials and Methods 
5.2.1 Materials  
G5-(NH2)128 dendrimers with a diaminobutane core were purchased from Andrews ChemServices 
(Berrien Springs, MI) and purified by dialysis against deionized water using Slide-A-Lyzer 
dialysis cassettes (MWCO 10 kDa, Thermo Fisher Scientific, Rockford, IL) to remove imperfect 
dendrimers and debris. N-acetylgalactosamine, 4-pentynoic acid, pyridine, trimethylphosphine 
solution (1.0 M in THF), triethylamine (TEA), acetic anhydride (Ac2O), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide hydrochloric acid (EDC.HCl), benzotriazol-1-ol (HOBt), 
trifluoroacetic acid (TFA), anhydrous dimethylsulfoxide (DMSO), anhydrous dichloromethane 
(DCM), anhydrous dimethylformamide (DMF), anhydrous tetrahydrofuran (THF), anhydrous 1,4-
dioxane, cis-aconitic anhydride (cis-Ac), alpha bromoacetic acid, sodium hydroxide (NaOH),  10% 
palladium on activated Carbon (Pd-C), fluorescein isothiocyanate (FITC) sodium methoxide (1.0 
M NaOMe solution) and bovine serum albumin (BSA) were purchased from Sigma-Aldrich Inc. 
(St. Louis, MO). Trimethylsilyl trifluoromethanesulfonate (TMSOTf), N,N-diisopropyl ethyl 
amine (DIPEA), camphor sulphonic acid (CSA), sodium azide (NaN3), N,N'-
dicyclohexylcarbodiimide (DCC), ethylacetate (EtOAc), ethanol (EtOH)  were purchased from 
Across Organics Chemicals (Geel, Belgium). N-hydroxysuccinimide-poly(ethylene glycol)-Boc 
(2 kDa) was purchased from JenKem Technology USA Inc (Plano, TX). 2-{2-(2-
Chloroethoxy)ethoxy}ethanol was purchased from TCI America (Portland, OR). Dialysis cassettes 
(MWCO 1–10 kDa) were purchased from Thermo Fisher Scientific (Rockford, IL). Minimum 
essential medium (MEM), OPTI-MEM reduced serum medium, fetal bovine serum (FBS), 0.25% 
trypsin/0.20% ethylenediaminetetraacetic acid (EDTA) solution, phosphate buffered saline (PBS), 




acid (NEAA) solution, and 0.4% trypan blue solutions were purchased from Life Technologies 
(Thermo Fisher Scientific, Rockford, IL). 
  
5.2.2 Spectra for Synthesis of Conjugates  
Complete NMR and time-of-flight matrix-assisted laser desorption/ionization (MALDI-TOF) 
spectra confirming the structural identity and composition of FI6-G5-cPEG-(NAcGalβ)3 (T2-T14) 
conjugates can be found in Appendix C. Control particles [(FITC)6-G5] and mono-valent G5-
[PEG-NAcGal]12.1 were synthesized according to our established protocols
17,18. 
 
5.2.3 Synthesis of FI6-G5-[cPEG-(NAcGalβ)3]y 
We chose a similar approach to our previously published strategies to synthesize PEGylated, 
(NAcGalβ)3-targeted G5 conjugates (Figure 30)
10,18. Briefly, D-N-acetylgalactosamine was 
treated with Ac2O and pyridine to obtain D-galactosepentaacetate (1), which was treated with 
TMSOT in DCM to obtain an oxazolidine derivative (compound 2). Commercially available 2-(2-
(2-chloroethoxy)ethoxy)ethan-1-ol was treated with NaN3 in DMF to obtain compound 3. The 
oxazolidine derivative compound 2, was reacted with an alcohol, 2-(2-(2-
azidoethoxy)ethoxy)ethan-1-ol (compound 3) in the presence of D-10-CSA in DMSO at 40 oC to 
yield compound 4 having an azide group at the terminal end. The azide functional group of 
compound 4 was reduced to an amine with Me3P in THF to obtain compound 5. Commercially 
available N6-carbobenzyloxy-L-Lysine was treated with α-bromoacetic acid and NaOH in water 
at 50ºC to obtain compound 6. The peptide coupling between triacid 6 and the D-galactosamine 















carbobenzyloxy-L-Lysine-(NAcGalβ)3 derivative (7) having (NAcGalβ)3 group at one end and 
Cbz-protected NH2 on the other end. The carbobenzyloxy (Cbz) group was deprotected by 
hydrogenolysis under 10% Pd on activated carbon in EtOH/EtOAc at room temperature to obtain 
6-NH2-L-Lysine-(NAcGalβ)3 (8), which was reacted with a hetero-functional PEG derivative, 
(BocNH-PEG-COONHS), EDC.HCl, HOBt, and DIPEA in DMF at room temperature to obtain 
(NAcGalβ)3-L-Lysine-6-NH-PEG-NHBoc (9). Acid hydrolysis of compound 9 with TFA:DCM 
created a Boc-deprotected material (NAcGalβ)3-L-Lysine-6-NH-PEG-NH2 (10), which after 
reaction with cis-aconitic anhydride in H2O:1,4 dioxane mixture gave a corresponding acid 
((NAcGalβ)3-L-Lysine-6-NH-PEG-NHc-acid; 11).  These acid functional groups were created to 
help in coupling them to G5-amine dendrimers. We fluorescently-labeled the G5 dendrimer with 
fluorescein isothiocyanate (FITC) by treating commercially available G5-(NH2)128 dendrimers 
with FITC in H2O:1,4-Dioxane to obtain compound 12. Compound 12 was reacted with different 
equivalents of ((NAcGalβ)3-L-Lysine-6-NH-PEG-NHc-acid (11) to obtain a library of conjugates 
with different targeting ligand concentration on the G5 dendrimer (compounds 13-18). These 
coupling reactions were carried out under EDC and HOBt reagents in 6.0 pH phosphate buffer 
solution.  The conjugates were individually reacted with Ac2O in pyridine to convert the G5 amines 
into N-acetyl amines. The materials were then purified by dialysis (10kDa MWCO) and 
lyophilized to obtain acetylated G5 particles which were further treated with NaOMe in methanol 
to deprotect the O-acetate groups from galactosamine moieties. The reaction mixture was purified 
by dialysis against deionized water (10kDa MWCO) for 2 days and lyophilized to obtain pure T2: 
(FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]2; T4: (FITC)6-G5-[cPEG-6-NH-Lysine-
(NAcGalβ)3]3.6; T6: (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]5.8; T8: (FITC)6-G5-[cPEG-6-




(FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]14.2 (Figure 30). For clarity purposes, we rounded 
branch loading to the nearest whole number, and therefore refer to the particles as having either 2, 
4, 6, 8, 11, or 14 cPEG-(NAcGal)3 branches attached. 
 
5.2.4 Characterization of triGal conjugates  
We measured the particle size of the nanoparticle formulations by dynamic light scattering (DLS) 
using a 90Plus particle size analyzer (Brookhaven Instruments, Holtsville, NY). The nanoparticle 
solution was diluted in DI water at 1:20 v/v with 10% tween 20 in order to limit nanoparticle 
aggregate formation. T2-T14 conjugates were then sterile-filtered through syringe filters with a pore 
size of 200 nm and warmed to 37℃ before measurements. Raw distribution data was plotted in 
Graphpad Prism software and fit using a Gaussian curve, with the mean being taken as the particle 
size for that replicate. The average of three separate replicates was taken to find the mean particle 
size ± standard error of the mean (SEM). We also determined the zeta potential of the conjugates 
using a 90Plus Zeta Potential Analyzer (Brookhaven Instruments, Holtsville, NY). Particle 
formulations were dissolved in DI water at 1:20 v/v and warmed to 37℃ before analysis. The 
average of three separate replicates was taken to find the mean zeta potential ± SEM. 
 
5.2.5 Cell Culture 
HepG2 cells were cultured in T-75 flasks using MEM supplemented with 10% FBS, 1% antibiotic-
antimycotic, 1% sodium pyruvate, 1% non-essential amino acids, and 1 mL gentamicin. HepG2 




every 48 hours. The cells were passaged at 80-90% confluency using a 0.25% trypsin/0.20% 
EDTA solution. 
 
5.2.6 Uptake of triGal vs. monoGal conjugates into hepatic cancer cells  
The internalization of triGal and monoGal conjugates into HepG2 cells was measured as a function 
of particle composition and concentration via flow cytometry. Briefly, 250,000 HepG2 cells were 
seeded in 24-well plates and allowed to adhere overnight. Treatment solutions of M12 or T2-T14 
conjugates (142-570 nM G5 concentration) were prepared in OPTI-MEM and then incubated with 
the cells for 24 hours at 37 ℃. After removing the treatment medium and washing the cells with 
warmed PBS twice, the adherent cells were removed from the plates using a 0.25% trypsin/0.20% 
EDTA solution and then suspended in fresh culture medium. The cells were then transferred to 
flow cytometry tubes, centrifuged at 1000 RPM for 5 minutes at 4℃, kept on ice, and resuspended 
immediately before analysis. Samples were analyzed by flow cytometry using the intrinsic 
fluorescence of FITC (λex: 488 nm; λem: 525 nm) on a Beckman Coulter Cyan ADP instrument 
provided by the Flow Cytometry Core at the University of Michigan (Ann Arbor, MI). Data is 
presented as the mean ± SEM for n=4 replicates, and we used untreated cells in blank OPTI-MEM 
as our negative control.  
 
5.2.7 Multi-spectral imaging flow cytometry of triGal vs. monoGal conjugates in HepG2 cells 
The internalized versus surface-bound ratio of triGal and monoGal conjugates in HepG2 cells was 
measured using multi-spectral imaging flow cytometry. First, 1x106 HepG2 cells were seeded in 
24-well plates and allowed to adhere overnight. Treatment solutions of M12 or T2-T14 conjugates 




24 hours at 37℃. After removing the treatment solution and washing the cells twice with PBS, the 
adherent cells were removed from the plates using a 0.25% trypsin/0.20% EDTA solution and then 
suspended in fresh culture medium. The cells were spun down at 1000 RPM at 4℃,  the supernatant 
aspirated, and then resuspended in PBS with 2% FBS at 107 cells/mL in microcentrifuge tubes.  
The cells were then kept on ice and resuspended immediately before analysis. On an Amnis 
ImagestreamX multi-spectral imaging flow cytometer provided by the Flow Cytometry Core, 
singular cells in focus were measured for their FITC signal. IDEAS software (EMD Millipore, 
Billerica, MA) was used to generate two populations of FITC-positive cells based on an 
internalization ratio determined by the software as a comparison between FITC intensity inside the 
cell versus the entire cell. We divided the high internalization group (high internalization ratio, I0) 
by the surface-bound group (low internalization ratio, I) in order to quantitatively assess the extent 
of nanoparticle internalization (I0/I) between M12 and T2-T14 conjugates. I
0/I values are represented 
as the mean  SEM of three replicates. We used a one-way ANOVA with Tukey’s multiple 
comparisons test to determine the significance between I0/I values for each group, with 




5.3 Results and Discussion  
5.3.1. Synthesis of T2-T14 Conjugates 
 
We synthesized G5 dendrimers functionalized with a varying density (n) of cPEG-(NAcGal)3 
branches by modifying our previous synthetic strategies to achieve FITC-labeled G5-[cPEG-
(NAcGal)3]n conjugates (Figure 30)
9,17. We used the same FITC-labeled G5-NH2 precursor for 
both monoGal (M12) and the library of triGal conjugates (T2-T14) to ensure equivalent fluorescence 
activity (6 moles of FITC) between each conjugate. We used N6-Cbz-lysine, a known starting 
material for synthesizing the triGal spacer23. N- alkylation of N6-Cbz-lysine with bromoacetic acid 
yielded an N6-carbobenzylaxy-L-lysine triacid (6), which was coupled to NAcGal-amine (5) to 
obtain compound 7.  The Cbz was deprotected by hydrogenolysis (8) and then coupled to a 
heterofunctional, 2kDa Boc-NH-PEG-NHS ester to obtain compound 9. After de-protecting the 
Boc group to establish compound 10, reaction with cis-aconitic anhydride yielded the cPEG-
(NAcGal)3 targeting arms (11). We coupled compound 11 with the FITC-labeled G5-NH2 
dendrimer (12) via peptide coupling at varying molar ratios to achieve 13-18 with different ratios 
of cPEG-(NAcGal)3 branches attached. Finally, the remaining primary G5 amines on these 
conjugates were acetylated and the O-acetyl groups from NAcGal ligands was de-protected to 
achieve conjugates T2-T14 (Figure 30). The conjugates were characterized by 1H-NMR and 
MALDI for their ligand concentration and molecular weights, which can be found in Table 5. 
 
The variation in loading of cPEG-(NAcGal)3 branches corresponded to 1.6, 2.8, 4.5, 6.3, 8.3, and 
11.1 mole% PEGylation of T2, T4, T6, T8, T11, and T14 conjugates, respectively. Given that PEG 




regime at higher densities, it is expected that T2-T14 conjugates should have differing PEG 
conformations based on their varying PEG density. PEG chains attached to spherical nanoparticles 
in the brush conformation typically impart higher hydrodynamic diameters (HD) to the 
nanoparticles, due to the thin, bristle-like extension of the PEG away from the nanoparticle surface. 
Conversely, nanoparticles with PEG in the mushroom conformation typically have smaller HDs 
due to the coiling of the PEG chains. We performed dynamic light scattering (DLS) to identify the 
HD of triGal conjugates, and found that all conjugates exhibit an HD of approximately 7 nm, with 
no statistical significance between them (Table 5). This suggests that the differences in 
PEGylation between T2-T14 conjugates that confers different PEG conformations does not impart 
significant impacts on the HD of NPs at the nanometer scale.  
 
All conjugates exhibited a size profile that confers the ability to surpass renal filtration from the 
blood (HD < 5nm25,26), thereby extending their retention time within the bloodstream. MALDI 
analysis confirmed that the molecular weight (MW) of triGal particles increased with increasing 
density of cPEG-(NAcGal)3 branches (Table 5). It is important to note that both T2 and T4 
conjugates (34,725 and 39,789 Da, respectively) fall under the MW cut-off (40,000 Da) estimated 
to enable nanoparticles to exploit the EPR effect13,27,28.  Studies in tumor-bearing mice will help 
identify whether these conjugates are retained within the bloodstream and cleared through the urine 
before they can concentrate into tumor tissue. T2-T14, however, have MWs that should enable their 
easy exploitation of the EPR effect. Finally, we measured the zeta potential of T2-T14 conjugates 
and confirmed that they are neutral (Table 5), which should prevent non-specific charge-charge 














5.3.2 Uptake of triGal vs. monoGal in hepatic cancer cells 
We used flow cytometry to establish whether the library of triGal conjugates could be recognized 
and internalized by hepatic cancer cells, and to identify how this internalization compared to that 
of monoGal conjugates. Briefly, we incubated M12 and T2-T14 conjugates at 142, 285, and 570 nM 
G5 concentration with HepG2 cells for 24 hours. We previously established that the internalization 
of G5-based conjugates targeted by monoGal ligands are internalized by hepatic cancer cells at a 
NAcGal concentration range of 100-4000 nM9,17,18. With 12-16 moles of cPEG-NAcGal attached 
to the dendrimers, these concentrations corresponded 7-285 nM of G5 dendrimers. At 142 and 285 
nM G5, we achieve 100% uptake into HepG2 cells with monoGal-targeted particles (M12). Similar 
to this we chose a concentration range of 142-570 nM in this study to compare the internalization 
of monoGal versus triGal conjugates into HepG2 cells. Results show that T2-T14 conjugates label 
HepG2 in a concentration-dependent manner, labeling only 2-4% of HepG2 cells at 142 nM G5 
but reaching 100% cell labeling at 570 nM (Figure 31). Interestingly, at a low concentration of 
142 nM, M12 labels 8- to 15-fold more cells than any of the triGal conjugates, reaching strong 
statistical significance between it and all triGal conjugates (p<0.0001, M12 vs. T2-T14). At 285 nM, 
the labeling of HepG2 cells by T2-T14 conjugates increases significantly (64-89% cells labeled). 
Of particular note, T8, T11, and T14 conjugates achieve higher cell labeling (89, 89 and 85%, 
respectively) than T2, T4, and T6 (64, 72, 72%, respectively) with statistical significance (p<0.01 
for all comparisons). Importantly, however, M12 is able to label virtually all cells (99%) with 
statistically significant differences from all triGal conjugates (p<0.001). At this concentration of 
G5, the NAcGal present on M12 conjugates (3420 nM) falls in between that displayed by T11 
(3135 nM) and T14 (3990 nM) conjugates. Regardless, M12 achieves statistically higher labeling 




of 570 nM G5, all conjugates label 100% of cells. Further, we investigated the uptake of triGal 
and monoGal conjugates in SK-Hep1 cells, an ASGPR-deficient HCC cell line31,32, to ensure that 
the uptake was mediated and dependent on this receptor (data not shown). For all particles, there 
was less than <10% internalization into SK-Hep1 cells at all concentrations after 24 hours, 




Figure 31: Uptake of triGal vs. monoGal into HepG2 cells. We measured the uptake of monoGal and triGal 
conjugates into HepG2 cells via flow cytometry. M12, T2, T4, T6, T8, T11, and T14 conjugates were incubated at G5 
concentrations of 142, 285, and 570 nM, which corresponded to various NAcGal concentrations based on the 
loading density, as seen in the table. Results show that both monoGal and triGal are able to label HepG2 cells 
with increasing concentration, with monoGal achieving higher labeling at lower conjugate concentrations. T2, T4, 
and T6 exhibited lower internalization than T8, T11, and T14 conjugates, likely due to their loaded NAcGal 
differences. Results are presented as the mean of four replicates  SEM. Two-way ANOVA was used to 




Taken together, our results show that triGal conjugates are ASGPR-specific and able to label 100% 
HepG2 cells at the highest concentrations, while at lower concentrations they achieve cell labeling 
but to a lower extent. However, M12 conjugates label 1.5-8 folds more HepG2 cells at lower G5 
concentrations (i.e 142-285 nM), suggesting that mono-valent NAcGal-targeting of G5 
dendrimers is more efficient at being recognized by hepatic cancer cells.  
 
5.3.3 Surface versus internal localization of triGal vs monoGal in HepG2 cells 
Given our initial flow cytometry results, we sought to understand why triGal conjugates, while 
being able to label HepG2 cells, cannot do so as efficiently as their monoGal counterparts despite 
similar concentrations of NAcGal. We hypothesized that the decrease in cell labeling may come 
from one of a few theories related to valency-dependent cell-binding. In particular, many 
investigators have described receptor cross-linking using coiled-coil networks, which describes 
molecules targeting a receptor at the cell surface that are connected to a larger polymer network 
(i.e. coiled-coil), creating a crosslinking of receptors through this extracellular network and 
rendering them deficient or even sometimes leading to apoptosis induction33,34. We hypothesized 
that triGal conjugates could be inducing a similar “receptor crosslinking” phenomenon. This would 
be possible if the same cPEG-(NAcGal)3 branch was bound to multiple ASGPRs, where both 
would “pull” on the same NP for endocytosis, but face competition by an equal and opposite force 
from another engaged receptor. In this way, the G5 dendrimer would be the “network” causing the 
receptor crosslinking, and while triGal conjugates would be bound to the cell surface they may not 
be internalized fully. Due to the limitations of conventional flow cytometry, our previous results 




bound and internalized nanoparticles. We therefore turned to multi-spectral imaging flow 
cytometry, which adds the ability to microscopically image cells being sorted by flow cytometry 
in order to identify the cellular localization of the fluorescence, and in this case, the nanoparticles 
35. We incubated either M12 or T2-T14 conjugates at 285 nM for 24 hours with HepG2 cells (Figure 
32), and used the data collection software to measure the internalization ratio of each FITC-labeled 
 
Figure 32: Surface versus internalized localization of monoGal and triGal conjugates in HepG2 cells. We 
used multi-spectral imaging flow cytometry to visualize surface-bound conjugates and internalized conjugates, as 
assessed by an IDEAS software-based internalization algorithm. Results show that monoGal and triGal conjugates 




cell and separate them into cells with surface-bound nanoparticles or cells with mostly internalized 
ones. It is important to note that these two populations are presented as a percentage of all FITC-
labeled cells, so differences in cell labeling mentioned above are accounted for in this analysis and 
are not relevant. Results indicate that the localization of nanoparticles does not differ between 
triGal and monoGal conjugates, and also does not differ between the triGal conjugates themselves. 
Images collected for all treatments during flow cytometry show both punctate fluorescence at cell 
membranes, indicating surface-bound nanoparticles, and diffuse fluorescence within the cell 
indicating nanoparticle diffusion throughout the cell body (Figure 32).  
 
We also quantitatively evaluated the extent of internalization for all nanoparticle treatments by 
determining I0/I, a metric comparing the extent of nanoparticle internalization (I0) versus surface 
localization (I) (Figure 33). I0/I > 1 would indicate higher internalization than surface-bound 
localization, while I0/I < 1 would indicate higher surface localization than internalization. Results 
show that I0/I ranged from 3.2 for T2 conjugates up to 4.1 for T8 conjugates, with no statistical 
significance between any of the treatment groups. This indicates that there was significantly higher 
internalization than surface localization for all treatments. Further, the lack of difference in I0/I 
values between triGal and monoGal conjugates indicates that there are in fact no higher surface-
localized triGal conjugates than there are monoGal conjugates. Since these populations are contain 
an equivalent number of cells that are labeled by the NPs, the equivalence in internalized versus 
surface-bound particles between monoGal and triGal treatments indicates that the internalization 
kinetics are similar between the two.  
 




the differences in valency contribute to the kinetics of receptor binding, but not of internalization 
once the particles are bound to the ASGPR. We believe therefore that receptor-crosslinking may 
not be occurring with triGal conjugates. It is possible that the geometric spacing between NAcGal 
ligands at the tip of cPEG-(NAcGal)3 branches affects their kinetics of binding to the ASGPR. 
Khorev et al. showed through molecular modeling that the length of the flexible spacer attaching 
NAcGal ligands to the backbone as well as the space between each NAcGal ligand specifically 
impacted their binding affinity to ASGPR22. Zacco et al. built off of this work to create a 
glycopeptide library studying various combinations of spacer lengths and distances between 
 
Figure 33: Internalized versus surface bound ratio (I0/I) of T2-T14 and M12 conjugates. We quantitatively 
assessed the ratio of FITC-labeled cells with high internalization (I0) versus low internalization (I) by 
determining I0/I. Results show that for all treatment groups, the conjugates were internalized to a much greater 
extent than they were maintained at the surface, as indicated by I0/I values > 1. Further, the I0/I values between 
monoGal and triGal conjugates are not statistically different, indicating that they achieve the same ratio of 
internalized particles when they label cells. Results are presented as the mean of three replicates  SEM. A one-




NAcGal ligands, identifying that NAcGal ligands spaced 7 amino acids from each other on a 
peptide backbone and at the tip of an 18 angstrom spacer achieved the best targeting of the 
ASGPR34. The molecular modeling and geometric measurements of our triGal library is currently 
ongoing, and is very important to help elucidate the differences in binding of ASGPR between 
monoGal and triGal conjugates. Nevertheless, this study suggests that the internalization process 
of monoGal versus triGal is similar, and an equivalent density of conjugates can be internalized to 
the cell body compared to being localized at the cell surface.  
 
5.4. Conclusions 
This study focuses on the synthesis and validation of a library of G5 dendrimers displaying a 
varying density (n=2, 4, 6, 8, 11, or 14) of tri-valent (NAcGal)3 ligands as potential drug delivery 
vehicles for hepatic cancer therapy. Our results indicate that triGal conjugates achieve 
concentration-dependent internalization into hepatic cancer cells that is comparable to our-
previously established mono-valent, NAcGal-targeted dendrimers. Differences are noticed 
however at low concentrations, where monoGal more efficiently labels hepatic cancer cells than 
triGal conjugates. Multi-spectral imaging flow cytometry confirmed that the localization of triGal 
conjugates is both intracellular and at the surface, similar to their monoGal counterparts. Taken 
together, it is evident that binding of G5 dendrimers to the ASGPR is affected by NAcGal valency, 
but the process of how they are internalized is less susceptible to the difference. To the best of our 
knowledge, this is the first study to describe the effect of multi-valent NAcGal ligands on 
nanoparticle targeting of hepatic cancer cells. With the success of this conjugate library reported 




drug delivery depending on fabrication, biodistribution, or therapeutic load constraints, ultimately 
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1. Synthesis of (NAcGal)3-PEGc-G5-FITC Particles: 
General Experimental Procedures: All reactions were carried out under nitrogen with anhydrous 
solvents in flame-dried glassware, unless otherwise noted. All glycosylation reactions were 
performed in the presence of molecular sieves, which were flame-dried right before the reaction 
under high vacuum. Solvents were dried using a solvent purification system and used directly 
without further drying. Chemicals used were reagent grade as supplied except where noted. 
Analytical thin-layer chromatography was performed using silica gel 60 F254 glass plates. 
Compound spots were visualized by UV light (254 nm) and by staining with a yellow solution 
containing Ce(NH4)2(NO3)6 (0.5 g) and (NH4)6Mo7O24·4H2O (24.0 g) in 6% H2SO4 (500 mL). 
Flash column chromatography was performed on silica gel 60 (230–400Mesh). NMR spectra were 
referenced using Me4Si (0 ppm), residual CHCl3 (δ 
1H-NMR 7.26 ppm, 13C-NMR 77.00 ppm), 
CD3OD (δ 
1H-NMR 3.35 ppm, 13C-NMR 49.2 ppm) and D2O (δ 
1H-NMR 4.65 ppm). Peak and 
coupling constant assignments are based on 1H-NMR.  
Characterization of anomeric stereochemistry: The stereochemistry of the newly formed 
glycosidic linkages in N-acetyl galactosamine derivative was determined by JH1,H2 through 
1H-
NMR. Smaller coupling constants of JH1,H2 (below 4 Hz) indicate α linkages and larger coupling 
constants JH1,H2 (6.0 Hz or larger) indicate β linkages.  
Mass spectrometry (MS) analysis: ESI-MS measurements were performed according to the 
published protocols on a Q-TOF Ultima API LC-MS instrument with Waters 2795 Separation 
Module (Waters Corporation, Milford, MA). All samples passed through an EagleEye HPLC C18 
column, 3 mm × 150 mm, 5 μm at a flow rate of 0.5 mL/min with a linear gradient from 10% 
eluent B to 26% eluent B over eight minutes with the column temperature maintained at 45 °C. 
All injections were performed in the full-loop injection mode using a 10 μL sample loop. Eluent 
A consisted of a pure aqueous solution and eluent B contained 75% acetonitrile/25% aqueous 
solution (v/v).  The following instrument settings were common for analyses S16 performed in 
both positive and negative ion modes: source temperature 120 °C, desolvation temperature 400 
°C, collision energy 10 eV. When operated in negative ion mode, the mass spectrometer used the 




The following instrumental parameters were used for data acquisition in positive ion mode: 
capillary voltage 3.5 kV, cone voltage 35 V. Sample concentrations were 1mg/mL. MALDI mass 
spectra were recorded on a Shimadzu Axima-CFR plus MALDI-TOF. The matrix used was 2,5-
dihydroxy-benzoic acid (DHB) and Melittin from honeybee venom (M2272 from Sigma-Aldrich) 
as the calibration compound.  
2. Experimental Section  
Synthesis of G5 dendrimer Nano conjugates: Complete NMR and time-of-flight matrix-assisted 
laser desorption/ionization (MALDI-TOF) spectra confirming the structural identity and 
composition of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]n (T1-T6) conjugates can be found 
in this Appendix C. Control Nano particles ((FITC)6-G5 conjugate (12 or T0) was synthesized 
according to our previously established protocol.[1] We have reported the synthesis and analytical 
data for compounds 1-5 in our previous work[1]. Below, we describe the synthesis and analytical 
data for compounds 6-18 & T1-T6 conjugates. 
 
2.1. Synthesis of 2,2'-((5-(((benzyloxy)carbonyl)amino)-1-carboxypentyl)azanediyl)diacetic acid 
(6) 
Commercially available N6-Cbz-L-Lysine  (1.0 g, 3.56 mmol) was taken in 1.5 M solution of 
NaOH (45 mL) and added alpha bromoacetic acid (0.77 mL, 10.70 mmol) dissolved in 1.5 M 
solution of NaOH (90 mL) and stirred at 50 oC for 24 h, then neutralized with 1 N HCl solution 
to pH 2-3. And the resulted solid was filtered and washed thoroughly with water and dried under 
vacume to obtain compound 6 (1.21 g, 86%).  
1H-NMR (500 MHz, CD3OD): δ 1.34-1.56 (m, 4H, Hb, 2Hc, Hd), 1.60-1.72 (m, 1H, Hd), 1.72-
1.86 (m, 1H, Hb), 3.11 (t, 2H, J = 6.0 Hz, He), 3.45 (t, 1H, J = 7.0 Hz, Ha), 3.61 (q, 4H, J = 15.0 
& 17.5 Hz, 2Hf), 4.92 (s, 2H, Cbz CH2), 7.22-7.38 (m, 5H, Cbz aromatic protons); 
13C-NMR 
(125 MHz, CD3OD): δ 24.62 (Cc), 30.50 (Cb), 30.70 (Cd), 41.46 (Ce), 55.29 (Cf), 66.68 (Ca), 
67.32 (CH2 Cbz), 128.76, 128.91, 129.44, 138.47, 158.92 (Cbz carbonyl), 175.92 (acid 
carbonyl). ESI-MS: [M-H]- C18H23N2O8 calcd 395.1458, obsd 395.1454. 




Compound 6 (0.025 g, 0.063 mmol) was dissolved in DMF:DMSO (3:1; 2 mL) and  added DCC 
(78 mg, 0.37 mmol), HOBt (50 mg, 0.37 mmol), freshly activated 4 Ao MS (0.1 g) and stirred at 
RT for 15 min. Then, the D-galactosamine sugar amine 5 (270 mg, 0.567 mmol) in anhydrous 
DMF:DMSO (3:1; 1.5 mL) was added and stirred for 24 h at RT, followed by increasing the 
reaction temperature to 35 oC for 2 days, then 45 oC for additional 1 day. The reaction mixture was 
cooled to RT and filtered through celite pad, purified via dialysis (MWCO 1 KDa) against DI water 
for 36 hours, water was lyophilized to obtain compound 7 as an off-white solid (78 mg, 70% yield).  
1H NMR (500 MHz, CDCl3): δ 1.40 (t, 2H, J = 6.5 Hz), 1.56-1.73 (m, 4H, 2CH2), 1.87-2.18 (s, 
36H, 12CH3, 9OCOCH3 + 3NHCOCH3), 2.70-3.70 (m, 43H, 6 x 3 x2 = 36 ethylene oxide protons), 
3.70-3.80 (m, 6H), 3.85-3.95 (m, 3H), 4.00-4.45 (m, 12H, Gal-protons), 4.70-4.80 (m, 1H), 4.80-
4.90 (m, 2H), 4.90-5.20 (m, 6H), 5.25-5.40 (m, 3H), 5.60 (bs, 1H), 6.85 (d, 1H, J = 8.5 Hz, NH), 
7.22-7.38 (m, 5H, Cbz-Ar-H), 7.57 (d, 3H, J = 8.0 Hz, NH), 7.79 (d, 3H, J = 8.0 Hz, NH), 8.09 
(bs, 1H, NH); 13C NMR (125 MHz, CDCl3):  δ 19.35, 20.67, 20.70, 20.83, 22.65, 22.99, 23.15, 
29.32, 29.66, 30.89, 31.89, 38.97, 39.22, 40.53, 41.83, 47.30, 50.74, 53.36, 60.37, 61.01, 61.53, 
61.64, 62.63, 65.50, 66.40, 66.77, 68.51, 69.09, 69.51, 69.96, 70.20, 70.28, 70.56, 72.43, 79.04, 
79.06, 101.51, 106.44, 110.65, 118.47, 124.30, 125.57, 127.97, 128.09, 128.45, 142.95, 170.11, 
170.49, 170.60. ESI-MS: [M+H]+ C78H121N8O38 calcd 1777.7782, obsd 1778.21. 
2.3. Synthesis of N6-NH2-L-Lysine-(NAcGalβ)3) (8) 
Compound 7 (70 mg, 0.039 mmol) was dissolved in EtOH:EtOAc (3:1; 4 mL) and  added Pd-on 
activated carbon (20 mg) followed by 2 drops of AcOH and stirred under hydrogen gas at RT for 
24 h. The reaction mixture was filtered through celite pad, purified via column chromatography to 
obtain compound 8 as an off-white solid (53 mg, 82% yield).  
1H NMR (500 MHz, CDCl3): δ 1.42 (t, 2H, J = 6.5 Hz), 1.54-1.68 (m, 4H, 2CH2), 1.78-2.08 (s, 
36H, 12CH3, 9OCOCH3 + 3NHCOCH3), 2.42-2.50 (m, 2H), 2.55-3.00 (m, 6H), 3.00-3.70 (m, 
43H, 6 x 3 x 2 = 36 ethylene oxide protons), 3.75-3.90 (m, 4H), 3.85-4.60 (m, 18H, Gal-protons), 
4.75-4.85 (m, 3H), 4.85-4.95 (m, 2H), 4.95-5.30 (m, 8H), 7.50 (d, 3H, J = 7.0 Hz, NH), 7.64 (d, 
3H, J = 8.0 Hz, NH), 7.72-7.76 (m, 1H, NH); 13C NMR (125 MHz, CDCl3):  δ 18.58, 18.72, 20.29, 
20.34, 20.37, 20.44, 20.50, 20.91, 22.31, 22.35, 22.41, 22.44, 22.57, 23.83, 38.72, 38.84, 38.97, 
41.87, 42.54, 43.35, 46.68, 47.86, 49.64, 49.96, 50.13, 53.54, 55.40, 56.73, 57.12, 60.81, 61.28, 




69.62, 69.69, 69.72,69.78, 69.90, 69.97, 70.02, 70.07, 70.19, 70.28, 76.31, 76.44, 76.53, 78.85, 
78.88, 91.53, 101.34, 106.04, 106.27, 110.76, 114.60, 117.68, 124.39, 124.87, 125.42, 127.59, 
142.43, 170.25, 170.35, 170.43, 170.54, 170.69, 174.89. ESI-MS: [M+H]+ C70H115N8O36 calcd 
1643.7414, obsd 1644.16. 
2.3.Synthesis of (NAcGalβ)3-Lysine-6-NH-PEG-NHBoc (9) 
NHS-PEG-NHBoc (65 mg, 0.0328 mmol) was taken in DMF (2.0 mL) and added EDC.HCl (12.5 
mg, 0.0656 mmol), HOBt (4.4 mg, 0.0328 mmol), DIPEA (0.005 mL, 0.0292 mmol) and stirred 
for 15 min. Then, compound 8 (45 mg, 0.0274 mmol) was dissolved in DMF (1.5 mL) and  added 
slowly and stirred at RT for 1 day, then at 40 oC for 3 days. The reaction mixture was cooled to 
RT and purified by dialysis (MWCO 2 kDa) against DI water for 48 h, then lyophilized to obtain 
compound 9 as an off-white solid (86 mg, 90% yield).  
1H NMR (500 MHz, CDCl3): δ 1.13 (s, 9H, Boc protons), 1.42 (t, 2H, J = 6.5 Hz), 1.44-1.66 (m, 
4H, 2CH2), 1.88-2.14 (s, 36H, 12CH3, 9OCOCH3 + 3NHCOCH3), 2.28-2.60 (m, 6H), 2.60-2.72 
(m, 3H), 2.60-2.72 (m, 3H), 2.75-3.00 (m, 6H), 3.00-3.80 (m, 225H, 6 x 3 x 2 = 36 ethylene oxide 
protons + PEG-H), 3.80-3.90 (m, 4H), 4.02 (bs, 2H), 4.01-4.35 (m, 18H, Gal-protons), 4.65-4.90 
(m, 2H), 4.90-5.20 (m, 3H), 5.28-5.38 (m, 2H), 6.88 (d, 3H, J = 7.0 Hz, NH), 7.52 (bs, 3H, NH), 
7.60 (d, 3H, NH), 7.88 (d, 1H, J = 8.0 Hz, NH). MALDI: [M+PEG+H]+ C70H115N8O36 + PEG-
NHBoc calcd 3527.8, obsd 3430.7.  
2.4. Synthesis of (NAcGalβ)3-Lysine-6-NH-PEG-NH2 (10) 
Compound 9 (70 mg, 0.0198 mmol) was dissolved in DCM:TFA (1.5:1, 2.5 mL) and stirred at 
room temperature for 16 hours. The solvents were evaporated under reduced pressure, and the 
residue was co-evaporated three times with DCM (3 x 3 mL) to remove all TFA. The residue 
washed twice with cold Et2O (4 mL), decanted before evaporation to obtain compound 10 (61 mg, 
90%) as a syrup and utilized for the next reaction without purification.  
1H NMR (500 MHz, D2O): δ 1.62-2.10 (m, 38H, including 12CH3, 9OCOCH3 + 3NHCOCH3), 
2.20-2.60 (m, 6H), 2.60-2.85 (m, 6H), 2.80-4.00 (m, 225H, 6 x 3 x 2 = 36 ethylene oxide protons 
+ PEG-H + sugar protons), 4.00-4.25 (m, 18H, Gal-protons), 4.96 (d, 2H, J = 6.5 Hz), 5.10-5.30 
(m, 3H), 6.86 (d, 3H, J = 7.0 Hz, NH), 6.92 (bs, 3H, NH), 7.27 (d, 3H, NH), 7.67 (d, 1H, J = 5.5 
Hz, NH).  ESI-MS: [M+PEG+H]+ C76H126N8O30+PEG-NH2 calcd 3427.8, obsd 3400.1.  




Compound 10 (50 mg, 0.0147 mmol) was dissolved in DI water (3 mL) followed by addition of 
cis-aconitic anhydride (11.4 mg, 0.0735 mmol) in 1,4-dioxane (0.75 mL). The pH was adjusted 
to 8.5-8.7 by drop wise addition of 0.5 M NaOH and solution stirred for 10 minutes at room 
temperature. The pH was then adjusted to 7.4-7.5 via addition of ice-cold 1N HCl solution and 
reaction mixture stirred at 0 oC for 5 minutes before further acidification to pH 2.5-3.0 while 
stirring for 5 minutes at 0 oC. The reaction mixture was purified by dialysis (MWCO 1 kDa) 
against DI water for 36 hours and lyophilized to obtain compound 11 as an off-white solid in 40 
mg; 80% yield.  
1H NMR (500 MHz, D2O): δ 1.62-2.10 (m, 38H, including 12CH3, 9OCOCH3 + 3NHCOCH3), 
2.20-2.60 (m, 6H), 2.60-2.85 (m, 6H), 2.90-3.80 (m, 225H, 6 x 3 x 2 = 36 ethylene oxide protons 
+ PEG-H + sugar protons), 3.80-4.00 (m, 18H, Gal-protons), 4.00-4.35 (m, 18H, Gal-protons), 
4.94 (d, 3H, J = 9.0 Hz), 5.15-5.30 (m, 3H), 6.84 (d, 3H, J = 8.5 Hz, NH), 7.25 (bs, 3H, NH), 7.66 
(d, 3H, J = 8.5 Hz, NH), 8.03 (d, 1H, J = 10.5 Hz, NH); 13C NMR (125 MHz, CDCl3): δ 13.96, 
19.52, 20.34, 20.36, 20.43, 20.52, 22.21, 22.35, 22.41, 22.44, 22.57, 23.83, 29.39, 29.76, 31.93, 
35.28, 35.71, 39.02, 40.91, 42.09, 43.41, 52.29, 53.08, 54.15, 55.75, 59.31, 59.80, 60.27, 61.91, 
63.46, 64.49, 66.27, 67.69, 68.18, 69.38, 69.50, 69.81, 69.85, 69.97, 70.13, 70.22, 70.44, 71.63, 
72.45, 75.52, 75.65, 79.53, 81.54, 99.53, 106.04, 110.76, 115.58, 127.75, 129.87, 131.05, 132.26, 
136.96, 139.63, 142.08, 170.56, 170.79, 171.22, 171.65, 172.59, 175.92, 176.22, 178.59. 
2.6. Synthesis of G5-FITC)6 (12 or T0)  
Commercially available G5-amine (40 mg, 1.59 x 10-3 mmol, 1 eq) was dissolved in DI water (4 
mL) and added FITC (9.3 mg, 2.38 x 10-2 mmol, 15 eq) in 1, 4-Dioxane (1 mL) and stirred at RT 
for 36 h. Reaction mixture was transferred in to dialysis cassette (7 kDa) and dialyszed for 2 days 
against DI water, followed by lyophilization afforded compound 12 or T0 (40 mg, 92% yield).  
1H-NMR (500 MHz, D2O): δ 2.04-2.30 (m, 258H, G5-H), 2.30-2.50 (m, 120H, G5-H), 2.50-2.75 
(m, 235, G5-H), 2.75-2.95 (m, 96H, G5-H), 2.95 (t, 16H, J = 6.0 Hz, pentyne-H), 3.05-3.35 (m, 
260H, G5-H), 3.40-3.44 (bs, 5H), 3.50-3.75 (bs, 15H), 6.30-6.50 (m, 26H), 6.75-6.80 (m, 2H), 
6.95-7.20 (m, 19H), 7.20-7.30 (m, 4H), 7.30-7.60 (m, 7H), 7.60-7.85 (m, 7H). MALDI analysis: 
The molecular weight of parent G5-amine was observed at 25120.00 and the molecular weight 




This is attributed to FITC units, each FITC contributes 389.38 daltons. Therefore obtained FITC 
functionality is 6 units. 
2.7.  Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ-Ac)3]2 (13) 
Compound 11 (6.2 mg, 1.63 x 10-3 mmol, 3 eq.) was dissolved in 0.1 M potassium phosphate 
buffer (pH 6.0, 1.5 mL) followed by addition of EDC.HCl (1.2 mg, 6.53 x 10-3 mmol; 1:4 with 
acid) and reaction mixture was stirred at room temperature for 30 minutes. G5-(Fl)6 (12, 15 mg, 
5.46 x 10-4 mmol) in MeOH (2 mL) was added and solution adjusted to pH 8.0 via drop wise 
addition of 0.5 M Na2CO3 solution, followed by stirring at room temperature in the dark for 36 
hours. The reaction was purified by dialysis (MWCO 10 kDa) against DI water for 36 hours and 
lyophilized to obtain compound 13 as a light yellow fluffy material in 19 mg; 90% yield based 
on weight obtained.  
1H NMR (700 MHz, CDCl3): δ 0.70-0.82 (m, 6H, L-Lysine aliphatic protons), 0.95-1.60 (m, 
24H), 1.92 (s, 80H, including NH-CH3), 2.05-2.40 (m, 240H, G5-H), 2.40-2.60 (m, 120H, G5-
H), 2.60-2.82 (m, 240H, G5-H), 3.05-3.22 (m, 280H, 240 from G5-H), 3.36 (s, 12H), 3.52-3.62 
(m, 400H, 6 x 3 x 2 = 36 ethylene oxide protons + 360 PEG-H + sugar protons), 3.76-3.92 (m, 
12H, Gal-protons), 4.12 (d, 10H, J = 9.0 Hz), 6.40-6.60 (m, 12H), 6.77 (d, 6H, J = 9.0 Hz), 6.83 
(m, 10H), 7.05 (m, 8H, NH), 7.65 (d, 6H, J = 8.5 Hz, NH), 7.80-8.05 (m, 18H). Based on the 
NMR, we calculated the molecular weight of the conjugate 13 is Mnmr: 35020. 
2.8. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ-Ac)3]3.6 (14) 
Compound 11 (12.4 mg, 3.27 x 10-3 mmol, 6 eq.) was dissolved in 0.1 M potassium phosphate 
buffer (pH 6.0, 1.5 mL) followed by addition of EDC.HCl (2.5 mg, 1.30 x 10-2 mmol; 1:4 with 
acid) and reaction mixture was stirred at room temperature for 30 minutes. G5-(Fl)6 (12, 15 mg, 
5.46 x 10-4 mmol) in MeOH (2 mL) was added and solution adjusted to pH 8.0 via drop wise 
addition of 0.5 M Na2CO3 solution, followed by stirring at room temperature in the dark for 36 
hours. The reaction was purified, lyophilized as described for compound 13 to obtain 14 as a 
light yellow fluffy material in 19 mg; 84% yield based on weight obtained.  
1H NMR (700 MHz, CDCl3): δ 0.62-0.82 (m, 12H, L-Lysine aliphatic protons), 0.95-1.30 (m, 
48H), 1.32-1.56 (m, 12H), 1.86 (s, 120H, including OAc & NH-CH3), 2.05-2.40 (m, 240H, G5-
H), 2.40-2.60 (m, 120H, G5-H), 2.60-2.82 (m, 240H, G5-H), 3.05-3.22 (m, 280H, 240 from G5-




sugar protons), 3.78-3.80 (m, 16H, Gal-protons), 4.12 (d, 10H, J = 9.0 Hz), 4.50 (bs, 6H, Gal-
protons), 5.20 (bs, 6H, Gal-protons), 6.40-6.60 (m, 12H), 6.77 (d, 6H, J = 9.0 Hz), 6.90-7.05 (m, 
6H), 7.10 (bs, 8H, NH), 7.65 (bs, 10H, NH), 7.80-8.05 (m, 22H). Based on the NMR, we 
calculated the molecular weight of the conjugate 14 is Mnmr: 41060. 
2.9. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ-Ac)3]5.8 (15) 
Compound 11 (12.4 mg, 3.27 x 10-3 mmol, 9 eq.) was dissolved in 0.1 M potassium phosphate 
buffer (pH 6.0, 1.5 mL) followed by addition of EDC.HCl (2.5 mg, 1.31 x 10-2 mmol; 1:4 with 
acid) and reaction mixture was stirred at room temperature for 30 minutes. G5-(Fl)6 (12, 10 mg, 
3.64 x 10-4 mmol) in MeOH (2 mL) was added and solution adjusted to pH 8.0 via drop wise 
addition of 0.5 M Na2CO3 solution, followed by stirring at room temperature in the dark for 36 
hours. The reaction was purified, lyophilized as described for compound 13 to obtain 15 as a 
light yellow fluffy material in 18.6 mg; 83% yield based on weight obtained.  
1H NMR (700 MHz, CDCl3): δ 0.62-0.82 (m, 24H, L-Lysine aliphatic protons), 0.95-1.30 (m, 
68H), 1.40-1.56 (m, 20H), 1.86 (s, 120H, including OAc & NH-CH3), 2.00-2.05 (m, 12H), 2.05-
2.40 (m, 240H, G5-H), 2.40-2.60 (m, 120H, G5-H), 2.60-2.82 (m, 240H, G5-H), 3.05-3.24 (m, 
280H, 240 from G5-H), 3.36 (s, 12H), 3.52-3.62 (m, 1100H, 6 x 3 x 2 = 36 ethylene oxide 
protons + 1020 PEG-H + sugar protons), 3.78 (s, 16H, Gal-protons), 3.95 (s, 8H), 4.12 (bs, 12H, 
Gal-protons), 4.52 (bs, 4H, Gal-protons), 5.26 (bs, 6H, Gal-protons), 6.40-6.60 (m, 12H), 6.77 
(d, 6H, J = 9.0 Hz), 6.90-7.05 (m, 6H), 7.65 (bs, 10H, NH), 7.80-8.05 (m, 22H). Based on the 
NMR, we calculated the molecular weight of the conjugate 15 is Mnmr: 49380. 
2.10. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ-Ac)3]8.1 (16) 
Compound 11 (16.5 mg, 4.37 x 10-3 mmol, 12 eq.) was dissolved in 0.1 M potassium phosphate 
buffer (pH 6.0, 1.5 mL) followed by addition of EDC.HCl (3.3 mg, 1.74 x 10-2 mmol; 1:4 with 
acid) and reaction mixture was stirred at room temperature for 30 minutes. G5-(Fl)6 (12, 10 mg, 
3.64 x 10-4 mmol) in MeOH (2 mL) was added and solution adjusted to pH 8.0 via drop wise 
addition of 0.5 M Na2CO3 solution, followed by stirring at room temperature in the dark for 36 
hours. The reaction was purified, lyophilized as described for compound 13 to obtain 16 as a 
light yellow fluffy material in 22 mg; 83% yield based on weight obtained.  
1H NMR (700 MHz, CDCl3): δ 0.62-0.84 (m, 24H, L-Lysine aliphatic protons), 0.95-1.34 (m, 




2.40 (m, 240H, G5-H), 2.40-2.60 (m, 120H, G5-H), 2.60-2.82 (m, 240H, G5-H), 3.05-3.24 (m, 
280H, 240 from G5-H), 3.36 (s, 12H), 3.52-3.62 (m, 1500H, 6 x 3 x 2 = 36 ethylene oxide 
protons + 1410 PEG-H + sugar protons), 3.80 (s, 16H, Gal-protons), 3.95 (s, 8H), 4.12 (bs, 12H, 
Gal-protons), 4.52 (bs, 4H, Gal-protons), 5.26 (bs, 6H, Gal-protons), 6.40-6.60 (m, 12H), 6.77 
(bs, 6H), 6.90-7.05 (m, 2H), 7.65 (bs, 10H, NH), 7.80-8.05 (m, 22H). Based on the NMR, we 
calculated the molecular weight of the conjugate 16 is Mnmr: 58079. 
2.11. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ-Ac)3]10.6 (17) 
Compound 11 (20.7 mg, 5.46 x 10-3 mmol, 15 eq.) was dissolved in 0.1 M potassium phosphate 
buffer (pH 6.0, 1.5 mL) followed by addition of EDC.HCl (4.1 mg, 2.18 x 10-2 mmol; 1:4 with 
acid) and reaction mixture was stirred at room temperature for 30 minutes. G5-(Fl)6 (12, 10 mg, 
3.64 x 10-4 mmol) in MeOH (2 mL) was added and solution adjusted to pH 8.0 via drop wise 
addition of 0.5 M Na2CO3 solution, followed by stirring at room temperature in the dark for 36 
hours. The reaction was purified, lyophilized as described for compound 13 to obtain 17 as a 
light yellow fluffy material in 25 mg; 81% yield based on weight obtained.  
1H NMR (700 MHz, CDCl3): δ 0.62-0.84 (m, 24H, L-Lysine aliphatic protons), 0.95-1.34 (m, 
68H), 1.40-1.56 (m, 20H), 1.86 (s, 120H, including OAc & NH-CH3), 2.00-2.05 (m, 12H), 2.05-
2.40 (m, 240H, G5-H), 2.40-2.60 (m, 120H, G5-H), 2.60-2.82 (m, 240H, G5-H), 3.05-3.24 (m, 
280H, 240 from G5-H), 3.36 (s, 12H), 3.52-3.62 (m, 1880H, 6 x 3 x 2 = 36 ethylene oxide 
protons + 1800 PEG-H + sugar protons), 3.82-3.94 (m, 24H, Gal-protons), 4.12 (bs, 12H, Gal-
protons), 4.52 (bs, 4H, Gal-protons), 5.26 (bs, 6H, Gal-protons), 6.40-6.60 (m, 12H), 6.77 (bs, 
6H), 6.90-7.05 (m, 2H), 7.65 (bs, 10H, NH), 7.80-8.05 (m, 22H). Based on the NMR, we 
calculated the molecular weight of the conjugate 17 is Mnmr: 67538. 
2.12. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ-Ac)3]14.2  (18) 
Compound 11 (24.8 mg, 6.55 x 10-3 mmol, 18 eq.) was dissolved in 0.1 M potassium phosphate 
buffer (pH 6.0, 1.5 mL) followed by addition of EDC.HCl (9.9 mg, 2.62 x 10-2 mmol; 1:4 with 
acid) and reaction mixture was stirred at room temperature for 30 minutes. G5-(Fl)6 (12, 10 mg, 
3.64 x 10-4 mmol) in MeOH (2 mL) was added and solution adjusted to pH 8.0 via drop wise 
addition of 0.5 M Na2CO3 solution, followed by stirring at room temperature in the dark for 36 
hours. The reaction was purified, lyophilized as described for compound 13 to obtain 18 as a 




1H NMR (700 MHz, CDCl3): δ 0.62-0.84 (m, 24H, L-Lysine aliphatic protons), 0.95-1.34 (m, 
68H), 1.40-1.56 (m, 20H), 1.86 (s, 120H, including OAc & NH-CH3), 2.00-2.05 (m, 12H), 2.05-
2.40 (m, 240H, G5-H), 2.40-2.60 (m, 120H, G5-H), 2.60-2.82 (m, 240H, G5-H), 3.05-3.24 (m, 
280H, 240 from G5-H), 3.36 (s, 12H), 3.52-3.62 (m, 2580H, 6 x 3 x 2 = 36 ethylene oxide 
protons + 2500 PEG-H + sugar protons), 3.82-3.94 (m, 24H, Gal-protons), 4.12 (bs, 12H, Gal-
protons), 4.44 (bs, 12H, Gal-protons), 4.52 (bs, 4H, Gal-protons), 5.26 (bs, 6H, Gal-protons), 
6.40-6.60 (m, 12H), 6.77 (bs, 6H), 6.90-7.05 (m, 2H), 7.65 (bs, 10H, NH), 7.80-8.05 (m, 22H). 
Based on the NMR, we calculated the molecular weight of the conjugate 18 is Mnmr: 80799. 
2.13. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]2 (T1) 
Compound 13 (19 mg, 5.42 x 10-4 mmoles) was dissolved in anhydrous MeOH (2 mL), followed 
by addition of Et3N (0.2 mL), excess of Ac2O (0.15 mL) and reaction mixture stirred at room 
temperature for 48 hours. Solvents were removed under reduced pressure and residue purified by 
dialysis (MWCO 10 KDa) against sterile water for 48 hours and lyophilized. This compound was 
then dissolved in anhydrous MeOH (2 mL) and added 1 M NaOMe solution (0.3 mL) and 
reaction mixture stirred at room temperature for 48 hours. Solvents were removed under reduced 
pressure and the residue purified by dialysis (MWCO 10 kDa) against DI water for 48 hours and 
lyophilized to obtain compound T1 with deprotected NAcGal –OH groups as a light orange solid 
in 16.5 mg, 87% yield.  
1H NMR (700 MHz, D2O): δ 0.65-0.82 (m, 7H, L-Lysine aliphatic protons), 0.92-1.00 (m, 12H), 
1.00-1.20 (m, 10H), 1.88 (s, 9H, NH-CH3), 2.02-2.40 (m, 266H, G5-H), 2.40-2.56 (m, 120H, 
G5-H), 2.56-2.78 (m, 262H, G5-H), 2.95-3.05 (m, 126H, G5-H), 3.05-3.22 (m, 145H, G5-H), 
3.30-3.40 (m, 122H, G5-H), 3.55-3.65 (m, 297H, PEG-H + sugar protons), 3.72-3.82 (bs, 8H, 
Gal-protons), 4.22 (bs, 2H, Gal-protons), 6.30-6.50 (m, 24H), 6.90-7.20 (m, 17H), 7.35-7.60 (m, 
6H), 7.70-8.00 (m, 6H, NH).  
NMR Analysis: We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal 
standard to calculate the incoming, coupled PEG protons after attachment. We observed 297 
protons for PEG protons. Each 2 kDa PEG molecule have approximately 172 protons, therefore 
we were able to attach 1.72 units of -cPEG-6-NH-Lysine-(NAcGalβ)3. 
MALDI analysis: The molecular weight of parent particle G5-(FITC)6 is 27,460.8. The 
molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 34,274.5 which 




(NAcGalβ)3 units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore 
obtained G5-conjugate functionality is 1.99 units. 
 
2.14. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]3.6  (T2) 
Compound 14 (19 mg, 4.62 x 10-4 mmoles) was dissolved in anhydrous MeOH (2 mL), followed 
by addition of Et3N (0.2 mL), excess of Ac2O (0.15 mL) and reaction mixture stirred at room 
temperature for 48 hours. Solvents were removed under reduced pressure and residue purified by 
dialysis (MWCO 10 kDa) against DI water for 48 hours and lyophilized. This compound was 
then dissolved in anhydrous MeOH (2 mL) and added 1 M NaOMe solution (0.3 mL) and 
reaction mixture stirred at room temperature for 48 hours. The reaction was purified, lyophilized 
as described for compound T1 to obtain T2 as a light orange solid in 17 mg, 89% yield. 
  
1H NMR (700 MHz, D2O): δ 0.65-0.82 (m, 12H, L-Lysine aliphatic protons), 0.92-1.00 (m, 
14H), 1.00-1.22 (m, 18H), 1.88 (s, 13H, NH-CH3), 2.02-2.40 (m, 256H, G5-H), 2.40-2.56 (m, 
120H, G5-H), 2.56-2.78 (m, 244H, G5-H), 2.95-3.05 (m, 121H, G5-H), 3.05-3.22 (m, 150H, G5-
H), 3.30-3.40 (m, 121H, G5-H), 3.55-3.65 (m, 627H, PEG-H + sugar protons), 3.78-3.85 (bs, 
11H, Gal-protons), 4.20 (bs, 10H, Gal-protons), 4.30-4.42 (m, 9H, Gal-protons), 6.30-6.50 (m, 
32H), 6.90-7.20 (m, 28H), 7.38-7.60 (m, 13H), 7.70-8.00 (m, 12H). 
NMR Analysis: We observed 628 protons for PEG protons. Each 2 kDa PEG molecule have 
approximately 172 protons, therefore we were able to attach 3.65 units of -cPEG-6-NH-Lysine-
(NAcGalβ)3.  
MALDI analysis: The molecular weight of parent particle G5-(FITC)6 is 27,460.8. The 
molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 39,789.0 which 
has 12,328.2 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-
(NAcGalβ)3 units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore 
obtained G5-conjugate functionality is 3.6 units. 
 
 
2.15. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]5.8  (T3) 
Compound 15 (18.6 mg, 3.76 x 10-4 mmoles) was dissolved in anhydrous MeOH (2 mL), 




room temperature for 48 hours. Solvents were removed under reduced pressure and residue 
purified by dialysis (MWCO 10 kDa) against sterile water for 48 hours and lyophilized. This 
compound was then dissolved in anhydrous MeOH (2 mL) and added 1 M NaOMe solution (0.3 
mL) and reaction mixture stirred at room temperature for 48 hours. The reaction was purified, 
lyophilized as described for compound T1 to obtain T3 as a light orange solid in 16 mg, 86% 
yield.  
1H NMR (700 MHz, D2O): δ 0.62-0.80 (m, 16H, L-Lysine aliphatic protons), 0.92-1.00 (m, 
14H), 1.00-1.18 (m, 24H), 1.88 (s, 15H, NH-CH3), 2.04-2.42 (m, 234H, G5-H), 2.42-2.58 (m, 
120H, G5-H), 2.58-2.84 (m, 242H, G5-H), 2.95-3.26 (m, 284H, G5-H), 3.30-3.42 (m, 130H, G5-
H), 3.55-3.70 (m, 1033H, PEG-H + sugar protons), 3.78-3.85 (bs, 18H, Gal-protons), 3.90-4.00 
(m, 12H, Gal-protons), 4.22 (bs, 12H, Gal-protons), 4.30-4.42 (m, 9H, Gal-protons), 6.30-6.50 
(m, 36H), 6.90-7.20 (m, 10H), 7.38-7.60 (m, 4H), 7.60-8.00 (m, 5H). 
NMR Analysis: We observed 1033 of PEG protons. Each 2 kDa PEG molecule have 
approximately 172 protons, therefore we were able to attach 6 units of -cPEG-6-NH-Lysine-
(NAcGalβ)3.  
MALDI analysis: The molecular weight of parent particle G5-(FITC)6 is 27,460.8. The 
molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 47,230.3 which 
has 19,769.4 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-
(NAcGalβ)3 units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore 
obtained G5-conjugate functionality is 5.8 units. 
 
2.16. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]8.1  (T4) 
Compound 16 (22 mg, 3.78 x 10-4 mmoles) was dissolved in anhydrous MeOH (2 mL), followed 
by addition of Et3N (0.2 mL), excess of Ac2O (0.15 mL) and reaction mixture stirred at room 
temperature for 48 hours. Solvents were removed under reduced pressure and residue purified by 
dialysis (MWCO 10 KDa) against sterile water for 48 hours and lyophilized. This compound was 
then dissolved in anhydrous MeOH (2 mL) and added 1 M NaOMe solution (0.3 mL) and 
reaction mixture stirred at room temperature for 48 hours. The reaction was purified, lyophilized 





1H NMR (700 MHz, D2O): δ 0.62-0.80 (m, 22H, L-Lysine aliphatic protons), 0.92-1.00 (m, 
16H), 1.00-1.18 (m, 28H), 1.88 (s, 19H, NH-CH3), 2.04-2.40 (m, 248H, G5-H), 2.40-2.58 (m, 
120H, G5-H), 2.58-2.80 (m, 264H, G5-H), 2.95-3.05 (m, 128H, G5-H), 3.05-3.22 (m, 177H, G5-
H), 3.30-3.42 (m, 143H, G5-H), 3.55-3.76 (m, 1335H, PEG-H + sugar protons), 3.78-3.85 (bs, 
12H, Gal-protons), 3.90-4.00 (m, 8H, Gal-protons), 4.22 (bs, 13H, Gal-protons), 4.30-4.42 (m, 
9H, Gal-protons), 6.30-6.50 (m, 22H), 6.90-7.20 (m, 16H), 7.50-8.00 (m, 6H). 
NMR Analysis: We observed 1335 of PEG protons. Each 2 kDa PEG molecule have 
approximately 172 protons, therefore we were able to attach7.8 units of -cPEG-6-NH-Lysine-
(NAcGalβ)3.  
MALDI analysis: The molecular weight of parent particle G5-(FITC)6 is 27,460.8. The 
molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 55,256.0 which 
has 27,795.2 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-
(NAcGalβ)3 units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore 
obtained G5-conjugate functionality is 8.1 units. 
 
2.17. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]10.6  (T5) 
Compound 17 (25 mg, 3.70 x 10-4 mmoles) was dissolved in anhydrous MeOH (2 mL), followed 
by addition of Et3N (0.2 mL), excess of Ac2O (0.15 mL) and reaction mixture stirred at room 
temperature for 48 hours. Solvents were removed under reduced pressure and residue purified by 
dialysis (MWCO 10 KDa) against sterile water for 48 hours and lyophilized. This compound was 
then dissolved in anhydrous MeOH (2 mL) and added 1 M NaOMe solution (0.3 mL) and 
reaction mixture stirred at room temperature for 48 hours. The reaction was purified, lyophilized 
as described for compound T1 to obtain T5 as a light orange solid in 22 mg, 88% yield.  
 
1H NMR (700 MHz, D2O): δ 0.62-0.82 (m, 28H, L-Lysine aliphatic protons), 0.95-1.05 (m, 
16H), 1.05-1.30 (m, 40H), 1.88 (s, 25H, NH-CH3), 2.05-2.40 (m, 328H, G5-H), 2.40-2.58 (m, 
120H, G5-H), 2.58-2.84 (m, 317H, G5-H), 2.95-3.25 (m, 344H, G5-H), 3.30-3.42 (m, 156H, G5-
H), 3.55-3.76 (m, 1465H, PEG-H + sugar protons), 3.78-3.85 (bs, 16H, Gal-protons), 3.90-4.00 
(m, 15H, Gal-protons), 4.20 (bs, 13H, Gal-protons), 6.30-6.50 (m, 26H), 6.90-7.20 (m, 19H), 




NMR Analysis: We observed 1466 (1634) of PEG protons. Each 2 kDa PEG molecule have 
approximately 172 protons, therefore we were able to attach 8.5 units of -cPEG-6-NH-Lysine-
(NAcGalβ)3.  
MALDI analysis: The molecular weight of parent particle G5-(FITC)6 is 27,460.8. The 
molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 63,863.2 which 
has 36,402.4 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-
(NAcGalβ)3 units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore 
obtained G5-conjugate functionality is 10.6 units. 
 
2.18. Synthesis of (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]14.2 (T6) 
Compound 18 (26 mg, 3.21 x 10-4 mmoles) was dissolved in anhydrous MeOH (2 mL), followed 
by addition of Et3N (0.2 mL), excess of Ac2O (0.15 mL) and reaction mixture stirred at room 
temperature for 48 hours. Solvents were removed under reduced pressure and residue purified by 
dialysis (MWCO 10 KDa) against sterile water for 48 hours and lyophilized. This compound was 
then dissolved in anhydrous MeOH (2 mL) and added 1 M NaOMe solution (0.3 mL) and 
reaction mixture stirred at room temperature for 48 hours. The reaction was purified, lyophilized 
as described for compound T1 to obtain T6 as a light orange solid in 24 mg, 92% yield.  
 
1H NMR (700 MHz, D2O): δ 0.62-0.82 (m, 36H, L-Lysine aliphatic protons), 0.95-1.05 (m, 
24H), 1.05-1.30 (m, 60H), 1.88 (s, 29H, NH-CH3), 1.96-2.05 (m, 38H), 2.10-2.42 (m, 262H, G5-
H), 2.40-2.62 (m, 120H, G5-H), 2.62-2.95 (m, 224H, G5-H), 2.95-3.30 (m, 307H, G5-H), 3.30-
3.42 (m, 133H, G5-H), 3.55-3.76 (m, 2372H, PEG-H + sugar protons), 3.80(bs, 21H, Gal-
protons), 3.90-4.00 (m, 16H, Gal-protons), 4.05-4.26 (m, 32H, Gal-protons), 6.30-6.50 (m, 27H), 
6.90-7.50 (m, 26H), 7.50-7.95 (m, 8H). 
NMR Analysis: We observed 2372 of PEG protons. Each 2 kDa PEG molecule have 
approximately 172 protons, therefore we were able to attach 13.8 units of -cPEG-6-NH-Lysine-
(NAcGalβ)3.  
MALDI analysis: The molecular weight of parent particle G5-(FITC)6 is 27,460.8. The 
molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 76,220.8 which 




(NAcGalβ)3 units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore 
obtained G5-conjugate functionality is 14.2 units. 
 
References: 
1. G. Tiruchinapally, S. H. Medina, M. V. Chevliakov, Y. Y. Durmaz, R. N. Stender, W. D. 
Ensminger, D. S. Shewach, and M. E.H. ElSayed, "Targeting hepatic cancer cells with 
PEGylated dendrimers displaying N-acetylgalactosamine and SP94 peptide ligands", Advanced 






































































































































Figure C11 1H NMR of conjugate 12 in D2O (expansion region from 1.5-8 ppm) 
NMR Analysis: 
We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal standard to calculate 
the incoming, coupled FITC protons after attachment. We observed 62 protons for PEG protons. 












Figure C12 1H NMR of conjugate 12 in D2O (expansion region from 0-200 ppm) 
 








Figure C14 Maldi Spectrum of 12, (FITC)6-G5-(NH2)122 
Maldi Analysis: 
The molecular weight of parent particle G5-(NH2)128 is 25,120.0 
The molecular weight observed for (FITC)6-G5-(NH2)122 is 27,460.8 which has 2,348.8 daltons more 
than its parent dendrimer. This is attributed to FITC units; each FITC molecule contributes 389.38 daltons. 


































































































Figure C22 1H NMR of conjugate T2 in D2O (expansion region from 0-9 ppm), 700 MHz 
NMR Analysis: 
We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal standard to calculate 
the incoming, coupled PEG protons after attachment. We observed 297 protons for PEG protons. 
Each 2 kDa PEG molecule have approximately 172 protons, therefore we were able to attach 1.72 









Figure C23 Maldi Spectrum of T2, (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]2 
Maldi Analysis: 
The molecular weight of parent particle G5-(FITC)6 is 27,460.8 
The molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 34,274.5 which has 
6,813.7 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-(NAcGalβ)3 
units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore obtained G5-conjugate 




















Figure C25 1H NMR of conjugate T4 in D2O (expansion region from 0.2-8.5 ppm), 700 MHz 
NMR Analysis: 
We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal standard to calculate 
the incoming, coupled PEG protons after attachment. We observed 628 protons for PEG protons. 
Each 2 kDa PEG molecule have approximately 172 protons, therefore we were able to attach 3.65 








Figure C26 Maldi Spectrum of T4, (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]3.6 
 Maldi Analysis: 
The molecular weight of parent particle G5-(FITC)6 is 27,460.8 
The molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 39,789.0 which has 
12,328.2 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-(NAcGalβ)3 
units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore obtained G5-conjugate 


















Figure C28 1H NMR of conjugate T6 in D2O (expansion region from 0.2-8.5 ppm), 700 MHz 
NMR Analysis: 
We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal standard to calculate 
the incoming, coupled PEG protons after attachment. We observed 1033 of PEG protons. Each 2 










Figure C29 Maldi Spectrum of T6, (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]5.8 
 Maldi Analysis: 
The molecular weight of parent particle G5-(FITC)6 is 27,460.8 
The molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 47,230.3 which has 
19,769.4 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-(NAcGalβ)3 
units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore obtained G5-conjugate 





















Figure C31 1H NMR of conjugate T8 in D2O (expansion region from 0.2-8.5 ppm), 700 MHz 
NMR Analysis: 
We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal standard to calculate 
the incoming, coupled PEG protons after attachment. We observed 1335 of PEG protons. Each 2 










Figure C32 Maldi Spectrum of T8, (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]8.1 
 Maldi Analysis: 
The molecular weight of parent particle G5-(FITC)6 is 27,460.8 
The molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 55,256.0 which has 
27,795.2 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-(NAcGalβ)3 
units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore obtained G5-conjugate 




















Figure C34 1H NMR of conjugate T11 in D2O (expansion region from 0.2-8.5 ppm), 700 MHz 
NMR Analysis: 
We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal standard to calculate 
the incoming, coupled PEG protons after attachment. We observed 1466 (1634) of PEG protons. 
Each 2 kDa PEG molecule have approximately 172 protons, therefore we were able to attach 8.5 









Figure C35 Maldi Spectrum of T11, (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]10.6 
 Maldi Analysis: 
The molecular weight of parent particle G5-(FITC)6 is 27,460.8 
The molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 63,863.2 which has 
36,402.4 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-(NAcGalβ)3 
units; each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore obtained G5-conjugate 










Figure C36 1H NMR of conjugate T14 in D2O, 700 MHz 
 






Figure C38 1H NMR of conjugate T14 in D2O (expansion region from 1.2-5.0 ppm), 700 MHz 
NMR Analysis: 
We took the un overlapped G5-protons at 2.36-2.50 ppm as standard internal standard to calculate 
the incoming, coupled PEG protons after attachment. We observed 2372 of PEG protons. Each 2 
kDa PEG molecule have approximately 172 protons, therefore we were able to attach 13.8 units 









Figure C39 Maldi Spectrum of T14, (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]14.2 
 Maldi Analysis: 
The molecular weight of parent particle G5-(FITC)6 is 27,460.8 
The molecular weight observed for (FITC)6-G5-[cPEG-6-NH-Lysine-(NAcGalβ)3]x is 76,220.8 which has 
48,760 daltons more than its parent dendrimer. This is attributed to cPEG-6-NH-Lysine-(NAcGalβ)3 units; 
each cPEG-6-NH-Lysine-(NAcGalβ)3 contributes 3420.2 daltons. Therefore obtained G5-conjugate 







Conclusions and Future Work 
 
6.1 Conclusions 
This thesis focused on the development of targeted, enzyme-activated nano-conjugates for hepatic 
cancer therapy, or HCC. We first began by fabricating NAcGal-targeted, DOX-loaded G5 
conjugates and tested their ability to target and kill hepatic cancer cells in vitro in Chapter III. Our 
results showed that we could synthesize P1 and P2 conjugates with reproducible drug-loading and 
targeting branch density, and further that the particles exhibit high biocompatibility. We showed 
that P1/P2 conjugates were able to efficiently be internalized into hepatic cancer cells, and this 
internalization correlated with cytotoxicity towards the cells, modulated by linkage chemistry (P2 
more toxic than P2). To further elucidate the differences observed in cell toxicity, we use 
metabolomics techniques to identify that P1 and P2 conjugates release unique DOX metabolites 
unlike that of free DOX, which accordingly induced a unique metabolic response within cancer 
cells. These findings are very important because the discovery of these metabolites have never 
been identified as downstream digestion products of parent DOX molecules. Also, these findings 
are valuable to the greater drug delivery community because we identified that delivering a drug 
through a nanoparticle altered the intracellular digestion of the drug and therefore corresponded to 




ensure that a certain drug is actually being delivered when the formulation is changed, such as 
through the use of a nanoparticle.  
 
Given the success of the therapy in vitro, in Chapter IV we set off to measure the efficacy of P1 
and P2 conjugates in a tumor-bearing mouse model. Our results showed that we could achieve 
comparable efficacy of P1/P2 conjugates to free DOX, and possibly even improve its antitumor 
efficacy. Interestingly, in an animal model, P1 and P2 behaved more similarly in therapeutic 
efficacy than we predicted given their differences in linkage chemistry, highlighting important 
considerations to be made when translating a therapy from in vitro to in vivo development. After 
observing that P1/P2 conjugates exhibited comparable antitumor efficacy, we turned to cardiac 
MRI of mice undergoing treatment to measure the induced cardiotoxicity. Results showed that 
while the free DOX-treated mice suffered decreases in cardiac function across the board, P1 and 
P2 conjugates did not induce any changes in cardiac function compared to the saline control. Taken 
together, these results indicated the ability to rescue the clinical toxicity observed with a 
conventional, FDA-approved chemotherapeutic drug using nanoparticle-mediated delivery.  
 
In Chapter V, we explored the potential to modulate the ability to target HCC in vivo by developing 
a library of targeted G5 dendrimers that exploit multi-valent targeting ligands. We determined 
through our synthesis and pilot experiments that the use of triGal conjugates has merits, providing 
a variety of chemical structures, physicochemical properties, and drug-loading abilities that can all 
target hepatic cancer cells. However, monoGal is still a robust and more effective way of targeting 
hepatic cancer cells. These are interesting findings given that for small molecules, previous work 




while our work shows that they do not do so when attached to nanoparticles. To the best of our 
knowledge, this has never been reported before.  
 
6.2. Future Experimental Work 
 
6.2.1. Identify the mechanisms behind monoGal and triGal targeting  
Our results in Chapter V showed that triGal-targeted G5 dendrimers did not improve 
internalization of hepatic cancer cells over monoGal-targeted ones as the literature suggested. Our 
hypothesis for this discrepancy is that the geometric spacing of PEG-NAcGal chains at the tip of 
triGal branches may have a very important role in the affinity and transportation kinetics of the 
nanoparticles into hepatic cancer cells. Zacco et al. showed the significance of NAcGal ligand 
spacing on ASGPR binding kinetics (Figure 34).1 The next experimental steps of this work should 
look into the spacing between PEG branches and NAcGal ligands. In particular, molecular 
modeling may help elucidate this phenomenon and explain the observed discrepancies.  
 
 
Figure 34. Influence of geometry on ligand-binding. The 
geometry of NAcGal ligands in tri-valent format may be 
influencing the binding of triGal particles compared to 




6.2.2. Measure the efficacy of P1 and P2 conjugates in an orthotopic tumor model 
Our preliminary results in vivo identified that P1 and P2 conjugates are able to inhibit tumor growth 
and maintain cardiac function in treated mice, exhibiting their therapeutic advantage of the free 
drug. The next step to better measure their therapeutic value is to test their biodistribution and their 
antitumor efficacy in an orthotopic tumor model.  
 
During this thesis, preliminary work was performed in establishing an orthotopic tumor model in 
NSG mice. We used MRI to monitor tumor growth over time and to assess its vascularization 
using gadolinium-enhanced MRI. We developed two different murine HCC models, cellular 
orthotopic injection (COI) (representing a traditional model) or surgical orthotopic implantation 
(SOI) of tumor fragments (representing a patient-derived orthotopic xenograft model) (Figures 35 
and 36). Results showed that the morphology of the two models varied significantly, and this 
corresponded to stark differences in vascularization as well. Namely, the COI model developed 
homogeneously in tumor morphology, and enabled rapid Gd permeation upon injection, 
suggesting that the developed tumors were well-perfused with vasculature. On the other hand, the 
SOI tumors exhibited tortuous morphology and poor Gd permeation, suggesting that the 
development of the tumor is much more varied and that angiogenesis is limited within the depths 
of the tumor tissue. This phenomenon is not surprising, given that COI tumors begin to develop at 
day 0 with complete infiltration of the surrounding environment, given the porosity of the gel 
matrix. On the other hand, SOI tumors are already solidified tumor fragments that potentially have 
differences in access to the microenvironment depending on the depth of the tumor. In other words, 
the surface of the tumor may be able to induce angiogenesis easily due to facile access to the liver 





These results are interesting and very important for the HCC community as well as the greater 
oncology field, because we are seeing that tumor morphology and vascularization are prominently 
different depending on the type of tumor model used. Particularly when measuring a therapy 
employing vascular access to treat the tumor, the choice of tumor model can have a significant 
impact on the observed results.  
 
  
Figure 35. MRI images of COI and SOI orthotopic HCC tumors. A) 2.5x106 HepG2 cells were 
injected into the left lobe of the liver as a cell suspension and imaged at week 4 with ROI indicating 
the tumor nodule (green highlighted region). B) A 5x5 mm2 fragment of tumor, initially grown 
subcutaneously in another animal, was implanted in the left lateral lobe and imaged at week 3 with 






6.2.3. Co-loading of L3- and L4-DOX onto same conjugates 
Given the high control over synthesis we have achieved in the development of P1 and P2 
conjugates, combined with the ability to engineer the release kinetics of DOX depending on the 
linkage chemistry, it would be an interesting study to co-load both L3-DOX (from P1) and L4-
DOX (from P2) linkages onto the same G5 dendrimer (Figure 37). We hypothesize that this may 
enable controlled release at both a “slow” and “fast” rate, given the differences in the lability of 
the linkages. This may be useful for particular patients that respond best to an initial bolus dose of 
DOX, and then a sustained dose over time afterwards. The complex control that is required for 
such a controlled release system is possible with the P1/P2 conjugate chemistry. Further, in the 
age of personalized medicine, we can hypothetically measure the presence of azoreductase 
enzymes within an HCC patient and tailor the loading of L3- and L4-DOX linkages based on how 




the patient may respond to either linkage. The versatility of this system offers many possibilities 
to customize and improve HCC therapy, and therein lies the advantage of nanoparticle-mediated 








6.3. Future Directions for Nanomedicine 
Overall, this thesis contributes to the goal of improving therapy not just for HCC, but for cancer 
in general. The ability to exploit a tumor-specific signal, such as an antigen or a receptor, provides 
the specificity required to target tumor cells specifically and release a therapeutic payload directly 
at that site. The use of nanoparticles as the vehicle offers the versatility of a multi-functional 
particle that can be loaded with a variety of therapeutic agents, while at the same time being able 
to home to a specific target. The recent success of combinatorial therapy in the clinic suggests that 
the co-loading of multiple therapeutic agents may be the next step for cancer therapy, and 
dendrimers may be the ideal vehicle for this given their ability to co-load a variety of drugs.  
 
Further, our work looking into enzyme-mediated drug release provides one more engineering 
“handle” on the temporal and spatial localization of a drug. As we venture more and more towards 
precision medicine, being able to identify certain malignant biomarkers or malfunctioning cellular 
machinery and exploiting them to release or activate a drug will further our mission.  
 
Finally, the success of immunotherapy in being able to reprogram or turn off suppression of the 
immune system to fight cancer, say be engineered T-cells, offers a whole new arena for 
nanoparticles to enter. The biocompatibility, unique biodistribution properties, and multi-
functionality make nanoparticles to be promising vehicles and modulators of immunotherapies 
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SYNOPSIS: We report the use of semi-quantitative dynamic contrast enhanced (DCE)-MRI to 
identify differences in the growth and vascular environment seen within two murine hepatocellular 
carcinoma (HCC) models - cellular orthotopic injection (COI) (representing a traditional tumor 
model) or surgical orthotopic implantation (SOI) of tumor fragments (representing a patient-
derived orthotopic xenograft model, or PDOX). Uptake curves of gadolinium contrast agent 
indicate differences in vasculature between the two models, highlighting important considerations 
to be made when trying to use PDOX methods to model HCC in the clinic. 
 
INTRODUCTION: Hepatocellular carcinoma (HCC) is the 5th most commonly-occurring cancer 
worldwide1 and 2nd highest cause for cancer-related deaths globally.2 While the use of MR for the 
diagnosis and treatment of HCC in the clinic is undeniably significant,3,4 its application to murine 
HCC models has been limited due to animal size, equipment costs, and expertise required.5 
Recently, the use of patient-derived orthotopic xenograft (PDOX) tumor models in mice has 
elucidated growth characteristics, vascularization, and metastatic capacity of HCC tissue.6 Here 
we report the use of semi-quantitative dynamic contrast enhanced (DCE)-MRI to identify 
differences in the growth and vascular environment seen within two murine HCC models, cellular 
orthotopic injection (COI) (representing a traditional model) or surgical orthotopic implantation 
(SOI) of tumor fragments (representing a PDOX model). Uptake curves of gadolinium contrast 
agent indicate differences in vasculature between the two models, highlighting important 
considerations to be made when trying to use PDOX methods to model HCC in the clinic. 
 
METHODS: All animal work was approved by the Institutional Animal Care and Use Committee 
(IACUC) at the University of Michigan. 
Orthotopic tumors: Male, nod scid gamma (NSG) mice (6-10 weeks of age; n=10) were used in 
this study. Mice were given an immunosuppressive dose of cyclophosphamide 24 hours before 
tumor inoculation. On the day of surgery, after a pre-emptive injection of carprofen, mice were 
anesthetized and aseptically prepared for a laparotomy. The left lateral lobe of the liver was 
exposed and either 2.5 x 106 HepG2 cells (prepared 1:1 medium:Matrigel) were injected (n=5), or 




and immobilized in the liver with surgical glue (n=5). After 2-3 weeks, the animals underwent 
weekly imaging via MR to assess tumor volume and vascular environment. 
Tumor volume: Animals were anesthetized using 2% isoflurane, 1 L/min O2 carrier gas and 
imaged on a 7T small animal MRI system (Agilent Technologies, CA). Rectal temperature was 
controlled to within ± 0.2 °C. Tumors were visualized using a coronal 2D fast spin echo (FSE) 
acquisition: TR/TEeff 2000/20 ms, echo spacing 10 ms, echo train length 8, field of view (30 mm)
2, 
matrix 256x128 zero-filled to 5122, slice thickness 1 mm, NEX 16 (due to respiratory motion). 
Tumor volume was quantified using semi-automatic thresholding and user verification in Analyze 
(Analyze Direct).  
Gd-enhancement: Three to four weeks after implantation, gadolinium (Gd) was used to study 
vascularization of the tumors. The FSEMS coronal images were used to plan a gradient echo 
acquisition: 60 frames at one location (1 frame/10 secs), TR/TE 20/3.03 ms, field of view (30 
mm)2, flip angle 30o, matrix 1282 zero-filled to 2562, slice thickness 1 mm, NEX 4. Approximately 
100 µL of Gd (Magnevist) was administered via a tail vein catheter at ~frame 10. The signal 
intensity of a region of interest (ROI) in the tumors was quantified for all 60 frames using 
MRVision (MRVision Co.), normalizing to the average baseline signal intensity in frames 1-9.  
 
RESULTS & DISCUSSION: Tumor-take was 60% and 100% for the COI and SOI models, 
respectively. Figure 1 illustrates typical COI and SOI tumors at 3-4 weeks. Tumor volume for 
COI tumors increased from 9.4, 29.9, and 45.3 mm3 at week 3 to 44.6, 113.8 mm3, and 59.2 mm3 
at week 4, respectively.  The SOI tumors had a varied response with tumor volumes of 228, 285, 
151, 150, and 49.9 mm3 at week 2 and volumes of 152, 234, 221, 157, and 157 mm3 at week 3. 
This data suggests that for some of the SOI animals, the tumor may be necrosing due to inadequate 
integration with native blood supply. 
Gadolinium uptake curves are shown in Figure 2. For the COI group, one animal developed three 
tumor nodules; thus, n=5 total nodules were used for the curve. Evaluating semi-quantitative DCE-
MRI metrics in the first 90 seconds after injection: wash-in slope was 0.070 and 0.016 AU/sec for 
COI and SOI tumors, respectively. This was more strongly driven by a reduced time to peak for 
COI tumors (COI ~ 20 secs v. SOI ~ 90 secs), whereas maximum enhancement was nearly the 
same for both models (~1.4). Based on these measurements, the COI tumors have increased 
vascular density and/or permeability, with their uptake curve shape associated with malignancy.7  
 
CONCLUSION: It is well established that the blood supply to a tumor is a major factor in growth 
and metastasis, as well as drug delivery. With the increasing use of PDOX models, it is critical to 
understand if, how, and when the implant is well integrated into the local vascular network and 
how that represents, or not, the human condition. 
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